Title: 2882 non-redundant connections with p < 0.05 via enrichment analysis sig profile score s_comparison s_sampleA s_sampleB p_comparison p_sampleA p_sampleB GDS2221.0.3 GDS2221.0.2 1.85 agent untreated lipopolysaccharide agent untreated galectin-1 GDS1732.0.1 GDS1665.0.1 1.80 disease state normal papillary thyroid cancer disease state normal papillary thyroid carcinoma GDS2367.0.1.4 GDS2367.0.2.4 1.76 agent vehicle estradiol agent vehicle tamoxifen GDS2221.0.3 GDS2221.1.2 1.73 agent untreated lipopolysaccharide agent vehicle galectin-1 GDS2221.1.3 GDS2221.1.2 1.73 agent vehicle lipopolysaccharide agent vehicle galectin-1 GDS2341.0.2.5 GDS2341.0.3.5 1.70 agent untreated Type II IFN agent untreated Types I and II IFNs GDS2213.0.3 GDS2213.0.1 1.70 agent untreated 5-aza-dC plus TSA agent untreated 5-aza-dC GDS2250.0.3 GDS2250.0.2 1.68 disease state normal basal-like cancer disease state normal BRCA1-associated cancer GDS690.2.3.0 GDS690.2.5.0 1.68 agent control flagellin agent control TNFa GDS2250.0.1 GDS2250.0.2 1.65 disease state normal non-basal-like cancer disease state normal BRCA1-associated cancer GDS1989.1.5.0 GDS1989.1.7.0 1.63 disease state normal vertical growth phase melanoma disease state normal lymph node metastasis GDS2250.0.1 GDS2250.0.3 1.62 disease state normal non-basal-like cancer disease state normal basal-like cancer GDS2057.0.1.3 GDS2057.0.2.3 1.61 agent control DHT agent control RTI-018 GDS1783.0.1 GDS1783.0.2 1.61 agent control thapsigargin agent control high potassium GDS2118.0.1 GDS2118.0.3 1.60 disease state normal refractory anemia disease state normal refractory anemia with excess blasts GDS1615.0.2 GDS1615.0.1 1.59 disease state normal Crohn's disease disease state normal ulcerative colitis GDS1321.0.1 GDS1321.0.2 1.59 disease state normal Barrett's esophagus disease state normal adenocarcinoma GDS690.2.4.1 GDS690.2.3.1 1.59 agent control LTb agent control flagellin GDS2118.0.1 GDS2118.0.2 1.58 disease state normal refractory anemia disease state normal refractory anemia with ringed sideroblasts GDS2214.0.1 GDS2255.3.4.0 1.57 agent control lipopolysaccharide agent untreated endotoxin GDS2214.0.2 GDS2214.0.1 1.55 agent control HMGB1 agent control lipopolysaccharide GDS1956.0.9 GDS1956.0.10 1.55 disease state normal Calpain 3 mutation disease state normal dysferlin mutation GDS1617.0.2 GDS1617.0.5 1.54 agent control 50uM zinc agent control MGd/50uM zinc GDS1362.0.2 GDS1362.0.1 1.53 disease state non-failing heart ischemic cardiomyopathy disease state non-failing heart non-ischemic cardiomyopathy GDS2341.0.1.4 GDS2341.0.3.4 1.53 agent untreated Type I IFN agent untreated Types I and II IFNs GDS1956.0.10 GDS1956.0.11 1.53 disease state normal dysferlin mutation disease state normal FKRP mutation GDS2649.3.5.1 GDS2649.2.5.1 1.52 disease state uninfected chronic HIV infection disease state uninfected early HIV infection GDS2200.0.1 GDS2200.0.2 1.50 disease state normal actinic keratosis disease state normal squamous cell carcinoma GDS1956.0.8 GDS1956.0.10 1.50 disease state normal Duchenne muscular dystrophy disease state normal dysferlin mutation GDS1375.0.1 GDS1375.0.2 1.50 disease state normal benign nevi disease state normal malignant melanoma GDS1956.0.10 GDS1956.0.7 1.50 disease state normal dysferlin mutation disease state normal Becker muscular dystrophy GDS1989.1.7.0 GDS1989.1.6.0 1.49 disease state normal lymph node metastasis disease state normal metastatic growth phase melanoma GDS2767.5.8.0 GDS2767.7.8.0 1.49 agent water alcohol agent water red wine GDS1956.0.8 GDS1956.0.6 1.48 disease state normal Duchenne muscular dystrophy disease state normal Emery-Dreifuss muscular dystrophy GDS690.2.5.1 GDS690.2.4.1 1.48 agent control TNFa agent control LTb GDS2617.0.2 GDS2617.0.1 1.47 disease state normal tumorigenic cancer cell disease state normal non-tumorigenic cancer cell GDS715.0.7.18 GDS715.0.8.18 1.47 agent none 4,5-dianilinophthalimide agent none 1,10-phenanthroline GDS1956.0.9 GDS1956.0.7 1.47 disease state normal Calpain 3 mutation disease state normal Becker muscular dystrophy GDS1971.0.2 GDS1971.0.1 1.47 disease state healthy complicated malaria disease state healthy uncomplicated malaria GDS2767.7.8.0 GDS2767.6.8.0 1.47 agent water red wine agent water grape juice GDS2118.0.3 GDS2118.0.2 1.46 disease state normal refractory anemia with excess blasts disease state normal refractory anemia with ringed sideroblasts GDS1926.0.1.4 GDS1926.0.3.4 1.46 agent control thrombin agent control LTD4 and thrombin GDS1956.0.8 GDS1956.0.9 1.45 disease state normal Duchenne muscular dystrophy disease state normal Calpain 3 mutation GDS1397.0.2 GDS1397.0.1 1.44 agent untreated TNF-alpha agent untreated HIV GDS2767.5.8.0 GDS2767.6.8.0 1.44 agent water alcohol agent water grape juice GDS268.0.1 GDS268.0.2 1.43 disease state non-obese obese disease state non-obese morbidly obese GDS651.0.1 GDS651.0.2 1.42 disease state normal idiopathic dilated disease state normal ischemic GDS1375.0.2 GDS1989.1.7.0 1.41 disease state normal malignant melanoma disease state normal lymph node metastasis GDS2367.3.4.2 GDS2367.0.2.3 -1.41 infection control adenovirus adenovirus carrying estrogen receptor beta agent vehicle tamoxifen GDS1956.0.8 GDS1956.0.11 1.41 disease state normal Duchenne muscular dystrophy disease state normal FKRP mutation GDS1956.0.9 GDS1956.0.11 1.41 disease state normal Calpain 3 mutation disease state normal FKRP mutation GDS1989.1.6.0 GDS1989.1.5.0 1.41 disease state normal metastatic growth phase melanoma disease state normal vertical growth phase melanoma GDS1989.1.3.0 GDS1989.1.2.0 1.40 disease state normal atypical nevus disease state normal benign nevus GDS1956.0.8 GDS1956.0.7 1.40 disease state normal Duchenne muscular dystrophy disease state normal Becker muscular dystrophy GDS2214.0.2 GDS2255.3.4.0 1.39 agent control HMGB1 agent untreated endotoxin GDS2367.3.4.1 GDS2367.0.1.3 -1.37 infection control adenovirus adenovirus carrying estrogen receptor beta agent vehicle estradiol GDS1956.0.9 GDS1956.0.6 1.37 disease state normal Calpain 3 mutation disease state normal Emery-Dreifuss muscular dystrophy GDS715.0.7.16 GDS715.0.3.16 1.37 agent none 4,5-dianilinophthalimide agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2332.0.2 GDS2332.0.3 1.35 infection uninfected delta frpC/frpA mutant infection uninfected delta pilD mutant GDS715.0.8.16 GDS715.0.6.16 1.35 agent none 1,10-phenanthroline agent none 16-ketoestradiol GDS1259.0.1 GDS1956.0.2 1.34 disease state normal dermatomyositis disease state normal juvenile dermatomyositis GDS1926.0.1.4 GDS1926.0.2.4 1.33 agent control thrombin agent control LTD4 GDS810.0.2 GDS810.0.3 1.32 disease state control moderate AD disease state control severe AD GDS1956.0.8 GDS1956.0.2 1.32 disease state normal Duchenne muscular dystrophy disease state normal juvenile dermatomyositis GDS1956.0.1 GDS1956.0.6 1.32 disease state normal acute quadriplegic myopathy disease state normal Emery-Dreifuss muscular dystrophy GDS2341.0.1.4 GDS2341.0.2.4 1.32 agent untreated Type I IFN agent untreated Type II IFN GDS1956.0.11 GDS1956.0.7 1.31 disease state normal FKRP mutation disease state normal Becker muscular dystrophy GDS810.0.2 GDS810.0.1 1.31 disease state control moderate AD disease state control incipient AD GDS2250.0.1 GDS2635.0.3 1.31 disease state normal non-basal-like cancer disease state lobular control invasive ductal carcinoma GDS1926.0.3.4 GDS1926.0.2.4 1.30 agent control LTD4 and thrombin agent control LTD4 GDS1384.0.3 GDS1384.0.1 1.30 agent control 3MutC agent control c-Myb GDS1617.0.3 GDS1617.0.2 1.29 agent control MGd agent control 50uM zinc GDS1384.0.2 GDS1384.0.1 1.29 agent control v-Myb agent control c-Myb GDS1956.0.3 GDS1956.0.6 1.29 disease state normal amyotophic lateral sclerosis disease state normal Emery-Dreifuss muscular dystrophy GDS715.2.7.18 GDS715.2.8.18 1.28 agent negative control 4,5-dianilinophthalimide agent negative control 1,10-phenanthroline GDS715.0.7.16 GDS715.0.1.16 1.28 agent none 4,5-dianilinophthalimide agent none positive control GDS2418.0.1 GDS2200.0.2 1.27 disease state control vulvar intraepithelial neoplasia disease state normal squamous cell carcinoma GDS2705.0.2 GDS2705.0.3 1.27 agent control carboplatin agent control rosiglitazone plus carboplatin GDS1630.2.3.1 GDS1630.2.5.1 1.27 agent untreated mevalonate agent untreated atorvastatin and mevalonate GDS1375.0.2 GDS1989.1.5.0 1.26 disease state normal malignant melanoma disease state normal vertical growth phase melanoma GDS1384.0.2 GDS1384.0.3 1.26 agent control v-Myb agent control 3MutC GDS1956.0.5 GDS1956.0.2 1.26 disease state normal fascioscapulohumeral muscular dystrophy disease state normal juvenile dermatomyositis GDS2649.4.5.1 GDS2649.3.5.1 1.26 disease state uninfected non-progressive HIV infection disease state uninfected chronic HIV infection GDS1617.0.4 GDS1617.0.5 1.25 agent control MGd/25uM zinc agent control MGd/50uM zinc GDS2705.0.1 GDS2705.0.2 1.25 agent control rosiglitazone agent control carboplatin GDS1989.1.7.0 GDS1989.1.4.0 1.24 disease state normal lymph node metastasis disease state normal melanoma in situ GDS1428.0.2.10 GDS1428.0.3.10 1.24 agent untreated heat-killed HL60 cell lysate agent untreated HL60 cell lysate GDS1428.0.3.10 GDS1428.0.5.10 1.24 agent untreated HL60 cell lysate agent untreated Anaplasma phagocytophilum GDS1989.1.3.0 GDS1989.1.4.0 1.23 disease state normal atypical nevus disease state normal melanoma in situ GDS2215.0.2 GDS2215.0.1 1.23 agent control cyfluthrin agent control chlorpyrifos GDS1989.1.6.0 GDS1989.1.4.0 1.23 disease state normal metastatic growth phase melanoma disease state normal melanoma in situ GDS715.0.3.16 GDS715.0.1.16 1.23 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none positive control GDS1956.0.1 GDS1956.0.2 1.23 disease state normal acute quadriplegic myopathy disease state normal juvenile dermatomyositis GDS2705.0.1 GDS2705.0.3 1.23 agent control rosiglitazone agent control rosiglitazone plus carboplatin GDS2332.1.3 GDS2332.0.2 -1.22 infection wild type delta pilD mutant infection uninfected delta frpC/frpA mutant GDS2397.0.1 GDS2118.0.3 1.22 disease state normal idiopathic myelofibrosis disease state normal refractory anemia with excess blasts GDS1617.0.3 GDS1617.0.1 1.22 agent control MGd agent control 25uM zinc GDS715.0.10.18 GDS715.0.12.18 1.21 agent none pergolide methanesulfonate agent none 5-fluorouracil GDS1956.0.6 GDS1956.0.5 1.21 disease state normal Emery-Dreifuss muscular dystrophy disease state normal fascioscapulohumeral muscular dystrophy GDS715.0.13.18 GDS715.0.10.18 1.21 agent none 8-(3-chlorostyryl) caffeine agent none pergolide methanesulfonate GDS1428.0.3.10 GDS1428.0.4.10 1.21 agent untreated HL60 cell lysate agent untreated heat-killed Anaplasma phagocytophilum GDS1617.0.4 GDS1617.0.3 1.20 agent control MGd/25uM zinc agent control MGd GDS2250.0.3 GDS2418.0.1 1.20 disease state normal basal-like cancer disease state control vulvar intraepithelial neoplasia GDS1956.0.8 GDS1956.0.1 1.20 disease state normal Duchenne muscular dystrophy disease state normal acute quadriplegic myopathy GDS1956.0.3 GDS1956.0.5 1.20 disease state normal amyotophic lateral sclerosis disease state normal fascioscapulohumeral muscular dystrophy GDS1956.0.2 GDS1956.0.6 1.19 disease state normal juvenile dermatomyositis disease state normal Emery-Dreifuss muscular dystrophy GDS2367.0.2.3 GDS1549.3.4.2 1.19 agent vehicle tamoxifen agent control estradiol GDS1841.0.2 GDS1841.0.1 1.18 agent empty vector misfolded surfactant protein C agent empty vector wild-type surfactant protein C GDS1956.0.3 GDS1956.0.1 1.18 disease state normal amyotophic lateral sclerosis disease state normal acute quadriplegic myopathy GDS1956.0.3 GDS1956.0.2 1.18 disease state normal amyotophic lateral sclerosis disease state normal juvenile dermatomyositis GDS1375.0.2 GDS1989.1.6.0 1.17 disease state normal malignant melanoma disease state normal metastatic growth phase melanoma GDS2250.0.1 GDS2617.0.1 1.17 disease state normal non-basal-like cancer disease state normal non-tumorigenic cancer cell GDS1989.1.7.0 GDS1989.1.2.0 1.17 disease state normal lymph node metastasis disease state normal benign nevus GDS1989.1.5.0 GDS1989.1.2.0 1.17 disease state normal vertical growth phase melanoma disease state normal benign nevus GDS2767.6.8.0 GDS1331.0.2 -1.17 agent water grape juice disease state normal symptomatic GDS1617.0.4 GDS1617.0.2 1.16 agent control MGd/25uM zinc agent control 50uM zinc GDS1956.0.8 GDS1259.0.1 1.16 disease state normal Duchenne muscular dystrophy disease state normal dermatomyositis GDS715.0.9.18 GDS715.0.12.18 1.16 agent none 5-fluorouridine agent none 5-fluorouracil GDS1392.0.2 GDS1392.0.1 1.16 disease state normal myelodysplastic syndrome disease state normal rheumatoid arthritis, on methotrexate GDS1956.0.1 GDS1259.0.1 1.16 disease state normal acute quadriplegic myopathy disease state normal dermatomyositis GDS1956.0.10 GDS1956.0.6 1.16 disease state normal dysferlin mutation disease state normal Emery-Dreifuss muscular dystrophy GDS2216.0.3.5 GDS2216.0.2.5 1.15 agent control CyP plus LPS agent control CyP GDS2635.0.2 GDS2635.0.3 1.14 disease state lobular control invasive lobular carcinoma disease state lobular control invasive ductal carcinoma GDS715.2.9.18 GDS715.2.12.18 1.14 agent negative control 5-fluorouridine agent negative control 5-fluorouracil GDS715.0.13.18 GDS715.0.12.18 1.14 agent none 8-(3-chlorostyryl) caffeine agent none 5-fluorouracil GDS810.0.3 GDS810.0.1 1.14 disease state control severe AD disease state control incipient AD GDS715.2.13.18 GDS715.2.10.18 1.14 agent negative control 8-(3-chlorostyryl) caffeine agent negative control pergolide methanesulfonate GDS1989.1.4.0 GDS1989.1.5.0 1.13 disease state normal melanoma in situ disease state normal vertical growth phase melanoma GDS715.0.9.18 GDS715.0.14.18 1.13 agent none 5-fluorouridine agent none R-(-)-apomorphine HCl GDS1956.0.3 GDS1259.0.1 1.13 disease state normal amyotophic lateral sclerosis disease state normal dermatomyositis GDS2767.7.8.0 GDS1331.0.2 -1.13 agent water red wine disease state normal symptomatic GDS2021.0.1 GDS2021.0.2 1.12 agent control metoprolol agent control nebivolol GDS1989.1.4.0 GDS1989.1.2.0 1.12 disease state normal melanoma in situ disease state normal benign nevus GDS715.0.7.18 GDS715.2.8.18 1.12 agent none 4,5-dianilinophthalimide agent negative control 1,10-phenanthroline GDS715.2.11.18 GDS715.2.13.18 1.12 agent negative control scopolamine methyl bromide agent negative control 8-(3-chlorostyryl) caffeine GDS715.0.14.18 GDS715.0.1.18 1.12 agent none R-(-)-apomorphine HCl agent none positive control GDS715.2.13.18 GDS715.2.12.18 1.11 agent negative control 8-(3-chlorostyryl) caffeine agent negative control 5-fluorouracil GDS2250.0.3 GDS1989.1.7.0 1.10 disease state normal basal-like cancer disease state normal lymph node metastasis GDS2250.0.1 GDS2418.0.1 1.10 disease state normal non-basal-like cancer disease state control vulvar intraepithelial neoplasia GDS715.0.9.18 GDS715.0.10.18 1.10 agent none 5-fluorouridine agent none pergolide methanesulfonate GDS1282.0.1 GDS1282.0.2 1.10 disease state control Wilms' tumor disease state control clear cell sarcoma of the kidney GDS2767.5.8.4 GDS1331.0.2 -1.10 agent water alcohol disease state normal symptomatic GDS715.0.10.18 GDS715.0.14.18 1.09 agent none pergolide methanesulfonate agent none R-(-)-apomorphine HCl GDS1617.0.1 GDS1617.0.4 1.09 agent control 25uM zinc agent control MGd/25uM zinc GDS1746.2.3.0 GDS1746.2.4.0 1.09 disease state normal benign hyperplasia disease state normal basaloid GDS2250.0.1 GDS1439.0.2 1.09 disease state normal non-basal-like cancer disease state benign metastatic GDS1956.0.5 GDS1956.0.1 1.09 disease state normal fascioscapulohumeral muscular dystrophy disease state normal acute quadriplegic myopathy GDS1439.0.1 GDS1439.0.2 1.09 disease state benign primary disease state benign metastatic GDS1630.2.3.1 GDS1630.2.4.1 1.09 agent untreated mevalonate agent untreated atorvastatin GDS2767.7.8.0 GDS1362.0.1 -1.09 agent water red wine disease state non-failing heart non-ischemic cardiomyopathy GDS2643.0.3.5 GDS2643.0.1.5 1.08 disease state normal multiple myeloma disease state normal Waldenstrom's macroglobulinemia GDS2250.0.3 GDS2635.0.3 1.08 disease state normal basal-like cancer disease state lobular control invasive ductal carcinoma GDS2250.0.3 GDS2200.0.2 1.08 disease state normal basal-like cancer disease state normal squamous cell carcinoma GDS715.0.3.18 GDS715.0.6.18 1.08 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none 16-ketoestradiol GDS1956.0.9 GDS1956.0.1 1.08 disease state normal Calpain 3 mutation disease state normal acute quadriplegic myopathy GDS2649.4.5.1 GDS2649.2.5.1 1.08 disease state uninfected non-progressive HIV infection disease state uninfected early HIV infection GDS2333.0.2.3 GDS1783.0.2 1.07 infection uninfected delta pilD mutant agent control high potassium GDS1956.0.10 GDS1259.0.1 1.07 disease state normal dysferlin mutation disease state normal dermatomyositis GDS1331.0.1 GDS1331.0.2 1.06 disease state normal presymptomatic disease state normal symptomatic GDS1375.0.2 GDS1989.1.4.0 1.06 disease state normal malignant melanoma disease state normal melanoma in situ GDS1956.0.7 GDS1956.0.6 1.06 disease state normal Becker muscular dystrophy disease state normal Emery-Dreifuss muscular dystrophy GDS1617.0.5 GDS1617.0.3 1.06 agent control MGd/50uM zinc agent control MGd GDS1542.0.1 GDS2332.0.3 1.06 agent control tumor necrosis factor infection uninfected delta pilD mutant GDS1428.0.2.10 GDS1428.0.4.10 1.06 agent untreated heat-killed HL60 cell lysate agent untreated heat-killed Anaplasma phagocytophilum GDS2190.0.1 GDS810.0.2 1.06 disease state control bipolar disorder disease state control moderate AD GDS715.0.10.18 GDS715.2.4.18 -1.05 agent none pergolide methanesulfonate agent negative control a-methyl-L-p-tyrosine GDS2250.0.1 GDS2617.0.2 1.05 disease state normal non-basal-like cancer disease state normal tumorigenic cancer cell GDS1956.0.9 GDS1956.0.2 1.05 disease state normal Calpain 3 mutation disease state normal juvenile dermatomyositis GDS1428.0.1.10 GDS2255.3.4.0 1.05 agent untreated Staphylococcus aureus agent untreated endotoxin GDS2250.0.3 GDS1989.1.5.0 1.04 disease state normal basal-like cancer disease state normal vertical growth phase melanoma GDS2250.0.1 GDS1989.1.6.0 1.04 disease state normal non-basal-like cancer disease state normal metastatic growth phase melanoma GDS715.0.13.18 GDS715.2.10.18 1.04 agent none 8-(3-chlorostyryl) caffeine agent negative control pergolide methanesulfonate GDS1630.2.5.1 GDS1630.2.4.1 1.04 agent untreated atorvastatin and mevalonate agent untreated atorvastatin GDS1956.0.10 GDS1956.0.2 1.04 disease state normal dysferlin mutation disease state normal juvenile dermatomyositis GDS2250.0.3 GDS1989.1.6.0 1.03 disease state normal basal-like cancer disease state normal metastatic growth phase melanoma GDS715.2.9.18 GDS715.2.10.18 1.03 agent negative control 5-fluorouridine agent negative control pergolide methanesulfonate GDS2250.0.1 GDS2200.0.2 1.03 disease state normal non-basal-like cancer disease state normal squamous cell carcinoma GDS2332.1.2 GDS2332.1.3 1.03 infection wild type delta frpC/frpA mutant infection wild type delta pilD mutant GDS715.1.2.18 GDS715.2.14.18 1.03 agent negative control positive control agent negative control R-(-)-apomorphine HCl GDS715.2.14.18 GDS715.2.15.18 1.02 agent negative control R-(-)-apomorphine HCl agent negative control cyclazosin HCl GDS1617.0.1 GDS1617.0.2 1.02 agent control 25uM zinc agent control 50uM zinc GDS715.0.11.18 GDS715.0.13.18 1.02 agent none scopolamine methyl bromide agent none 8-(3-chlorostyryl) caffeine GDS715.0.12.18 GDS715.0.11.18 1.02 agent none 5-fluorouracil agent none scopolamine methyl bromide GDS2418.0.1 GDS1989.1.7.0 1.01 disease state control vulvar intraepithelial neoplasia disease state normal lymph node metastasis GDS2333.0.2.3 GDS1783.0.1 1.01 infection uninfected delta pilD mutant agent control thapsigargin GDS1313.0.1 GDS860.0.1 1.01 agent control TGFb1 agent untreated endothelin-1 GDS2250.0.1 GDS1312.0.1 1.01 disease state normal non-basal-like cancer disease state normal cancer GDS1956.0.7 GDS1956.0.2 1.01 disease state normal Becker muscular dystrophy disease state normal juvenile dermatomyositis GDS1956.0.9 GDS1259.0.1 1.01 disease state normal Calpain 3 mutation disease state normal dermatomyositis GDS2200.0.2 GDS1989.1.7.0 1.01 disease state normal squamous cell carcinoma disease state normal lymph node metastasis GDS715.1.2.18 GDS715.0.14.18 1.01 agent negative control positive control agent none R-(-)-apomorphine HCl GDS715.0.8.18 GDS715.0.3.18 1.00 agent none 1,10-phenanthroline agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2250.0.3 GDS1312.0.1 1.00 disease state normal basal-like cancer disease state normal cancer GDS715.2.6.18 GDS715.2.3.18 1.00 agent negative control 16-ketoestradiol agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1956.0.11 GDS1956.0.6 1.00 disease state normal FKRP mutation disease state normal Emery-Dreifuss muscular dystrophy GDS715.2.9.18 GDS715.2.14.18 1.00 agent negative control 5-fluorouridine agent negative control R-(-)-apomorphine HCl GDS715.0.15.18 GDS715.0.14.18 1.00 agent none cyclazosin HCl agent none R-(-)-apomorphine HCl GDS2250.0.1 GDS1989.1.7.0 1.00 disease state normal non-basal-like cancer disease state normal lymph node metastasis GDS715.0.9.18 GDS715.2.10.18 1.00 agent none 5-fluorouridine agent negative control pergolide methanesulfonate GDS2200.0.2 GDS1989.1.6.0 1.00 disease state normal squamous cell carcinoma disease state normal metastatic growth phase melanoma GDS1362.0.1 GDS2191.0.1 -1.00 disease state non-failing heart non-ischemic cardiomyopathy disease state control bipolar disorder GDS1428.0.1.10 GDS1428.0.5.10 1.00 agent untreated Staphylococcus aureus agent untreated Anaplasma phagocytophilum GDS715.0.8.18 GDS715.0.1.18 0.99 agent none 1,10-phenanthroline agent none positive control GDS2418.0.1 GDS2200.0.1 0.99 disease state control vulvar intraepithelial neoplasia disease state normal actinic keratosis GDS715.0.10.18 GDS715.0.11.18 0.99 agent none pergolide methanesulfonate agent none scopolamine methyl bromide GDS2250.0.3 GDS1375.0.2 0.99 disease state normal basal-like cancer disease state normal malignant melanoma GDS715.2.6.18 GDS715.2.8.18 0.99 agent negative control 16-ketoestradiol agent negative control 1,10-phenanthroline GDS2250.0.1 GDS1989.1.5.0 0.99 disease state normal non-basal-like cancer disease state normal vertical growth phase melanoma GDS715.0.5.18 GDS715.0.4.18 0.99 agent none sulmazole agent none a-methyl-L-p-tyrosine GDS1956.0.5 GDS1956.0.8 0.99 disease state normal fascioscapulohumeral muscular dystrophy disease state normal Duchenne muscular dystrophy GDS715.0.6.18 GDS715.0.1.18 0.98 agent none 16-ketoestradiol agent none positive control GDS1362.0.1 GDS1956.0.3 0.98 disease state non-failing heart non-ischemic cardiomyopathy disease state normal amyotophic lateral sclerosis GDS715.0.14.18 GDS715.0.3.18 0.98 agent none R-(-)-apomorphine HCl agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.14.18 GDS715.2.10.18 0.97 agent negative control R-(-)-apomorphine HCl agent negative control pergolide methanesulfonate GDS715.2.6.18 GDS715.2.7.18 0.97 agent negative control 16-ketoestradiol agent negative control 4,5-dianilinophthalimide GDS2200.0.1 GDS1989.1.6.0 0.97 disease state normal actinic keratosis disease state normal metastatic growth phase melanoma GDS2216.0.2.5 GDS2216.0.1.5 0.97 agent control CyP agent control LPS GDS2367.3.4.2 GDS1549.3.4.2 -0.97 infection control adenovirus adenovirus carrying estrogen receptor beta agent control estradiol GDS715.2.8.18 GDS715.2.3.18 0.97 agent negative control 1,10-phenanthroline agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.11.18 GDS715.2.12.18 0.97 agent negative control scopolamine methyl bromide agent negative control 5-fluorouracil GDS1392.0.2 GDS2118.0.1 0.97 disease state normal myelodysplastic syndrome disease state normal refractory anemia GDS2214.0.1 GDS1428.0.1.10 0.97 agent control lipopolysaccharide agent untreated Staphylococcus aureus GDS2767.5.8.0 GDS1362.0.1 -0.97 agent water alcohol disease state non-failing heart non-ischemic cardiomyopathy GDS2767.6.8.0 GDS1362.0.1 -0.97 agent water grape juice disease state non-failing heart non-ischemic cardiomyopathy GDS2250.0.2 GDS1989.1.5.0 0.96 disease state normal BRCA1-associated cancer disease state normal vertical growth phase melanoma GDS1428.0.5.10 GDS1428.0.4.10 0.96 agent untreated Anaplasma phagocytophilum agent untreated heat-killed Anaplasma phagocytophilum GDS715.2.15.18 GDS715.2.7.18 0.96 agent negative control cyclazosin HCl agent negative control 4,5-dianilinophthalimide GDS1362.0.1 GDS1956.0.5 0.96 disease state non-failing heart non-ischemic cardiomyopathy disease state normal fascioscapulohumeral muscular dystrophy GDS2767.7.8.0 GDS2191.0.1 0.96 agent water red wine disease state control bipolar disorder GDS715.2.6.18 GDS715.1.2.18 0.96 agent negative control 16-ketoestradiol agent negative control positive control GDS2418.0.1 GDS1989.1.6.0 0.95 disease state control vulvar intraepithelial neoplasia disease state normal metastatic growth phase melanoma GDS715.2.4.18 GDS715.2.5.18 0.95 agent negative control a-methyl-L-p-tyrosine agent negative control sulmazole GDS1362.0.2 GDS2205.0.1 0.95 disease state non-failing heart ischemic cardiomyopathy disease state non-failing dilated cardiomyopathy GDS2250.0.1 GDS1375.0.2 0.95 disease state normal non-basal-like cancer disease state normal malignant melanoma GDS715.0.13.18 GDS715.2.4.18 -0.95 agent none 8-(3-chlorostyryl) caffeine agent negative control a-methyl-L-p-tyrosine GDS1989.1.6.0 GDS1989.1.2.0 0.95 disease state normal metastatic growth phase melanoma disease state normal benign nevus GDS2213.0.2 GDS2213.0.3 0.95 agent untreated TSA agent untreated 5-aza-dC plus TSA GDS2367.0.2.3 GDS2250.0.3 0.95 agent vehicle tamoxifen disease state normal basal-like cancer GDS2367.0.2.3 GDS1439.0.2 0.95 agent vehicle tamoxifen disease state benign metastatic GDS2418.0.1 GDS1989.1.5.0 0.94 disease state control vulvar intraepithelial neoplasia disease state normal vertical growth phase melanoma GDS2250.0.2 GDS2635.0.3 0.94 disease state normal BRCA1-associated cancer disease state lobular control invasive ductal carcinoma GDS715.2.9.18 GDS715.2.13.18 0.94 agent negative control 5-fluorouridine agent negative control 8-(3-chlorostyryl) caffeine GDS715.0.6.18 GDS715.0.7.18 0.94 agent none 16-ketoestradiol agent none 4,5-dianilinophthalimide GDS715.0.7.18 GDS715.0.15.18 0.94 agent none 4,5-dianilinophthalimide agent none cyclazosin HCl GDS2118.0.2 GDS1392.0.2 0.94 disease state normal refractory anemia with ringed sideroblasts disease state normal myelodysplastic syndrome GDS1543.0.1 GDS2414.0.1.4 0.94 agent control tumor necrosis factor agent control trophoblast conditioned medium GDS2200.0.2 GDS1989.1.5.0 0.94 disease state normal squamous cell carcinoma disease state normal vertical growth phase melanoma GDS1392.0.2 GDS2118.0.3 0.94 disease state normal myelodysplastic syndrome disease state normal refractory anemia with excess blasts GDS1375.0.1 GDS1989.1.4.0 0.94 disease state normal benign nevi disease state normal melanoma in situ GDS2250.0.2 GDS1989.1.7.0 0.93 disease state normal BRCA1-associated cancer disease state normal lymph node metastasis GDS2250.0.3 GDS2617.0.1 0.93 disease state normal basal-like cancer disease state normal non-tumorigenic cancer cell GDS715.2.7.18 GDS715.2.3.18 0.93 agent negative control 4,5-dianilinophthalimide agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.10.18 GDS715.0.12.18 0.93 agent negative control pergolide methanesulfonate agent none 5-fluorouracil GDS715.0.4.18 GDS715.0.8.18 0.93 agent none a-methyl-L-p-tyrosine agent none 1,10-phenanthroline GDS2250.0.1 GDS2635.0.2 0.93 disease state normal non-basal-like cancer disease state lobular control invasive lobular carcinoma GDS1439.0.2 GDS2250.0.3 0.93 disease state benign metastatic disease state normal basal-like cancer GDS715.2.3.18 GDS715.1.2.18 0.93 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control positive control GDS2307.0.1 GDS2307.0.2 0.92 agent untreated LDL agent untreated ox-LDL GDS2250.0.3 GDS1989.1.4.0 0.92 disease state normal basal-like cancer disease state normal melanoma in situ GDS1050.2.3.0 GDS1050.0.1.2 0.92 agent untreated valproic acid disease state normal polycystic ovary syndrome GDS715.2.12.18 GDS715.2.10.18 0.92 agent negative control 5-fluorouracil agent negative control pergolide methanesulfonate GDS1956.0.11 GDS1956.0.2 0.92 disease state normal FKRP mutation disease state normal juvenile dermatomyositis GDS2216.0.1.5 GDS2221.1.3 0.92 agent control LPS agent vehicle lipopolysaccharide GDS1956.0.3 GDS1956.0.8 0.92 disease state normal amyotophic lateral sclerosis disease state normal Duchenne muscular dystrophy GDS715.0.14.18 GDS715.0.7.18 0.92 agent none R-(-)-apomorphine HCl agent none 4,5-dianilinophthalimide GDS2649.2.5.1 GDS2250.0.1 0.92 disease state uninfected early HIV infection disease state normal non-basal-like cancer GDS715.2.7.18 GDS715.1.2.18 0.92 agent negative control 4,5-dianilinophthalimide agent negative control positive control GDS1574.8.9.12 GDS1615.0.2 0.91 agent control endotoxin disease state normal Crohn's disease GDS715.2.14.18 GDS715.2.3.18 0.91 agent negative control R-(-)-apomorphine HCl agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2216.0.3.5 GDS2216.0.1.5 0.91 agent control CyP plus LPS agent control LPS GDS1971.0.1 GDS1615.0.2 0.91 disease state healthy uncomplicated malaria disease state normal Crohn's disease GDS2214.0.2 GDS1428.0.1.10 0.91 agent control HMGB1 agent untreated Staphylococcus aureus GDS2367.3.4.2 GDS2250.0.1 -0.91 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal non-basal-like cancer GDS2367.3.4.2 GDS2737.0.1.3 -0.91 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal endometriosis GDS2341.0.3.5 GDS2611.0.3.9 0.91 agent untreated Types I and II IFNs agent untreated IFN-gamma GDS2643.0.2.4 GDS2643.0.1.4 0.91 disease state normal chronic lymphocytic leukemia disease state normal Waldenstrom's macroglobulinemia GDS1956.0.10 GDS1956.0.1 0.91 disease state normal dysferlin mutation disease state normal acute quadriplegic myopathy GDS2649.2.5.1 GDS2250.0.3 0.91 disease state uninfected early HIV infection disease state normal basal-like cancer GDS2250.0.2 GDS1989.1.6.0 0.90 disease state normal BRCA1-associated cancer disease state normal metastatic growth phase melanoma GDS1574.8.9.12 GDS1971.0.1 0.90 agent control endotoxin disease state healthy uncomplicated malaria GDS2250.0.3 GDS2617.0.2 0.90 disease state normal basal-like cancer disease state normal tumorigenic cancer cell GDS715.2.4.18 GDS715.2.8.18 0.90 agent negative control a-methyl-L-p-tyrosine agent negative control 1,10-phenanthroline GDS715.2.9.18 GDS715.0.12.18 0.90 agent negative control 5-fluorouridine agent none 5-fluorouracil GDS1362.0.1 GDS1783.0.2 0.90 disease state non-failing heart non-ischemic cardiomyopathy agent control high potassium GDS2332.1.2 GDS1353.0.1.2 0.90 infection wild type delta frpC/frpA mutant agent control dexamethasone GDS1259.0.1 GDS1956.0.6 0.89 disease state normal dermatomyositis disease state normal Emery-Dreifuss muscular dystrophy GDS715.0.8.18 GDS715.0.15.18 0.89 agent none 1,10-phenanthroline agent none cyclazosin HCl GDS1989.1.3.0 GDS1989.1.6.0 0.89 disease state normal atypical nevus disease state normal metastatic growth phase melanoma GDS2652.0.1 GDS2652.0.2 0.89 agent control ARA and low DHA agent control ARA and high DHA GDS715.2.7.18 GDS715.2.14.18 0.89 agent negative control 4,5-dianilinophthalimide agent negative control R-(-)-apomorphine HCl GDS715.0.9.18 GDS715.2.14.18 0.89 agent none 5-fluorouridine agent negative control R-(-)-apomorphine HCl GDS715.0.9.18 GDS715.0.13.18 0.89 agent none 5-fluorouridine agent none 8-(3-chlorostyryl) caffeine GDS715.2.8.18 GDS715.2.15.18 0.89 agent negative control 1,10-phenanthroline agent negative control cyclazosin HCl GDS2611.0.2.9 GDS2611.0.3.9 0.89 agent untreated IL-1b agent untreated IFN-gamma GDS2367.3.4.2 GDS715.1.2.18 0.89 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control positive control GDS715.2.8.18 GDS715.1.2.18 0.89 agent negative control 1,10-phenanthroline agent negative control positive control GDS715.2.4.18 GDS715.2.15.18 0.88 agent negative control a-methyl-L-p-tyrosine agent negative control cyclazosin HCl GDS2367.3.4.2 GDS1439.0.2 -0.88 infection control adenovirus adenovirus carrying estrogen receptor beta disease state benign metastatic GDS2367.3.4.2 GDS2250.0.3 -0.88 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal basal-like cancer GDS715.0.8.18 GDS715.0.14.18 0.87 agent none 1,10-phenanthroline agent none R-(-)-apomorphine HCl GDS2418.0.1 GDS2250.0.2 0.87 disease state control vulvar intraepithelial neoplasia disease state normal BRCA1-associated cancer GDS1989.1.3.0 GDS1989.1.7.0 0.87 disease state normal atypical nevus disease state normal lymph node metastasis GDS2333.0.2.3 GDS2643.0.3.5 0.87 infection uninfected delta pilD mutant disease state normal multiple myeloma GDS2397.0.1 GDS2118.0.1 0.87 disease state normal idiopathic myelofibrosis disease state normal refractory anemia GDS715.0.5.18 GDS715.0.8.18 0.87 agent none sulmazole agent none 1,10-phenanthroline GDS2367.3.4.1 GDS715.0.1.18 0.87 infection control adenovirus adenovirus carrying estrogen receptor beta agent none positive control GDS1375.0.1 GDS1989.1.7.0 0.87 disease state normal benign nevi disease state normal lymph node metastasis GDS2635.0.1 GDS2635.0.3 0.87 disease state lobular control ductal control disease state lobular control invasive ductal carcinoma GDS2767.6.8.0 GDS2643.0.1.5 -0.87 agent water grape juice disease state normal Waldenstrom's macroglobulinemia GDS2649.2.5.1 GDS2418.0.1 0.87 disease state uninfected early HIV infection disease state control vulvar intraepithelial neoplasia GDS2367.0.1.3 GDS715.1.2.18 -0.87 agent vehicle estradiol agent negative control positive control GDS715.0.10.18 GDS715.0.1.18 0.86 agent none pergolide methanesulfonate agent none positive control GDS2250.0.2 GDS2200.0.2 0.86 disease state normal BRCA1-associated cancer disease state normal squamous cell carcinoma GDS2200.0.1 GDS1989.1.7.0 0.86 disease state normal actinic keratosis disease state normal lymph node metastasis GDS1617.0.1 GDS1617.0.5 0.86 agent control 25uM zinc agent control MGd/50uM zinc GDS1447.0.2 GDS1447.0.1 0.86 agent control zinc agent control vanadium GDS715.0.5.18 GDS715.0.6.18 0.86 agent none sulmazole agent none 16-ketoestradiol GDS1956.0.7 GDS1259.0.1 0.86 disease state normal Becker muscular dystrophy disease state normal dermatomyositis GDS2200.0.2 GDS1375.0.2 0.86 disease state normal squamous cell carcinoma disease state normal malignant melanoma GDS715.2.5.18 GDS715.2.7.18 0.86 agent negative control sulmazole agent negative control 4,5-dianilinophthalimide GDS2367.0.2.3 GDS2418.0.1 0.86 agent vehicle tamoxifen disease state control vulvar intraepithelial neoplasia GDS2367.0.2.3 GDS2737.0.1.3 0.86 agent vehicle tamoxifen disease state normal endometriosis GDS1956.0.1 GDS1956.0.11 0.86 disease state normal acute quadriplegic myopathy disease state normal FKRP mutation GDS2057.0.1.4 GDS715.1.2.18 -0.86 agent control DHT agent negative control positive control GDS715.0.1.18 GDS715.2.3.18 0.85 agent none positive control agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.14.18 GDS715.2.8.18 0.85 agent negative control R-(-)-apomorphine HCl agent negative control 1,10-phenanthroline GDS2333.0.2.3 GDS1362.0.1 0.85 infection uninfected delta pilD mutant disease state non-failing heart non-ischemic cardiomyopathy GDS715.0.4.18 GDS715.0.6.18 0.85 agent none a-methyl-L-p-tyrosine agent none 16-ketoestradiol GDS715.0.4.18 GDS715.0.15.18 0.85 agent none a-methyl-L-p-tyrosine agent none cyclazosin HCl GDS715.0.6.18 GDS715.0.14.18 0.85 agent none 16-ketoestradiol agent none R-(-)-apomorphine HCl GDS1405.0.1 GDS1312.0.1 -0.85 agent untreated DCI disease state normal cancer GDS1542.0.1 GDS2332.0.2 0.85 agent control tumor necrosis factor infection uninfected delta frpC/frpA mutant GDS1312.0.1 GDS2200.0.2 0.85 disease state normal cancer disease state normal squamous cell carcinoma GDS2767.5.8.4 GDS2643.0.1.5 -0.85 agent water alcohol disease state normal Waldenstrom's macroglobulinemia GDS2767.6.8.0 GDS1331.0.1 -0.85 agent water grape juice disease state normal presymptomatic GDS2649.2.5.1 GDS1312.0.1 0.85 disease state uninfected early HIV infection disease state normal cancer GDS2767.7.8.0 GDS2643.0.1.5 -0.85 agent water red wine disease state normal Waldenstrom's macroglobulinemia GDS715.0.1.18 GDS715.0.15.18 0.84 agent none positive control agent none cyclazosin HCl GDS715.0.10.18 GDS715.2.5.18 -0.84 agent none pergolide methanesulfonate agent negative control sulmazole GDS1783.0.1 GDS2643.0.3.5 0.84 agent control thapsigargin disease state normal multiple myeloma GDS2367.0.1.3 GDS2250.0.3 0.84 agent vehicle estradiol disease state normal basal-like cancer GDS715.2.4.18 GDS715.2.3.18 0.84 agent negative control a-methyl-L-p-tyrosine agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.10.18 GDS715.2.4.18 -0.84 agent negative control pergolide methanesulfonate agent negative control a-methyl-L-p-tyrosine GDS2205.0.1 GDS1362.0.1 0.84 disease state non-failing dilated cardiomyopathy disease state non-failing heart non-ischemic cardiomyopathy GDS715.0.5.18 GDS715.0.7.18 0.84 agent none sulmazole agent none 4,5-dianilinophthalimide GDS715.0.13.18 GDS715.2.5.18 -0.84 agent none 8-(3-chlorostyryl) caffeine agent negative control sulmazole GDS715.0.9.18 GDS715.0.1.18 0.84 agent none 5-fluorouridine agent none positive control GDS2221.0.3 GDS2216.0.1.5 0.84 agent untreated lipopolysaccharide agent control LPS GDS1257.0.1 GDS1257.0.2 0.84 disease state normal SCD with acute chest syndrome disease state normal SCD steady state GDS1989.1.5.0 GDS1989.1.3.0 0.84 disease state normal vertical growth phase melanoma disease state normal atypical nevus GDS715.2.5.18 GDS715.2.8.18 0.84 agent negative control sulmazole agent negative control 1,10-phenanthroline GDS1362.0.1 GDS1956.0.2 0.84 disease state non-failing heart non-ischemic cardiomyopathy disease state normal juvenile dermatomyositis GDS1428.0.1.10 GDS1428.0.2.10 -0.84 agent untreated Staphylococcus aureus agent untreated heat-killed HL60 cell lysate GDS2341.0.1.4 GDS2611.0.3.9 0.84 agent untreated Type I IFN agent untreated IFN-gamma GDS2767.5.8.0 GDS2643.0.3.5 -0.84 agent water alcohol disease state normal multiple myeloma GDS2767.7.8.0 GDS1331.0.1 -0.84 agent water red wine disease state normal presymptomatic GDS2367.0.2.3 GDS715.1.2.18 -0.84 agent vehicle tamoxifen agent negative control positive control GDS2250.0.2 GDS1439.0.2 0.83 disease state normal BRCA1-associated cancer disease state benign metastatic GDS2367.0.1.3 GDS715.0.1.18 -0.83 agent vehicle estradiol agent none positive control GDS1331.0.1 GDS1362.0.1 0.83 disease state normal presymptomatic disease state non-failing heart non-ischemic cardiomyopathy GDS2250.0.1 GDS1665.0.1 0.83 disease state normal non-basal-like cancer disease state normal papillary thyroid carcinoma GDS1331.0.2 GDS1362.0.1 0.83 disease state normal symptomatic disease state non-failing heart non-ischemic cardiomyopathy GDS2216.0.1.5 GDS2221.1.2 0.83 agent control LPS agent vehicle galectin-1 GDS715.2.11.18 GDS715.2.10.18 0.83 agent negative control scopolamine methyl bromide agent negative control pergolide methanesulfonate GDS2367.0.2.3 GDS2250.0.1 0.83 agent vehicle tamoxifen disease state normal non-basal-like cancer GDS1375.0.1 GDS1989.1.5.0 0.83 disease state normal benign nevi disease state normal vertical growth phase melanoma GDS2332.1.2 GDS1956.0.4 -0.83 infection wild type delta frpC/frpA mutant disease state normal spastic paraplegia GDS715.0.14.18 GDS715.2.10.18 0.83 agent none R-(-)-apomorphine HCl agent negative control pergolide methanesulfonate GDS2767.6.8.0 GDS2643.0.3.5 -0.83 agent water grape juice disease state normal multiple myeloma GDS1956.0.11 GDS2153.0.1 0.82 disease state normal FKRP mutation disease state normal dermatomyositis GDS2341.0.1.5 GDS1956.0.2 0.82 agent untreated Type I IFN disease state normal juvenile dermatomyositis GDS2367.3.4.2 GDS2250.0.2 -0.82 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal BRCA1-associated cancer GDS2250.0.1 GDS1667.0.1 0.82 disease state normal non-basal-like cancer infection HPV negative HPV positive GDS2250.0.1 GDS1989.1.4.0 0.82 disease state normal non-basal-like cancer disease state normal melanoma in situ GDS1331.0.2 GDS2643.0.1.5 0.82 disease state normal symptomatic disease state normal Waldenstrom's macroglobulinemia GDS1971.0.2 GDS1615.0.2 0.82 disease state healthy complicated malaria disease state normal Crohn's disease GDS2255.3.4.0 GDS1428.0.5.10 0.82 agent untreated endotoxin agent untreated Anaplasma phagocytophilum GDS2214.0.1 GDS1428.0.2.10 -0.82 agent control lipopolysaccharide agent untreated heat-killed HL60 cell lysate GDS2649.2.5.1 GDS2617.0.2 0.82 disease state uninfected early HIV infection disease state normal tumorigenic cancer cell GDS715.1.2.18 GDS715.0.15.18 0.82 agent negative control positive control agent none cyclazosin HCl GDS2767.7.8.0 GDS2643.0.3.5 -0.82 agent water red wine disease state normal multiple myeloma GDS2611.0.1.9 GDS2611.0.3.9 0.81 agent untreated keratinocyte growth factor agent untreated IFN-gamma GDS1375.0.2 GDS1989.1.2.0 0.81 disease state normal malignant melanoma disease state normal benign nevus GDS2213.0.1 GDS2213.0.2 0.81 agent untreated 5-aza-dC agent untreated TSA GDS2341.0.3.5 GDS2414.0.1.4 0.81 agent untreated Types I and II IFNs agent control trophoblast conditioned medium GDS2611.0.2.9 GDS2200.0.2 0.81 agent untreated IL-1b disease state normal squamous cell carcinoma GDS1375.0.1 GDS1989.1.6.0 0.81 disease state normal benign nevi disease state normal metastatic growth phase melanoma GDS2221.0.2 GDS2216.0.1.5 0.81 agent untreated galectin-1 agent control LPS GDS1956.0.3 GDS1956.0.9 0.81 disease state normal amyotophic lateral sclerosis disease state normal Calpain 3 mutation GDS1956.0.3 GDS1956.0.11 0.81 disease state normal amyotophic lateral sclerosis disease state normal FKRP mutation GDS2767.7.8.0 GDS1783.0.1 -0.81 agent water red wine agent control thapsigargin GDS2767.7.8.0 GDS715.2.4.18 0.81 agent water red wine agent negative control a-methyl-L-p-tyrosine GDS715.2.14.18 GDS715.2.12.18 0.80 agent negative control R-(-)-apomorphine HCl agent negative control 5-fluorouracil GDS1783.0.1 GDS1362.0.2 0.80 agent control thapsigargin disease state non-failing heart ischemic cardiomyopathy GDS1783.0.1 GDS1362.0.1 0.80 agent control thapsigargin disease state non-failing heart non-ischemic cardiomyopathy GDS715.2.4.18 GDS715.2.6.18 0.80 agent negative control a-methyl-L-p-tyrosine agent negative control 16-ketoestradiol GDS715.0.4.18 GDS715.0.3.18 0.80 agent none a-methyl-L-p-tyrosine agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1667.0.1 GDS2418.0.1 0.80 infection HPV negative HPV positive disease state control vulvar intraepithelial neoplasia GDS715.0.5.18 GDS715.0.3.18 0.80 agent none sulmazole agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1439.0.2 GDS1989.1.7.0 0.80 disease state benign metastatic disease state normal lymph node metastasis GDS2341.0.3.5 GDS1321.0.2 0.80 agent untreated Types I and II IFNs disease state normal adenocarcinoma GDS1956.0.7 GDS1956.0.1 0.80 disease state normal Becker muscular dystrophy disease state normal acute quadriplegic myopathy GDS2367.0.2.3 GDS1312.0.1 0.80 agent vehicle tamoxifen disease state normal cancer GDS1783.0.2 GDS1362.0.2 0.80 agent control high potassium disease state non-failing heart ischemic cardiomyopathy GDS2255.3.4.0 GDS2332.0.3 0.80 agent untreated endotoxin infection uninfected delta pilD mutant GDS2255.3.4.0 GDS1428.0.2.10 -0.80 agent untreated endotoxin agent untreated heat-killed HL60 cell lysate GDS2649.2.5.1 GDS715.1.2.18 -0.80 disease state uninfected early HIV infection agent negative control positive control GDS2767.5.8.4 GDS1331.0.1 -0.80 agent water alcohol disease state normal presymptomatic GDS2767.6.8.0 GDS1362.0.2 -0.80 agent water grape juice disease state non-failing heart ischemic cardiomyopathy GDS715.1.2.18 GDS715.0.8.18 0.80 agent negative control positive control agent none 1,10-phenanthroline GDS2767.7.8.0 GDS1783.0.2 -0.80 agent water red wine agent control high potassium GDS2767.7.8.0 GDS1362.0.2 -0.80 agent water red wine disease state non-failing heart ischemic cardiomyopathy GDS2418.0.1 GDS1375.0.2 0.79 disease state control vulvar intraepithelial neoplasia disease state normal malignant melanoma GDS715.0.10.18 GDS715.0.6.18 0.79 agent none pergolide methanesulfonate agent none 16-ketoestradiol GDS2200.0.1 GDS1989.1.5.0 0.79 disease state normal actinic keratosis disease state normal vertical growth phase melanoma GDS2367.3.4.2 GDS1630.2.4.1 0.79 infection control adenovirus adenovirus carrying estrogen receptor beta agent untreated atorvastatin GDS2250.0.1 GDS2737.0.1.3 0.79 disease state normal non-basal-like cancer disease state normal endometriosis GDS2341.0.3.4 GDS2216.0.1.5 0.79 agent untreated Types I and II IFNs agent control LPS GDS2341.0.2.5 GDS2414.0.1.4 0.79 agent untreated Type II IFN agent control trophoblast conditioned medium GDS2367.3.4.1 GDS2418.0.1 -0.79 infection control adenovirus adenovirus carrying estrogen receptor beta disease state control vulvar intraepithelial neoplasia GDS715.2.5.18 GDS715.2.6.18 0.79 agent negative control sulmazole agent negative control 16-ketoestradiol GDS1362.0.1 GDS1956.0.6 0.79 disease state non-failing heart non-ischemic cardiomyopathy disease state normal Emery-Dreifuss muscular dystrophy GDS1312.0.1 GDS2250.0.2 0.79 disease state normal cancer disease state normal BRCA1-associated cancer GDS2333.1.2.3 GDS1362.0.1 0.79 infection wild type delta pilD mutant disease state non-failing heart non-ischemic cardiomyopathy GDS2332.1.2 GDS1362.0.1 0.79 infection wild type delta frpC/frpA mutant disease state non-failing heart non-ischemic cardiomyopathy GDS715.2.13.18 GDS715.0.12.18 0.79 agent negative control 8-(3-chlorostyryl) caffeine agent none 5-fluorouracil GDS2767.6.8.0 GDS1783.0.2 -0.79 agent water grape juice agent control high potassium GDS2649.2.5.1 GDS2617.0.1 0.79 disease state uninfected early HIV infection disease state normal non-tumorigenic cancer cell GDS2767.7.8.0 GDS2332.1.2 -0.79 agent water red wine infection wild type delta frpC/frpA mutant GDS2250.0.2 GDS1375.0.2 0.78 disease state normal BRCA1-associated cancer disease state normal malignant melanoma GDS2250.0.2 GDS2617.0.1 0.78 disease state normal BRCA1-associated cancer disease state normal non-tumorigenic cancer cell GDS1783.0.1 GDS1926.0.2.4 0.78 agent control thapsigargin agent control LTD4 GDS2367.0.1.3 GDS1439.0.2 0.78 agent vehicle estradiol disease state benign metastatic GDS715.0.8.16 GDS2643.0.1.5 -0.78 agent none 1,10-phenanthroline disease state normal Waldenstrom's macroglobulinemia GDS2341.0.1.5 GDS1259.0.1 0.78 agent untreated Type I IFN disease state normal dermatomyositis GDS715.0.3.18 GDS715.0.15.18 0.78 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none cyclazosin HCl GDS1439.0.2 GDS1312.0.1 0.78 disease state benign metastatic disease state normal cancer GDS2341.0.3.5 GDS1321.0.1 0.78 agent untreated Types I and II IFNs disease state normal Barrett's esophagus GDS2341.0.3.5 GDS2221.0.3 0.78 agent untreated Types I and II IFNs agent untreated lipopolysaccharide GDS2341.0.2.5 GDS1321.0.2 0.78 agent untreated Type II IFN disease state normal adenocarcinoma GDS2341.0.2.5 GDS2611.0.3.9 0.78 agent untreated Type II IFN agent untreated IFN-gamma GDS1956.0.7 GDS1956.0.5 0.78 disease state normal Becker muscular dystrophy disease state normal fascioscapulohumeral muscular dystrophy GDS715.2.11.18 GDS715.2.14.18 0.78 agent negative control scopolamine methyl bromide agent negative control R-(-)-apomorphine HCl GDS2367.0.2.3 GDS715.0.1.18 -0.78 agent vehicle tamoxifen agent none positive control GDS1375.0.1 GDS1989.1.2.0 0.78 disease state normal benign nevi disease state normal benign nevus GDS1362.0.1 GDS1665.0.1 -0.78 disease state non-failing heart non-ischemic cardiomyopathy disease state normal papillary thyroid carcinoma GDS1956.0.5 GDS2153.0.1 0.78 disease state normal fascioscapulohumeral muscular dystrophy disease state normal dermatomyositis GDS690.2.3.0 GDS1362.0.1 0.78 agent control flagellin disease state non-failing heart non-ischemic cardiomyopathy GDS1956.0.10 GDS1956.0.5 0.78 disease state normal dysferlin mutation disease state normal fascioscapulohumeral muscular dystrophy GDS715.0.12.18 GDS715.0.14.18 0.78 agent none 5-fluorouracil agent none R-(-)-apomorphine HCl GDS2767.5.8.0 GDS2191.0.1 0.78 agent water alcohol disease state control bipolar disorder GDS2767.6.8.0 GDS1783.0.1 -0.78 agent water grape juice agent control thapsigargin GDS2649.2.5.1 GDS2635.0.3 0.78 disease state uninfected early HIV infection disease state lobular control invasive ductal carcinoma GDS2649.2.5.1 GDS2250.0.2 0.78 disease state uninfected early HIV infection disease state normal BRCA1-associated cancer GDS715.1.2.18 GDS715.2.15.18 0.78 agent negative control positive control agent negative control cyclazosin HCl GDS2767.7.8.0 GDS1956.0.3 -0.78 agent water red wine disease state normal amyotophic lateral sclerosis GDS2418.0.1 GDS1439.0.2 0.77 disease state control vulvar intraepithelial neoplasia disease state benign metastatic GDS2643.0.3.5 GDS690.2.4.1 0.77 disease state normal multiple myeloma agent control LTb GDS2643.0.3.5 GDS1783.0.2 0.77 disease state normal multiple myeloma agent control high potassium GDS2250.0.3 GDS1439.0.1 0.77 disease state normal basal-like cancer disease state benign primary GDS715.2.4.18 GDS715.0.12.18 -0.77 agent negative control a-methyl-L-p-tyrosine agent none 5-fluorouracil GDS2333.0.2.3 GDS2643.0.1.5 0.77 infection uninfected delta pilD mutant disease state normal Waldenstrom's macroglobulinemia GDS715.0.4.18 GDS715.0.7.18 0.77 agent none a-methyl-L-p-tyrosine agent none 4,5-dianilinophthalimide GDS715.0.15.18 GDS715.2.7.18 0.77 agent none cyclazosin HCl agent negative control 4,5-dianilinophthalimide GDS2367.3.4.2 GDS2617.0.1 -0.77 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal non-tumorigenic cancer cell GDS2250.0.1 GDS1549.3.4.1 0.77 disease state normal non-basal-like cancer agent control estradiol GDS1956.0.8 GDS1989.1.3.0 -0.77 disease state normal Duchenne muscular dystrophy disease state normal atypical nevus GDS1439.0.2 GDS2635.0.3 0.77 disease state benign metastatic disease state lobular control invasive ductal carcinoma GDS1331.0.2 GDS2414.0.1.3 0.77 disease state normal symptomatic agent control trophoblast conditioned medium GDS715.2.5.18 GDS715.2.15.18 0.77 agent negative control sulmazole agent negative control cyclazosin HCl GDS2190.0.1 GDS810.0.3 0.77 disease state control bipolar disorder disease state control severe AD GDS2635.0.2 GDS2250.0.2 0.76 disease state lobular control invasive lobular carcinoma disease state normal BRCA1-associated cancer GDS2418.0.1 GDS2635.0.3 0.76 disease state control vulvar intraepithelial neoplasia disease state lobular control invasive ductal carcinoma GDS2250.0.2 GDS1989.1.4.0 0.76 disease state normal BRCA1-associated cancer disease state normal melanoma in situ GDS1574.8.9.12 GDS1971.0.2 0.76 agent control endotoxin disease state healthy complicated malaria GDS715.2.14.18 GDS715.2.6.18 0.76 agent negative control R-(-)-apomorphine HCl agent negative control 16-ketoestradiol GDS2643.0.1.5 GDS715.0.4.18 -0.76 disease state normal Waldenstrom's macroglobulinemia agent none a-methyl-L-p-tyrosine GDS715.2.4.18 GDS715.0.5.18 0.76 agent negative control a-methyl-L-p-tyrosine agent none sulmazole GDS715.0.8.16 GDS2643.0.3.5 -0.76 agent none 1,10-phenanthroline disease state normal multiple myeloma GDS2367.3.4.2 GDS1326.2.3.1 0.76 infection control adenovirus adenovirus carrying estrogen receptor beta agent control E2 GDS715.0.9.18 GDS715.0.3.18 0.76 agent none 5-fluorouridine agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1428.0.5.10 GDS1428.0.2.10 0.76 agent untreated Anaplasma phagocytophilum agent untreated heat-killed HL60 cell lysate GDS1331.0.2 GDS2643.0.3.5 0.76 disease state normal symptomatic disease state normal multiple myeloma GDS1543.0.1 GDS2216.0.1.5 0.76 agent control tumor necrosis factor agent control LPS GDS2367.0.2.3 GDS2250.0.2 0.76 agent vehicle tamoxifen disease state normal BRCA1-associated cancer GDS2767.5.8.0 GDS1362.0.2 -0.76 agent water alcohol disease state non-failing heart ischemic cardiomyopathy GDS2367.0.2.3 GDS2649.2.5.1 0.76 agent vehicle tamoxifen disease state uninfected early HIV infection GDS2250.0.3 GDS1665.0.1 0.75 disease state normal basal-like cancer disease state normal papillary thyroid carcinoma GDS1783.0.1 GDS2414.0.1.3 0.75 agent control thapsigargin agent control trophoblast conditioned medium GDS2643.0.1.5 GDS715.2.4.18 -0.75 disease state normal Waldenstrom's macroglobulinemia agent negative control a-methyl-L-p-tyrosine GDS2643.0.1.5 GDS715.0.6.16 -0.75 disease state normal Waldenstrom's macroglobulinemia agent none 16-ketoestradiol GDS2367.0.1.3 GDS2737.0.1.3 0.75 agent vehicle estradiol disease state normal endometriosis GDS2367.0.1.3 GDS1312.0.1 0.75 agent vehicle estradiol disease state normal cancer GDS715.2.10.18 GDS715.0.11.18 0.75 agent negative control pergolide methanesulfonate agent none scopolamine methyl bromide GDS1956.0.11 GDS1956.0.5 0.75 disease state normal FKRP mutation disease state normal fascioscapulohumeral muscular dystrophy GDS1331.0.1 GDS2255.3.4.0 -0.75 disease state normal presymptomatic agent untreated endotoxin GDS2214.0.2 GDS1428.0.2.10 -0.75 agent control HMGB1 agent untreated heat-killed HL60 cell lysate GDS2367.3.4.2 GDS2617.0.2 -0.75 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal tumorigenic cancer cell GDS2635.0.3 GDS1989.1.7.0 0.75 disease state lobular control invasive ductal carcinoma disease state normal lymph node metastasis GDS2697.0.1 GDS2643.0.3.5 -0.75 disease state normal teratozoospermia disease state normal multiple myeloma GDS715.2.5.18 GDS715.2.3.18 0.75 agent negative control sulmazole agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1362.0.1 GDS2118.0.2 -0.75 disease state non-failing heart non-ischemic cardiomyopathy disease state normal refractory anemia with ringed sideroblasts GDS1783.0.2 GDS1220.0.1.3 0.75 agent control high potassium disease state normal malignant pleural mesothelioma GDS1783.0.2 GDS1956.0.5 0.75 agent control high potassium disease state normal fascioscapulohumeral muscular dystrophy GDS715.0.14.18 GDS715.0.11.18 0.75 agent none R-(-)-apomorphine HCl agent none scopolamine methyl bromide GDS2767.5.8.0 GDS1783.0.2 -0.75 agent water alcohol agent control high potassium GDS2767.5.8.0 GDS2255.3.4.0 0.75 agent water alcohol agent untreated endotoxin GDS2767.5.8.4 GDS715.2.4.18 0.75 agent water alcohol agent negative control a-methyl-L-p-tyrosine GDS2767.6.8.0 GDS2333.0.2.4 -0.75 agent water grape juice infection uninfected delta pilD mutant GDS2649.2.5.1 GDS2118.0.3 -0.75 disease state uninfected early HIV infection disease state normal refractory anemia with excess blasts GDS2767.7.8.0 GDS2333.0.2.4 -0.75 agent water red wine infection uninfected delta pilD mutant GDS2367.3.4.2 GDS2649.2.5.1 -0.75 infection control adenovirus adenovirus carrying estrogen receptor beta disease state uninfected early HIV infection GDS1549.3.4.2 GDS715.1.2.18 -0.75 agent control estradiol agent negative control positive control GDS2635.0.2 GDS2617.0.2 0.74 disease state lobular control invasive lobular carcinoma disease state normal tumorigenic cancer cell GDS2250.0.3 GDS2737.0.1.3 0.74 disease state normal basal-like cancer disease state normal endometriosis GDS1783.0.1 GDS1956.0.5 0.74 agent control thapsigargin disease state normal fascioscapulohumeral muscular dystrophy GDS2333.0.2.3 GDS1362.0.2 0.74 infection uninfected delta pilD mutant disease state non-failing heart ischemic cardiomyopathy GDS715.0.8.16 GDS715.2.4.18 0.74 agent none 1,10-phenanthroline agent negative control a-methyl-L-p-tyrosine GDS715.0.13.18 GDS715.0.4.18 -0.74 agent none 8-(3-chlorostyryl) caffeine agent none a-methyl-L-p-tyrosine GDS2221.0.3 GDS1427.0.2 -0.74 agent untreated lipopolysaccharide infection control v-Myb GDS2341.0.3.5 GDS2221.0.2 0.74 agent untreated Types I and II IFNs agent untreated galectin-1 GDS1331.0.2 GDS2332.1.2 0.74 disease state normal symptomatic infection wild type delta frpC/frpA mutant GDS1926.0.3.4 GDS2332.0.2 0.74 agent control LTD4 and thrombin infection uninfected delta frpC/frpA mutant GDS1956.0.2 GDS1321.0.1 0.74 disease state normal juvenile dermatomyositis disease state normal Barrett's esophagus GDS2057.0.1.4 GDS715.0.1.18 -0.74 agent control DHT agent none positive control GDS2767.6.8.0 GDS2191.0.1 0.74 agent water grape juice disease state control bipolar disorder GDS2649.2.5.1 GDS1375.0.2 0.74 disease state uninfected early HIV infection disease state normal malignant melanoma GDS715.2.4.18 GDS715.1.2.18 0.74 agent negative control a-methyl-L-p-tyrosine agent negative control positive control GDS2332.1.2 GDS2767.6.8.0 -0.74 infection wild type delta frpC/frpA mutant agent water grape juice GDS2332.0.2 GDS2118.0.1 -0.73 infection uninfected delta frpC/frpA mutant disease state normal refractory anemia GDS2635.0.2 GDS2250.0.3 0.73 disease state lobular control invasive lobular carcinoma disease state normal basal-like cancer GDS2418.0.1 GDS1312.0.1 0.73 disease state control vulvar intraepithelial neoplasia disease state normal cancer GDS715.0.4.18 GDS715.0.1.18 0.73 agent none a-methyl-L-p-tyrosine agent none positive control GDS715.2.9.18 GDS715.2.11.18 0.73 agent negative control 5-fluorouridine agent negative control scopolamine methyl bromide GDS715.2.9.18 GDS715.2.7.18 0.73 agent negative control 5-fluorouridine agent negative control 4,5-dianilinophthalimide GDS2205.0.1 GDS1558.0.1.3 0.73 disease state non-failing dilated cardiomyopathy disease state no atrial fibrillation permanent atrial fibrillation GDS2250.0.1 GDS1439.0.1 0.73 disease state normal non-basal-like cancer disease state benign primary GDS1331.0.2 GDS1783.0.1 0.73 disease state normal symptomatic agent control thapsigargin GDS1331.0.2 GDS1956.0.4 -0.73 disease state normal symptomatic disease state normal spastic paraplegia GDS1331.0.2 GDS715.2.4.18 -0.73 disease state normal symptomatic agent negative control a-methyl-L-p-tyrosine GDS1321.0.2 GDS1989.1.5.0 0.73 disease state normal adenocarcinoma disease state normal vertical growth phase melanoma GDS2332.0.3 GDS2118.0.2 -0.73 infection uninfected delta pilD mutant disease state normal refractory anemia with ringed sideroblasts GDS1850.0.1 GDS1665.0.1 0.73 disease state healthy carious disease state normal papillary thyroid carcinoma GDS1392.0.2 GDS2397.0.1 0.73 disease state normal myelodysplastic syndrome disease state normal idiopathic myelofibrosis GDS2367.0.2.3 GDS2200.0.2 0.73 agent vehicle tamoxifen disease state normal squamous cell carcinoma GDS2333.0.2.4 GDS2414.0.1.3 0.73 infection uninfected delta pilD mutant agent control trophoblast conditioned medium GDS1397.0.2 GDS1353.0.1.3 -0.73 agent untreated TNF-alpha agent control dexamethasone GDS2333.1.2.3 GDS1362.0.2 0.73 infection wild type delta pilD mutant disease state non-failing heart ischemic cardiomyopathy GDS2635.0.1 GDS2635.0.2 0.73 disease state lobular control ductal control disease state lobular control invasive lobular carcinoma GDS2767.5.8.4 GDS2332.1.2 -0.73 agent water alcohol infection wild type delta frpC/frpA mutant GDS715.1.2.18 GDS715.0.7.18 0.73 agent negative control positive control agent none 4,5-dianilinophthalimide GDS2767.7.8.0 GDS2255.3.4.0 0.73 agent water red wine agent untreated endotoxin GDS2767.7.8.0 GDS715.2.5.18 0.73 agent water red wine agent negative control sulmazole GDS715.0.10.18 GDS715.0.3.18 0.72 agent none pergolide methanesulfonate agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2250.0.2 GDS2617.0.2 0.72 disease state normal BRCA1-associated cancer disease state normal tumorigenic cancer cell GDS2414.0.1.3 GDS2216.0.1.5 0.72 agent control trophoblast conditioned medium agent control LPS GDS2414.0.1.3 GDS2221.0.3 0.72 agent control trophoblast conditioned medium agent untreated lipopolysaccharide GDS1783.0.1 GDS1956.0.1 0.72 agent control thapsigargin disease state normal acute quadriplegic myopathy GDS1220.0.1.3 GDS1312.0.1 0.72 disease state normal malignant pleural mesothelioma disease state normal cancer GDS1956.0.4 GDS1353.0.1.2 -0.72 disease state normal spastic paraplegia agent control dexamethasone GDS1362.0.2 GDS651.0.2 0.72 disease state non-failing heart ischemic cardiomyopathy disease state normal ischemic GDS690.2.5.0 GDS2333.0.2.4 0.72 agent control TNFa infection uninfected delta pilD mutant GDS2367.3.4.2 GDS2428.0.1.2 0.72 infection control adenovirus adenovirus carrying estrogen receptor beta agent untreated 5-aza-dC GDS2250.0.1 GDS2367.0.1.3 0.72 disease state normal non-basal-like cancer agent vehicle estradiol GDS715.0.3.18 GDS715.2.6.18 0.72 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 16-ketoestradiol GDS1439.0.2 GDS1989.1.5.0 0.72 disease state benign metastatic disease state normal vertical growth phase melanoma GDS1439.0.2 GDS2200.0.2 0.72 disease state benign metastatic disease state normal squamous cell carcinoma GDS2341.0.3.5 GDS1989.1.6.0 0.72 agent untreated Types I and II IFNs disease state normal metastatic growth phase melanoma GDS1956.0.7 GDS1956.0.3 0.72 disease state normal Becker muscular dystrophy disease state normal amyotophic lateral sclerosis GDS1331.0.2 GDS1783.0.2 0.72 disease state normal symptomatic agent control high potassium GDS2635.0.3 GDS2617.0.2 0.72 disease state lobular control invasive ductal carcinoma disease state normal tumorigenic cancer cell GDS715.2.15.18 GDS715.0.14.18 0.72 agent negative control cyclazosin HCl agent none R-(-)-apomorphine HCl GDS2332.0.3 GDS2216.0.1.5 0.72 infection uninfected delta pilD mutant agent control LPS GDS2190.0.1 GDS810.0.1 0.72 disease state control bipolar disorder disease state control incipient AD GDS2737.0.1.3 GDS1989.1.7.0 0.72 disease state normal endometriosis disease state normal lymph node metastasis GDS2737.0.1.3 GDS2428.0.1.2 -0.72 disease state normal endometriosis agent untreated 5-aza-dC GDS2221.0.2 GDS1427.0.2 -0.72 agent untreated galectin-1 infection control v-Myb GDS2649.2.5.0 GDS2118.0.1 0.72 disease state uninfected early HIV infection disease state normal refractory anemia GDS2767.5.8.0 GDS1956.0.3 -0.72 agent water alcohol disease state normal amyotophic lateral sclerosis GDS2767.5.8.4 GDS1783.0.1 -0.72 agent water alcohol agent control thapsigargin GDS2767.6.8.0 GDS1956.0.3 -0.72 agent water grape juice disease state normal amyotophic lateral sclerosis GDS2649.2.5.1 GDS715.0.1.18 -0.72 disease state uninfected early HIV infection agent none positive control GDS2767.7.8.0 GDS715.0.4.18 0.72 agent water red wine agent none a-methyl-L-p-tyrosine GDS1615.0.2 GDS266.0.1.4 -0.72 disease state normal Crohn's disease disease state no atopy atopy GDS1282.0.1 GDS505.0.1 0.72 disease state control Wilms' tumor disease state normal RCC GDS2332.0.2 GDS2118.0.3 -0.71 infection uninfected delta frpC/frpA mutant disease state normal refractory anemia with excess blasts GDS715.2.14.18 GDS715.2.13.18 0.71 agent negative control R-(-)-apomorphine HCl agent negative control 8-(3-chlorostyryl) caffeine GDS2200.0.1 GDS1989.1.4.0 0.71 disease state normal actinic keratosis disease state normal melanoma in situ GDS1783.0.1 GDS2332.1.2 0.71 agent control thapsigargin infection wild type delta frpC/frpA mutant GDS1783.0.1 GDS651.0.1 -0.71 agent control thapsigargin disease state normal idiopathic dilated GDS2617.0.2 GDS1375.0.2 0.71 disease state normal tumorigenic cancer cell disease state normal malignant melanoma GDS2221.1.2 GDS1427.0.2 -0.71 agent vehicle galectin-1 infection control v-Myb GDS2333.0.2.3 GDS690.2.3.0 0.71 infection uninfected delta pilD mutant agent control flagellin GDS2205.0.1 GDS651.0.2 0.71 disease state non-failing dilated cardiomyopathy disease state normal ischemic GDS715.0.7.18 GDS715.2.3.18 0.71 agent none 4,5-dianilinophthalimide agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2250.0.1 GDS1558.0.1.3 0.71 disease state normal non-basal-like cancer disease state no atrial fibrillation permanent atrial fibrillation GDS715.0.5.18 GDS715.0.1.18 0.71 agent none sulmazole agent none positive control GDS715.0.9.18 GDS715.0.8.18 0.71 agent none 5-fluorouridine agent none 1,10-phenanthroline GDS715.0.9.18 GDS715.0.7.18 0.71 agent none 5-fluorouridine agent none 4,5-dianilinophthalimide GDS690.2.4.1 GDS2367.3.4.1 -0.71 agent control LTb infection control adenovirus adenovirus carrying estrogen receptor beta GDS2341.0.3.5 GDS2221.1.3 0.71 agent untreated Types I and II IFNs agent vehicle lipopolysaccharide GDS1574.8.9.11 GDS715.0.14.18 0.71 agent control endotoxin agent none R-(-)-apomorphine HCl GDS2635.0.3 GDS1989.1.5.0 0.71 disease state lobular control invasive ductal carcinoma disease state normal vertical growth phase melanoma GDS2635.0.3 GDS1989.1.6.0 0.71 disease state lobular control invasive ductal carcinoma disease state normal metastatic growth phase melanoma GDS1926.0.2.4 GDS2332.0.2 0.71 agent control LTD4 infection uninfected delta frpC/frpA mutant GDS1321.0.2 GDS1989.1.7.0 0.71 disease state normal adenocarcinoma disease state normal lymph node metastasis GDS2697.0.1 GDS2643.0.1.5 -0.71 disease state normal teratozoospermia disease state normal Waldenstrom's macroglobulinemia GDS2367.0.2.3 GDS2617.0.2 0.71 agent vehicle tamoxifen disease state normal tumorigenic cancer cell GDS1362.0.1 GDS2737.0.1.4 -0.71 disease state non-failing heart non-ischemic cardiomyopathy disease state normal endometriosis GDS1783.0.2 GDS2332.1.2 0.71 agent control high potassium infection wild type delta frpC/frpA mutant GDS1783.0.2 GDS1956.0.3 0.71 agent control high potassium disease state normal amyotophic lateral sclerosis GDS2737.0.1.3 GDS2617.0.1 0.71 disease state normal endometriosis disease state normal non-tumorigenic cancer cell GDS2341.0.1.4 GDS1543.0.1 0.71 agent untreated Type I IFN agent control tumor necrosis factor GDS2214.0.1 GDS1574.8.9.12 0.71 agent control lipopolysaccharide agent control endotoxin GDS715.0.10.18 GDS715.0.4.18 -0.70 agent none pergolide methanesulfonate agent none a-methyl-L-p-tyrosine GDS2250.0.3 GDS1685.0.1 0.70 disease state normal basal-like cancer disease state normal hereditary gingival fibromatosis GDS1783.0.1 GDS2643.0.1.5 0.70 agent control thapsigargin disease state normal Waldenstrom's macroglobulinemia GDS2609.0.1 GDS1321.0.1 -0.70 disease state healthy control early onset colorectal cancer disease state normal Barrett's esophagus GDS1220.0.1.3 GDS1375.0.1 0.70 disease state normal malignant pleural mesothelioma disease state normal benign nevi GDS1220.0.1.3 GDS2609.0.1 -0.70 disease state normal malignant pleural mesothelioma disease state healthy control early onset colorectal cancer GDS2617.0.2 GDS1439.0.2 0.70 disease state normal tumorigenic cancer cell disease state benign metastatic GDS715.2.4.18 GDS715.2.7.18 0.70 agent negative control a-methyl-L-p-tyrosine agent negative control 4,5-dianilinophthalimide GDS2333.0.2.3 GDS1331.0.2 0.70 infection uninfected delta pilD mutant disease state normal symptomatic GDS1956.0.11 GDS1989.1.3.0 -0.70 disease state normal FKRP mutation disease state normal atypical nevus GDS1331.0.1 GDS1956.0.3 0.70 disease state normal presymptomatic disease state normal amyotophic lateral sclerosis GDS2367.3.4.2 GDS2200.0.2 -0.70 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal squamous cell carcinoma GDS2367.3.4.2 GDS1667.0.1 -0.70 infection control adenovirus adenovirus carrying estrogen receptor beta infection HPV negative HPV positive GDS885.0.1 GDS1453.0.1 0.70 agent control campthotecin agent untreated camptothecin GDS715.0.5.18 GDS715.0.15.18 0.70 agent none sulmazole agent none cyclazosin HCl GDS2341.0.3.4 GDS1574.8.9.13 0.70 agent untreated Types I and II IFNs agent control endotoxin GDS2341.0.2.5 GDS1321.0.1 0.70 agent untreated Type II IFN disease state normal Barrett's esophagus GDS715.2.8.18 GDS715.2.12.18 0.70 agent negative control 1,10-phenanthroline agent negative control 5-fluorouracil GDS1331.0.2 GDS2191.0.1 -0.70 disease state normal symptomatic disease state control bipolar disorder GDS1926.0.3.4 GDS2617.0.1 -0.70 agent control LTD4 and thrombin disease state normal non-tumorigenic cancer cell GDS1574.8.9.13 GDS2216.0.1.5 0.70 agent control endotoxin agent control LPS GDS715.2.11.18 GDS715.2.8.18 0.70 agent negative control scopolamine methyl bromide agent negative control 1,10-phenanthroline GDS2200.0.2 GDS1989.1.4.0 0.70 disease state normal squamous cell carcinoma disease state normal melanoma in situ GDS1956.0.2 GDS1989.1.3.0 -0.70 disease state normal juvenile dermatomyositis disease state normal atypical nevus GDS2332.0.3 GDS2214.0.1 0.70 infection uninfected delta pilD mutant agent control lipopolysaccharide GDS1850.0.1 GDS1989.1.6.0 0.70 disease state healthy carious disease state normal metastatic growth phase melanoma GDS1850.0.1 GDS1375.0.2 0.70 disease state healthy carious disease state normal malignant melanoma GDS2367.0.2.3 GDS1667.0.1 0.70 agent vehicle tamoxifen infection HPV negative HPV positive GDS1362.0.1 GDS2414.0.1.3 0.70 disease state non-failing heart non-ischemic cardiomyopathy agent control trophoblast conditioned medium GDS1362.0.1 GDS1956.0.1 0.70 disease state non-failing heart non-ischemic cardiomyopathy disease state normal acute quadriplegic myopathy GDS1362.0.1 GDS1376.2.3.1 0.70 disease state non-failing heart non-ischemic cardiomyopathy disease state normal thrombocythemia GDS1362.0.1 GDS2153.0.1 0.70 disease state non-failing heart non-ischemic cardiomyopathy disease state normal dermatomyositis GDS1783.0.2 GDS1850.0.1 -0.70 agent control high potassium disease state healthy carious GDS2255.3.4.0 GDS2216.0.1.5 0.70 agent untreated endotoxin agent control LPS GDS2367.3.4.0 GDS1362.0.1 -0.70 infection control adenovirus adenovirus carrying estrogen receptor beta disease state non-failing heart non-ischemic cardiomyopathy GDS2367.3.4.0 GDS2643.0.1.5 -0.70 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal Waldenstrom's macroglobulinemia GDS2767.5.8.4 GDS715.0.4.18 0.70 agent water alcohol agent none a-methyl-L-p-tyrosine GDS2767.6.8.0 GDS2153.0.1 -0.70 agent water grape juice disease state normal dermatomyositis GDS2767.6.8.0 GDS715.2.4.18 0.70 agent water grape juice agent negative control a-methyl-L-p-tyrosine GDS715.2.9.18 GDS715.1.2.18 0.70 agent negative control 5-fluorouridine agent negative control positive control GDS715.0.8.18 GDS715.2.3.18 0.69 agent none 1,10-phenanthroline agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.2.6.18 GDS715.0.8.18 0.69 agent negative control 16-ketoestradiol agent none 1,10-phenanthroline GDS2414.0.1.3 GDS1427.0.2 -0.69 agent control trophoblast conditioned medium infection control v-Myb GDS1783.0.1 GDS1956.0.3 0.69 agent control thapsigargin disease state normal amyotophic lateral sclerosis GDS715.2.7.18 GDS715.2.12.18 0.69 agent negative control 4,5-dianilinophthalimide agent negative control 5-fluorouracil GDS715.2.10.18 GDS715.2.5.18 -0.69 agent negative control pergolide methanesulfonate agent negative control sulmazole GDS2333.0.2.3 GDS715.2.4.18 -0.69 infection uninfected delta pilD mutant agent negative control a-methyl-L-p-tyrosine GDS715.0.4.18 GDS715.0.14.18 0.69 agent none a-methyl-L-p-tyrosine agent none R-(-)-apomorphine HCl GDS1746.2.4.0 GDS1667.0.1 0.69 disease state normal basaloid infection HPV negative HPV positive GDS2341.0.3.5 GDS2200.0.1 0.69 agent untreated Types I and II IFNs disease state normal actinic keratosis GDS2341.0.2.5 GDS2221.0.3 0.69 agent untreated Type II IFN agent untreated lipopolysaccharide GDS2414.0.1.4 GDS2221.0.2 0.69 agent control trophoblast conditioned medium agent untreated galectin-1 GDS1574.8.9.11 GDS715.2.14.18 0.69 agent control endotoxin agent negative control R-(-)-apomorphine HCl GDS1331.0.2 GDS715.0.9.18 0.69 disease state normal symptomatic agent none 5-fluorouridine GDS1543.0.1 GDS2221.1.2 0.69 agent control tumor necrosis factor agent vehicle galectin-1 GDS1926.0.2.4 GDS2362.6.7.2.5 -0.69 agent control LTD4 agent untreated chloroguine treated GDS715.2.11.18 GDS715.2.15.18 0.69 agent negative control scopolamine methyl bromide agent negative control cyclazosin HCl GDS715.2.3.18 GDS715.2.15.18 0.69 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control cyclazosin HCl GDS1321.0.2 GDS1989.1.6.0 0.69 disease state normal adenocarcinoma disease state normal metastatic growth phase melanoma GDS1312.0.1 GDS1665.0.1 0.69 disease state normal cancer disease state normal papillary thyroid carcinoma GDS1783.0.2 GDS1956.0.1 0.69 agent control high potassium disease state normal acute quadriplegic myopathy GDS1783.0.2 GDS2153.0.1 0.69 agent control high potassium disease state normal dermatomyositis GDS1783.0.2 GDS2643.0.1.5 0.69 agent control high potassium disease state normal Waldenstrom's macroglobulinemia GDS1549.3.4.2 GDS715.0.1.18 -0.69 agent control estradiol agent none positive control GDS715.0.14.18 GDS715.0.13.18 0.69 agent none R-(-)-apomorphine HCl agent none 8-(3-chlorostyryl) caffeine GDS2767.5.8.0 GDS2333.0.2.3 -0.69 agent water alcohol infection uninfected delta pilD mutant GDS2649.2.5.1 GDS1630.2.4.1 -0.69 disease state uninfected early HIV infection agent untreated atorvastatin GDS2649.2.5.1 GDS2737.0.1.3 0.69 disease state uninfected early HIV infection disease state normal endometriosis GDS2649.2.5.1 GDS1667.0.1 0.69 disease state uninfected early HIV infection infection HPV negative HPV positive GDS2649.2.5.1 GDS1549.3.4.2 0.69 disease state uninfected early HIV infection agent control estradiol GDS2767.7.8.0 GDS2153.0.1 -0.69 agent water red wine disease state normal dermatomyositis GDS2767.7.8.0 GDS1850.0.1 0.69 agent water red wine disease state healthy carious GDS715.2.10.18 GDS715.1.2.18 0.69 agent negative control pergolide methanesulfonate agent negative control positive control GDS2341.0.3.4 GDS2649.3.5.1 0.69 agent untreated Types I and II IFNs disease state uninfected chronic HIV infection GDS2737.0.1.3 GDS484.0.1 0.69 disease state normal endometriosis disease state normal leiomyoma GDS715.0.8.18 GDS715.0.12.18 0.68 agent none 1,10-phenanthroline agent none 5-fluorouracil GDS2255.3.4.1 GDS1971.0.1 0.68 agent untreated endotoxin disease state healthy uncomplicated malaria GDS2255.3.4.1 GDS1615.0.2 0.68 agent untreated endotoxin disease state normal Crohn's disease GDS2643.0.3.5 GDS2142.0.2 0.68 disease state normal multiple myeloma disease state normal severe cystic fibrosis GDS2611.0.3.9 GDS2200.0.1 0.68 agent untreated IFN-gamma disease state normal actinic keratosis GDS1574.8.9.12 GDS2221.1.3 0.68 agent control endotoxin agent vehicle lipopolysaccharide GDS2250.0.3 GDS1321.0.2 0.68 disease state normal basal-like cancer disease state normal adenocarcinoma GDS2200.0.1 GDS1375.0.2 0.68 disease state normal actinic keratosis disease state normal malignant melanoma GDS2414.0.1.3 GDS2221.1.3 0.68 agent control trophoblast conditioned medium agent vehicle lipopolysaccharide GDS1783.0.1 GDS2142.0.2 0.68 agent control thapsigargin disease state normal severe cystic fibrosis GDS1783.0.1 GDS1665.0.1 -0.68 agent control thapsigargin disease state normal papillary thyroid carcinoma GDS2367.0.1.3 GDS1630.2.4.1 -0.68 agent vehicle estradiol agent untreated atorvastatin GDS1220.0.1.3 GDS2200.0.2 0.68 disease state normal malignant pleural mesothelioma disease state normal squamous cell carcinoma GDS1397.0.1 GDS715.2.15.18 -0.68 agent untreated HIV agent negative control cyclazosin HCl GDS1331.0.1 GDS2643.0.1.5 0.68 disease state normal presymptomatic disease state normal Waldenstrom's macroglobulinemia GDS1362.0.2 GDS1850.0.1 -0.68 disease state non-failing heart ischemic cardiomyopathy disease state healthy carious GDS2214.0.2 GDS2118.0.3 -0.68 agent control HMGB1 disease state normal refractory anemia with excess blasts GDS715.0.7.18 GDS715.0.12.18 0.68 agent none 4,5-dianilinophthalimide agent none 5-fluorouracil GDS2367.3.4.2 GDS715.2.4.18 0.68 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control a-methyl-L-p-tyrosine GDS2250.0.1 GDS1321.0.2 0.68 disease state normal non-basal-like cancer disease state normal adenocarcinoma GDS1956.0.7 GDS1989.1.3.0 -0.68 disease state normal Becker muscular dystrophy disease state normal atypical nevus GDS1331.0.2 GDS715.0.4.18 -0.68 disease state normal symptomatic agent none a-methyl-L-p-tyrosine GDS2200.0.2 GDS1375.0.1 0.68 disease state normal squamous cell carcinoma disease state normal benign nevi GDS1956.0.2 GDS1220.0.1.3 0.68 disease state normal juvenile dermatomyositis disease state normal malignant pleural mesothelioma GDS2332.0.3 GDS2617.0.1 -0.68 infection uninfected delta pilD mutant disease state normal non-tumorigenic cancer cell GDS2057.0.1.4 GDS1375.0.2 0.68 agent control DHT disease state normal malignant melanoma GDS1362.0.1 GDS2239.0.1 0.68 disease state non-failing heart non-ischemic cardiomyopathy agent control hepatitis C virus core protein GDS1362.0.1 GDS1956.0.4 -0.68 disease state non-failing heart non-ischemic cardiomyopathy disease state normal spastic paraplegia GDS1956.0.5 GDS1956.0.9 0.68 disease state normal fascioscapulohumeral muscular dystrophy disease state normal Calpain 3 mutation GDS1312.0.1 GDS1375.0.1 0.68 disease state normal cancer disease state normal benign nevi GDS690.2.3.0 GDS1362.0.2 0.68 agent control flagellin disease state non-failing heart ischemic cardiomyopathy GDS2341.0.1.4 GDS1574.8.9.13 0.68 agent untreated Type I IFN agent control endotoxin GDS2332.1.2 GDS2191.0.1 -0.68 infection wild type delta frpC/frpA mutant disease state control bipolar disorder GDS1956.0.3 GDS1956.0.10 0.68 disease state normal amyotophic lateral sclerosis disease state normal dysferlin mutation GDS2649.2.5.0 GDS1989.1.6.0 0.68 disease state uninfected early HIV infection disease state normal metastatic growth phase melanoma GDS2767.6.8.0 GDS715.2.5.18 0.68 agent water grape juice agent negative control sulmazole GDS2649.2.5.1 GDS1989.1.7.0 0.68 disease state uninfected early HIV infection disease state normal lymph node metastasis GDS2341.0.3.5 GDS505.0.1 0.68 agent untreated Types I and II IFNs disease state normal RCC GDS715.2.5.18 GDS715.1.2.18 0.68 agent negative control sulmazole agent negative control positive control GDS2362.6.7.2.5 GDS651.0.1 0.67 agent untreated chloroguine treated disease state normal idiopathic dilated GDS715.0.1.18 GDS1312.0.1 -0.67 agent none positive control disease state normal cancer GDS2643.0.3.5 GDS651.0.1 -0.67 disease state normal multiple myeloma disease state normal idiopathic dilated GDS2643.0.3.5 GDS1630.2.4.0 -0.67 disease state normal multiple myeloma agent untreated atorvastatin GDS2250.0.3 GDS1549.3.4.1 0.67 disease state normal basal-like cancer agent control estradiol GDS2250.0.3 GDS2397.0.1 -0.67 disease state normal basal-like cancer disease state normal idiopathic myelofibrosis GDS1783.0.1 GDS2332.0.2 0.67 agent control thapsigargin infection uninfected delta frpC/frpA mutant GDS1783.0.1 GDS1220.0.1.3 0.67 agent control thapsigargin disease state normal malignant pleural mesothelioma GDS1783.0.1 GDS1850.0.1 -0.67 agent control thapsigargin disease state healthy carious GDS1783.0.1 GDS1989.1.3.0 -0.67 agent control thapsigargin disease state normal atypical nevus GDS2643.0.1.5 GDS715.2.9.18 0.67 disease state normal Waldenstrom's macroglobulinemia agent negative control 5-fluorouridine GDS2367.0.1.3 GDS1375.0.2 0.67 agent vehicle estradiol disease state normal malignant melanoma GDS1220.0.1.3 GDS1375.0.2 0.67 disease state normal malignant pleural mesothelioma disease state normal malignant melanoma GDS1220.0.1.3 GDS2250.0.1 0.67 disease state normal malignant pleural mesothelioma disease state normal non-basal-like cancer GDS2333.0.2.3 GDS1956.0.3 0.67 infection uninfected delta pilD mutant disease state normal amyotophic lateral sclerosis GDS1956.0.4 GDS2250.0.2 -0.67 disease state normal spastic paraplegia disease state normal BRCA1-associated cancer GDS1313.0.1 GDS1405.0.1 -0.67 agent control TGFb1 agent untreated DCI GDS715.0.15.18 GDS715.0.6.18 0.67 agent none cyclazosin HCl agent none 16-ketoestradiol GDS1746.2.4.0 GDS2418.0.1 0.67 disease state normal basaloid disease state control vulvar intraepithelial neoplasia GDS715.0.9.18 GDS715.0.6.18 0.67 agent none 5-fluorouridine agent none 16-ketoestradiol GDS1439.0.2 GDS1375.0.2 0.67 disease state benign metastatic disease state normal malignant melanoma GDS1439.0.2 GDS2617.0.1 0.67 disease state benign metastatic disease state normal non-tumorigenic cancer cell GDS1439.0.2 GDS1989.1.6.0 0.67 disease state benign metastatic disease state normal metastatic growth phase melanoma GDS2617.0.1 GDS1375.0.2 0.67 disease state normal non-tumorigenic cancer cell disease state normal malignant melanoma GDS2341.0.3.5 GDS2221.1.2 0.67 agent untreated Types I and II IFNs agent vehicle galectin-1 GDS715.2.8.18 GDS715.2.13.18 0.67 agent negative control 1,10-phenanthroline agent negative control 8-(3-chlorostyryl) caffeine GDS2118.0.2 GDS1392.0.1 0.67 disease state normal refractory anemia with ringed sideroblasts disease state normal rheumatoid arthritis, on methotrexate GDS1331.0.2 GDS2255.3.4.0 -0.67 disease state normal symptomatic agent untreated endotoxin GDS2635.0.3 GDS2617.0.1 0.67 disease state lobular control invasive ductal carcinoma disease state normal non-tumorigenic cancer cell GDS2635.0.3 GDS1321.0.2 0.67 disease state lobular control invasive ductal carcinoma disease state normal adenocarcinoma GDS1956.0.2 GDS1321.0.2 0.67 disease state normal juvenile dermatomyositis disease state normal adenocarcinoma GDS1956.0.2 GDS2142.0.1 -0.67 disease state normal juvenile dermatomyositis disease state normal mild cystic fibrosis GDS2332.0.3 GDS1850.0.1 0.67 infection uninfected delta pilD mutant disease state healthy carious GDS1850.0.1 GDS2200.0.1 0.67 disease state healthy carious disease state normal actinic keratosis GDS1850.0.1 GDS1956.0.10 0.67 disease state healthy carious disease state normal dysferlin mutation GDS715.2.5.18 GDS715.2.11.18 0.67 agent negative control sulmazole agent negative control scopolamine methyl bromide GDS2367.0.2.3 GDS2057.0.2.4 0.67 agent vehicle tamoxifen agent control RTI-018 GDS2367.0.2.3 GDS1375.0.2 0.67 agent vehicle tamoxifen disease state normal malignant melanoma GDS2367.0.2.3 GDS1630.2.4.1 -0.67 agent vehicle tamoxifen agent untreated atorvastatin GDS2367.0.2.3 GDS2397.0.1 -0.67 agent vehicle tamoxifen disease state normal idiopathic myelofibrosis GDS2367.0.2.3 GDS2428.0.1.2 -0.67 agent vehicle tamoxifen agent untreated 5-aza-dC GDS2221.1.3 GDS2250.0.3 0.67 agent vehicle lipopolysaccharide disease state normal basal-like cancer GDS1362.0.1 GDS1989.1.2.0 -0.67 disease state non-failing heart non-ischemic cardiomyopathy disease state normal benign nevus GDS1362.0.1 GDS1850.0.1 -0.67 disease state non-failing heart non-ischemic cardiomyopathy disease state healthy carious GDS1312.0.1 GDS1989.1.4.0 0.67 disease state normal cancer disease state normal melanoma in situ GDS2737.0.1.3 GDS2200.0.2 0.67 disease state normal endometriosis disease state normal squamous cell carcinoma GDS2737.0.1.3 GDS1439.0.2 0.67 disease state normal endometriosis disease state benign metastatic GDS2142.0.1 GDS2142.0.2 0.67 disease state normal mild cystic fibrosis disease state normal severe cystic fibrosis GDS2341.0.1.4 GDS2414.0.1.4 0.67 agent untreated Type I IFN agent control trophoblast conditioned medium GDS2214.0.1 GDS1428.0.5.10 0.67 agent control lipopolysaccharide agent untreated Anaplasma phagocytophilum GDS2332.1.2 GDS2118.0.2 -0.67 infection wild type delta frpC/frpA mutant disease state normal refractory anemia with ringed sideroblasts GDS1376.2.3.1 GDS1783.0.2 0.67 disease state normal thrombocythemia agent control high potassium GDS1549.3.4.2 GDS2397.0.1 -0.67 agent control estradiol disease state normal idiopathic myelofibrosis GDS715.0.14.18 GDS715.2.3.18 0.67 agent none R-(-)-apomorphine HCl agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS505.0.1 GDS1956.0.2 0.67 disease state normal RCC disease state normal juvenile dermatomyositis GDS2767.5.8.0 GDS690.2.3.0 -0.67 agent water alcohol agent control flagellin GDS2767.5.8.4 GDS715.2.5.18 0.67 agent water alcohol agent negative control sulmazole GDS2649.3.5.0 GDS1574.8.9.13 0.67 disease state uninfected chronic HIV infection agent control endotoxin GDS2649.2.5.1 GDS1439.0.2 0.67 disease state uninfected early HIV infection disease state benign metastatic GDS2649.2.5.1 GDS2367.0.1.3 0.67 disease state uninfected early HIV infection agent vehicle estradiol GDS715.1.2.18 GDS1312.0.1 -0.67 agent negative control positive control disease state normal cancer GDS2767.7.8.0 GDS2414.0.1.3 -0.67 agent water red wine agent control trophoblast conditioned medium GDS2767.7.8.0 GDS1956.0.5 -0.67 agent water red wine disease state normal fascioscapulohumeral muscular dystrophy GDS2767.7.8.0 GDS1956.0.4 0.67 agent water red wine disease state normal spastic paraplegia GDS2341.0.2.5 GDS505.0.1 0.67 agent untreated Type II IFN disease state normal RCC GDS2332.0.2 GDS1313.0.1 0.66 infection uninfected delta frpC/frpA mutant agent control TGFb1 GDS2635.0.2 GDS2617.0.1 0.66 disease state lobular control invasive lobular carcinoma disease state normal non-tumorigenic cancer cell GDS1259.0.1 GDS1989.1.6.0 0.66 disease state normal dermatomyositis disease state normal metastatic growth phase melanoma GDS2418.0.1 GDS2617.0.2 0.66 disease state control vulvar intraepithelial neoplasia disease state normal tumorigenic cancer cell GDS2643.0.3.5 GDS1850.0.1 -0.66 disease state normal multiple myeloma disease state healthy carious GDS2250.0.2 GDS1439.0.1 0.66 disease state normal BRCA1-associated cancer disease state benign primary GDS2250.0.3 GDS1667.0.1 0.66 disease state normal basal-like cancer infection HPV negative HPV positive GDS715.2.6.18 GDS715.2.15.18 0.66 agent negative control 16-ketoestradiol agent negative control cyclazosin HCl GDS1783.0.1 GDS1630.2.4.0 -0.66 agent control thapsigargin agent untreated atorvastatin GDS2367.0.1.3 GDS2418.0.1 0.66 agent vehicle estradiol disease state control vulvar intraepithelial neoplasia GDS2367.0.1.3 GDS2250.0.2 0.66 agent vehicle estradiol disease state normal BRCA1-associated cancer GDS2609.0.1 GDS1685.0.1 -0.66 disease state healthy control early onset colorectal cancer disease state normal hereditary gingival fibromatosis GDS2333.0.2.3 GDS715.0.4.18 -0.66 infection uninfected delta pilD mutant agent none a-methyl-L-p-tyrosine GDS2333.0.2.3 GDS1630.2.4.0 -0.66 infection uninfected delta pilD mutant agent untreated atorvastatin GDS715.0.8.16 GDS2255.3.4.0 0.66 agent none 1,10-phenanthroline agent untreated endotoxin GDS715.2.9.18 GDS715.0.4.18 -0.66 agent negative control 5-fluorouridine agent none a-methyl-L-p-tyrosine GDS690.2.5.0 GDS1362.0.1 0.66 agent control TNFa disease state non-failing heart non-ischemic cardiomyopathy GDS690.2.5.0 GDS1362.0.2 0.66 agent control TNFa disease state non-failing heart ischemic cardiomyopathy GDS2153.0.1 GDS1989.1.2.0 -0.66 disease state normal dermatomyositis disease state normal benign nevus GDS2214.0.2 GDS2118.0.2 -0.66 agent control HMGB1 disease state normal refractory anemia with ringed sideroblasts GDS2367.3.4.2 GDS2635.0.3 -0.66 infection control adenovirus adenovirus carrying estrogen receptor beta disease state lobular control invasive ductal carcinoma GDS2367.3.4.2 GDS2239.0.1 -0.66 infection control adenovirus adenovirus carrying estrogen receptor beta agent control hepatitis C virus core protein GDS2250.0.1 GDS860.0.1 0.66 disease state normal non-basal-like cancer agent untreated endothelin-1 GDS2367.3.4.1 GDS2118.0.3 0.66 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal refractory anemia with excess blasts GDS2216.0.1.5 GDS1428.0.5.10 0.66 agent control LPS agent untreated Anaplasma phagocytophilum GDS2332.0.3 GDS2221.0.3 0.66 infection uninfected delta pilD mutant agent untreated lipopolysaccharide GDS1850.0.1 GDS2142.0.2 -0.66 disease state healthy carious disease state normal severe cystic fibrosis GDS2057.0.1.4 GDS1549.3.4.2 0.66 agent control DHT agent control estradiol GDS1312.0.1 GDS1667.0.1 0.66 disease state normal cancer infection HPV negative HPV positive GDS1783.0.2 GDS1956.0.2 0.66 agent control high potassium disease state normal juvenile dermatomyositis GDS1783.0.2 GDS2367.0.2.4 0.66 agent control high potassium agent vehicle tamoxifen GDS1783.0.2 GDS1333.0.1 -0.66 agent control high potassium agent baseline oxandrolone GDS1783.0.2 GDS1989.1.2.0 -0.66 agent control high potassium disease state normal benign nevus GDS2737.0.1.3 GDS1989.1.5.0 0.66 disease state normal endometriosis disease state normal vertical growth phase melanoma GDS505.0.1 GDS1282.0.2 0.66 disease state normal RCC disease state control clear cell sarcoma of the kidney GDS2767.5.8.0 GDS690.2.5.0 -0.66 agent water alcohol agent control TNFa GDS2767.5.8.0 GDS2367.3.4.1 0.66 agent water alcohol infection control adenovirus adenovirus carrying estrogen receptor beta GDS2767.7.8.0 GDS715.0.10.18 -0.66 agent water red wine agent none pergolide methanesulfonate GDS2767.7.8.0 GDS2367.3.4.1 0.66 agent water red wine infection control adenovirus adenovirus carrying estrogen receptor beta GDS1956.0.8 GDS505.0.1 0.66 disease state normal Duchenne muscular dystrophy disease state normal RCC GDS2332.0.2 GDS2216.0.1.5 0.65 infection uninfected delta frpC/frpA mutant agent control LPS GDS1259.0.1 GDS2200.0.2 0.65 disease state normal dermatomyositis disease state normal squamous cell carcinoma GDS2643.0.3.5 GDS1220.0.1.3 0.65 disease state normal multiple myeloma disease state normal malignant pleural mesothelioma GDS2250.0.2 GDS1665.0.1 0.65 disease state normal BRCA1-associated cancer disease state normal papillary thyroid carcinoma GDS2250.0.3 GDS860.0.1 0.65 disease state normal basal-like cancer agent untreated endothelin-1 GDS1783.0.1 GDS1989.1.2.0 -0.65 agent control thapsigargin disease state normal benign nevus GDS2142.0.2 GDS2200.0.1 -0.65 disease state normal severe cystic fibrosis disease state normal actinic keratosis GDS1331.0.1 GDS2432.0.1 -0.65 disease state normal presymptomatic disease state control pituitary adenoma predisposition GDS1362.0.2 GDS1665.0.1 -0.65 disease state non-failing heart ischemic cardiomyopathy disease state normal papillary thyroid carcinoma GDS715.0.6.18 GDS715.0.13.18 0.65 agent none 16-ketoestradiol agent none 8-(3-chlorostyryl) caffeine GDS2214.0.2 GDS1428.0.5.10 0.65 agent control HMGB1 agent untreated Anaplasma phagocytophilum GDS2367.3.4.2 GDS715.2.9.18 -0.65 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control 5-fluorouridine GDS2367.3.4.2 GDS715.0.9.18 -0.65 infection control adenovirus adenovirus carrying estrogen receptor beta agent none 5-fluorouridine GDS715.0.13.18 GDS715.2.7.18 -0.65 agent none 8-(3-chlorostyryl) caffeine agent negative control 4,5-dianilinophthalimide GDS715.0.3.18 GDS715.0.13.18 0.65 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none 8-(3-chlorostyryl) caffeine GDS715.0.11.18 GDS715.2.13.18 0.65 agent none scopolamine methyl bromide agent negative control 8-(3-chlorostyryl) caffeine GDS2341.0.2.5 GDS2221.0.2 0.65 agent untreated Type II IFN agent untreated galectin-1 GDS1331.0.2 GDS1926.0.2.4 0.65 disease state normal symptomatic agent control LTD4 GDS1331.0.2 GDS715.0.10.18 0.65 disease state normal symptomatic agent none pergolide methanesulfonate GDS1331.0.2 GDS1353.0.1.2 0.65 disease state normal symptomatic agent control dexamethasone GDS1926.0.2.4 GDS651.0.1 -0.65 agent control LTD4 disease state normal idiopathic dilated GDS2332.0.3 GDS2118.0.3 -0.65 infection uninfected delta pilD mutant disease state normal refractory anemia with excess blasts GDS2367.0.2.3 GDS2617.0.1 0.65 agent vehicle tamoxifen disease state normal non-tumorigenic cancer cell GDS2057.0.1.4 GDS2397.0.1 -0.65 agent control DHT disease state normal idiopathic myelofibrosis GDS1362.0.1 GDS1312.0.1 -0.65 disease state non-failing heart non-ischemic cardiomyopathy disease state normal cancer GDS1783.0.2 GDS2414.0.1.3 0.65 agent control high potassium agent control trophoblast conditioned medium GDS1783.0.2 GDS1665.0.1 -0.65 agent control high potassium disease state normal papillary thyroid carcinoma GDS690.2.3.0 GDS2332.1.2 0.65 agent control flagellin infection wild type delta frpC/frpA mutant GDS1376.2.3.1 GDS1783.0.1 0.65 disease state normal thrombocythemia agent control thapsigargin GDS715.0.14.18 GDS715.2.7.18 0.65 agent none R-(-)-apomorphine HCl agent negative control 4,5-dianilinophthalimide GDS2767.5.8.0 GDS2697.0.1 0.65 agent water alcohol disease state normal teratozoospermia GDS2767.5.8.4 GDS2153.0.1 -0.65 agent water alcohol disease state normal dermatomyositis GDS2767.5.8.4 GDS715.0.5.18 0.65 agent water alcohol agent none sulmazole GDS2767.6.8.0 GDS1850.0.1 0.65 agent water grape juice disease state healthy carious GDS2767.7.8.0 GDS2333.1.2.3 -0.65 agent water red wine infection wild type delta pilD mutant GDS2767.7.8.0 GDS2697.0.1 0.65 agent water red wine disease state normal teratozoospermia GDS1667.0.1 GDS1062.2.3.0 -0.65 infection HPV negative HPV positive disease state no metastasis metastasis GDS715.0.9.18 GDS715.1.2.18 0.65 agent none 5-fluorouridine agent negative control positive control GDS1321.0.2 GDS1062.2.3.0 0.65 disease state normal adenocarcinoma disease state no metastasis metastasis GDS2332.0.2 GDS1926.0.1.4 0.64 infection uninfected delta frpC/frpA mutant agent control thrombin GDS2255.3.4.1 GDS1971.0.2 0.64 agent untreated endotoxin disease state healthy complicated malaria GDS2643.0.3.5 GDS2414.0.1.3 0.64 disease state normal multiple myeloma agent control trophoblast conditioned medium GDS2250.0.3 GDS1375.0.1 0.64 disease state normal basal-like cancer disease state normal benign nevi GDS2367.0.1.3 GDS2057.0.2.4 0.64 agent vehicle estradiol agent control RTI-018 GDS715.2.4.18 GDS715.2.11.18 0.64 agent negative control a-methyl-L-p-tyrosine agent negative control scopolamine methyl bromide GDS2333.0.2.3 GDS2153.0.1 0.64 infection uninfected delta pilD mutant disease state normal dermatomyositis GDS2333.0.2.3 GDS2367.3.4.1 -0.64 infection uninfected delta pilD mutant infection control adenovirus adenovirus carrying estrogen receptor beta GDS2397.0.1 GDS2118.0.2 0.64 disease state normal idiopathic myelofibrosis disease state normal refractory anemia with ringed sideroblasts GDS715.2.9.18 GDS715.2.8.18 0.64 agent negative control 5-fluorouridine agent negative control 1,10-phenanthroline GDS1331.0.1 GDS1956.0.5 0.64 disease state normal presymptomatic disease state normal fascioscapulohumeral muscular dystrophy GDS1313.0.1 GDS2307.0.2 -0.64 agent control TGFb1 agent untreated ox-LDL GDS1746.2.4.0 GDS2200.0.2 0.64 disease state normal basaloid disease state normal squamous cell carcinoma GDS2341.0.1.5 GDS2221.1.3 0.64 agent untreated Type I IFN agent vehicle lipopolysaccharide GDS1971.0.1 GDS1615.0.1 0.64 disease state healthy uncomplicated malaria disease state normal ulcerative colitis GDS2250.0.1 GDS2609.0.1 -0.64 disease state normal non-basal-like cancer disease state healthy control early onset colorectal cancer GDS715.0.9.18 GDS715.0.11.18 0.64 agent none 5-fluorouridine agent none scopolamine methyl bromide GDS715.0.11.18 GDS715.0.1.18 0.64 agent none scopolamine methyl bromide agent none positive control GDS1439.0.2 GDS1989.1.4.0 0.64 disease state benign metastatic disease state normal melanoma in situ GDS2414.0.1.4 GDS2221.1.2 0.64 agent control trophoblast conditioned medium agent vehicle galectin-1 GDS1447.0.1 GDS2216.0.1.5 0.64 agent control vanadium agent control LPS GDS1956.0.7 GDS1333.0.1 -0.64 disease state normal Becker muscular dystrophy agent baseline oxandrolone GDS1331.0.2 GDS715.0.6.16 -0.64 disease state normal symptomatic agent none 16-ketoestradiol GDS1956.0.2 GDS2341.0.3.4 0.64 disease state normal juvenile dermatomyositis agent untreated Types I and II IFNs GDS2332.0.3 GDS2214.0.2 0.64 infection uninfected delta pilD mutant agent control HMGB1 GDS1989.1.5.0 GDS1321.0.1 0.64 disease state normal vertical growth phase melanoma disease state normal Barrett's esophagus GDS2367.0.2.3 GDS1989.1.5.0 0.64 agent vehicle tamoxifen disease state normal vertical growth phase melanoma GDS2367.0.2.3 GDS1989.1.7.0 0.64 agent vehicle tamoxifen disease state normal lymph node metastasis GDS2221.1.3 GDS2250.0.1 0.64 agent vehicle lipopolysaccharide disease state normal non-basal-like cancer GDS1362.0.1 GDS2142.0.2 0.64 disease state non-failing heart non-ischemic cardiomyopathy disease state normal severe cystic fibrosis GDS1362.0.1 GDS2643.0.1.5 0.64 disease state non-failing heart non-ischemic cardiomyopathy disease state normal Waldenstrom's macroglobulinemia GDS1956.0.5 GDS651.0.1 -0.64 disease state normal fascioscapulohumeral muscular dystrophy disease state normal idiopathic dilated GDS2255.3.4.0 GDS1665.0.1 0.64 agent untreated endotoxin disease state normal papillary thyroid carcinoma GDS690.2.3.0 GDS1956.0.5 0.64 agent control flagellin disease state normal fascioscapulohumeral muscular dystrophy GDS1956.0.10 GDS1989.1.3.0 -0.64 disease state normal dysferlin mutation disease state normal atypical nevus GDS2214.0.1 GDS2216.0.1.5 0.64 agent control lipopolysaccharide agent control LPS GDS715.2.13.18 GDS715.2.4.18 -0.64 agent negative control 8-(3-chlorostyryl) caffeine agent negative control a-methyl-L-p-tyrosine GDS1376.2.3.1 GDS2643.0.3.5 0.64 disease state normal thrombocythemia disease state normal multiple myeloma GDS1376.2.3.1 GDS1956.0.5 0.64 disease state normal thrombocythemia disease state normal fascioscapulohumeral muscular dystrophy GDS1549.3.4.2 GDS1439.0.2 0.64 agent control estradiol disease state benign metastatic GDS2649.3.5.0 GDS266.0.1.4 -0.64 disease state uninfected chronic HIV infection disease state no atopy atopy GDS2767.6.8.3 GDS1956.0.4 0.64 agent water grape juice disease state normal spastic paraplegia GDS2649.3.5.1 GDS2250.0.3 0.64 disease state uninfected chronic HIV infection disease state normal basal-like cancer GDS2767.7.8.4 GDS1574.8.9.11 -0.64 agent water red wine agent control endotoxin GDS2767.5.8.4 GDS2414.0.1.3 -0.64 agent water alcohol agent control trophoblast conditioned medium GDS2649.2.5.1 GDS2428.0.1.2 -0.64 disease state uninfected early HIV infection agent untreated 5-aza-dC GDS2767.7.8.0 GDS2118.0.2 0.64 agent water red wine disease state normal refractory anemia with ringed sideroblasts GDS2767.7.8.0 GDS1989.1.2.0 0.64 agent water red wine disease state normal benign nevus GDS2767.7.8.0 GDS1989.1.3.0 0.64 agent water red wine disease state normal atypical nevus GDS2418.0.1 GDS2617.0.1 0.63 disease state control vulvar intraepithelial neoplasia disease state normal non-tumorigenic cancer cell GDS715.0.1.18 GDS1615.0.2 0.63 agent none positive control disease state normal Crohn's disease GDS2643.0.3.5 GDS2367.3.4.1 -0.63 disease state normal multiple myeloma infection control adenovirus adenovirus carrying estrogen receptor beta GDS2250.0.2 GDS860.0.1 0.63 disease state normal BRCA1-associated cancer agent untreated endothelin-1 GDS1574.8.9.12 GDS2221.0.2 0.63 agent control endotoxin agent untreated galectin-1 GDS1574.8.9.12 GDS2362.6.7.2.5 -0.63 agent control endotoxin agent untreated chloroguine treated GDS715.2.6.18 GDS715.0.7.18 0.63 agent negative control 16-ketoestradiol agent none 4,5-dianilinophthalimide GDS1783.0.1 GDS1956.0.2 0.63 agent control thapsigargin disease state normal juvenile dermatomyositis GDS2643.0.1.5 GDS715.0.9.18 0.63 disease state normal Waldenstrom's macroglobulinemia agent none 5-fluorouridine GDS2367.0.1.3 GDS2118.0.3 -0.63 agent vehicle estradiol disease state normal refractory anemia with excess blasts GDS2617.0.2 GDS2200.0.2 0.63 disease state normal tumorigenic cancer cell disease state normal squamous cell carcinoma GDS2221.1.2 GDS2200.0.2 0.63 agent vehicle galectin-1 disease state normal squamous cell carcinoma GDS1956.0.11 GDS1989.1.2.0 -0.63 disease state normal FKRP mutation disease state normal benign nevus GDS715.2.9.18 GDS715.2.3.18 0.63 agent negative control 5-fluorouridine agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1331.0.1 GDS2333.0.2.4 0.63 disease state normal presymptomatic infection uninfected delta pilD mutant GDS1331.0.1 GDS1783.0.1 0.63 disease state normal presymptomatic agent control thapsigargin GDS1331.0.1 GDS2191.0.1 -0.63 disease state normal presymptomatic disease state control bipolar disorder GDS1313.0.1 GDS1665.0.1 0.63 agent control TGFb1 disease state normal papillary thyroid carcinoma GDS2341.0.1.5 GDS1956.0.8 0.63 agent untreated Type I IFN disease state normal Duchenne muscular dystrophy GDS715.0.7.18 GDS715.0.10.18 0.63 agent none 4,5-dianilinophthalimide agent none pergolide methanesulfonate GDS715.0.6.16 GDS1574.8.9.11 0.63 agent none 16-ketoestradiol agent control endotoxin GDS2250.0.1 GDS1685.0.1 0.63 disease state normal non-basal-like cancer disease state normal hereditary gingival fibromatosis GDS2250.0.1 GDS1630.2.4.1 -0.63 disease state normal non-basal-like cancer agent untreated atorvastatin GDS2341.0.3.4 GDS2118.0.3 0.63 agent untreated Types I and II IFNs disease state normal refractory anemia with excess blasts GDS715.0.13.18 GDS715.2.9.18 0.63 agent none 8-(3-chlorostyryl) caffeine agent negative control 5-fluorouridine GDS690.2.4.1 GDS2643.0.1.5 0.63 agent control LTb disease state normal Waldenstrom's macroglobulinemia GDS2341.0.2.5 GDS2200.0.1 0.63 agent untreated Type II IFN disease state normal actinic keratosis GDS1331.0.2 GDS690.2.3.0 0.63 disease state normal symptomatic agent control flagellin GDS1331.0.2 GDS1428.0.1.10 -0.63 disease state normal symptomatic agent untreated Staphylococcus aureus GDS2635.0.3 GDS2200.0.2 0.63 disease state lobular control invasive ductal carcinoma disease state normal squamous cell carcinoma GDS2635.0.3 GDS1989.1.4.0 0.63 disease state lobular control invasive ductal carcinoma disease state normal melanoma in situ GDS1926.0.3.4 GDS2333.0.2.4 0.63 agent control LTD4 and thrombin infection uninfected delta pilD mutant GDS2697.0.1 GDS1333.0.1 0.63 disease state normal teratozoospermia agent baseline oxandrolone GDS2697.0.1 GDS1574.8.9.11 0.63 disease state normal teratozoospermia agent control endotoxin GDS2643.0.1.4 GDS1971.0.2 0.63 disease state normal Waldenstrom's macroglobulinemia disease state healthy complicated malaria GDS2332.0.3 GDS2221.0.2 0.63 infection uninfected delta pilD mutant agent untreated galectin-1 GDS2332.0.3 GDS2221.1.3 0.63 infection uninfected delta pilD mutant agent vehicle lipopolysaccharide GDS2341.0.2.4 GDS1574.8.9.13 0.63 agent untreated Type II IFN agent control endotoxin GDS1362.0.1 GDS2084.0.1 0.63 disease state non-failing heart non-ischemic cardiomyopathy disease state control polycystic ovary syndrome GDS1362.0.1 GDS1353.0.1.2 0.63 disease state non-failing heart non-ischemic cardiomyopathy agent control dexamethasone GDS1362.0.1 GDS715.0.5.18 -0.63 disease state non-failing heart non-ischemic cardiomyopathy agent none sulmazole GDS1362.0.1 GDS1989.1.3.0 -0.63 disease state non-failing heart non-ischemic cardiomyopathy disease state normal atypical nevus GDS1312.0.1 GDS1989.1.7.0 0.63 disease state normal cancer disease state normal lymph node metastasis GDS1783.0.2 GDS2332.0.2 0.63 agent control high potassium infection uninfected delta frpC/frpA mutant GDS1783.0.2 GDS651.0.1 -0.63 agent control high potassium disease state normal idiopathic dilated GDS1783.0.2 GDS2697.0.1 -0.63 agent control high potassium disease state normal teratozoospermia GDS690.2.3.0 GDS1956.0.2 0.63 agent control flagellin disease state normal juvenile dermatomyositis GDS690.2.3.0 GDS2367.3.4.1 -0.63 agent control flagellin infection control adenovirus adenovirus carrying estrogen receptor beta GDS1282.0.1 GDS2250.0.3 0.63 disease state control Wilms' tumor disease state normal basal-like cancer GDS2341.0.1.4 GDS2428.0.1.3 0.63 agent untreated Type I IFN agent untreated 5-aza-dC GDS2341.0.1.4 GDS2216.0.1.5 0.63 agent untreated Type I IFN agent control LPS GDS2214.0.1 GDS2118.0.3 -0.63 agent control lipopolysaccharide disease state normal refractory anemia with excess blasts GDS1549.3.4.2 GDS1312.0.1 0.63 agent control estradiol disease state normal cancer GDS2649.3.5.1 GDS2221.0.3 0.63 disease state uninfected chronic HIV infection agent untreated lipopolysaccharide GDS2649.3.5.1 GDS1989.1.6.0 0.63 disease state uninfected chronic HIV infection disease state normal metastatic growth phase melanoma GDS2767.5.8.4 GDS1956.0.4 0.63 agent water alcohol disease state normal spastic paraplegia GDS2767.6.8.0 GDS2367.3.4.0 0.63 agent water grape juice infection control adenovirus adenovirus carrying estrogen receptor beta GDS2767.6.8.0 GDS2697.0.1 0.63 agent water grape juice disease state normal teratozoospermia GDS2767.6.8.0 GDS1989.1.2.0 0.63 agent water grape juice disease state normal benign nevus GDS2767.6.8.0 GDS715.0.4.18 0.63 agent water grape juice agent none a-methyl-L-p-tyrosine GDS715.1.2.18 GDS1630.2.4.1 0.63 agent negative control positive control agent untreated atorvastatin GDS2767.7.8.0 GDS2239.0.1 -0.63 agent water red wine agent control hepatitis C virus core protein GDS1956.0.9 GDS505.0.1 0.63 disease state normal Calpain 3 mutation disease state normal RCC GDS1259.0.1 GDS1321.0.1 0.62 disease state normal dermatomyositis disease state normal Barrett's esophagus GDS1259.0.1 GDS2414.0.1.3 0.62 disease state normal dermatomyositis agent control trophoblast conditioned medium GDS715.0.8.18 GDS715.2.14.18 0.62 agent none 1,10-phenanthroline agent negative control R-(-)-apomorphine HCl GDS1574.8.9.12 GDS1615.0.1 0.62 agent control endotoxin disease state normal ulcerative colitis GDS2414.0.1.3 GDS2332.0.2 0.62 agent control trophoblast conditioned medium infection uninfected delta frpC/frpA mutant GDS1220.0.1.3 GDS2617.0.2 0.62 disease state normal malignant pleural mesothelioma disease state normal tumorigenic cancer cell GDS715.0.1.16 GDS715.2.10.18 0.62 agent none positive control agent negative control pergolide methanesulfonate GDS2333.0.2.3 GDS690.2.4.1 0.62 infection uninfected delta pilD mutant agent control LTb GDS2333.0.2.3 GDS715.2.5.18 -0.62 infection uninfected delta pilD mutant agent negative control sulmazole GDS1956.0.6 GDS1989.1.2.0 -0.62 disease state normal Emery-Dreifuss muscular dystrophy disease state normal benign nevus GDS1331.0.1 GDS1362.0.2 0.62 disease state normal presymptomatic disease state non-failing heart ischemic cardiomyopathy GDS1362.0.2 GDS1956.0.3 0.62 disease state non-failing heart ischemic cardiomyopathy disease state normal amyotophic lateral sclerosis GDS1667.0.1 GDS1439.0.2 0.62 infection HPV negative HPV positive disease state benign metastatic GDS2341.0.1.5 GDS1956.0.9 0.62 agent untreated Type I IFN disease state normal Calpain 3 mutation GDS2214.0.2 GDS2221.0.2 0.62 agent control HMGB1 agent untreated galectin-1 GDS715.0.9.18 GDS715.0.15.18 0.62 agent none 5-fluorouridine agent none cyclazosin HCl GDS715.0.3.18 GDS715.0.12.18 0.62 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent none 5-fluorouracil GDS2221.0.3 GDS2250.0.1 0.62 agent untreated lipopolysaccharide disease state normal non-basal-like cancer GDS2221.0.3 GDS2250.0.2 0.62 agent untreated lipopolysaccharide disease state normal BRCA1-associated cancer GDS2221.0.3 GDS1427.0.1 -0.62 agent untreated lipopolysaccharide infection control c-Myb GDS2341.0.2.5 GDS2221.1.3 0.62 agent untreated Type II IFN agent vehicle lipopolysaccharide GDS2341.0.2.5 GDS1989.1.6.0 0.62 agent untreated Type II IFN disease state normal metastatic growth phase melanoma GDS1331.0.2 GDS1956.0.5 0.62 disease state normal symptomatic disease state normal fascioscapulohumeral muscular dystrophy GDS1331.0.2 GDS690.2.5.0 0.62 disease state normal symptomatic agent control TNFa GDS1331.0.2 GDS1956.0.3 0.62 disease state normal symptomatic disease state normal amyotophic lateral sclerosis GDS1543.0.1 GDS2221.0.2 0.62 agent control tumor necrosis factor agent untreated galectin-1 GDS1543.0.1 GDS2221.1.3 0.62 agent control tumor necrosis factor agent vehicle lipopolysaccharide GDS1926.0.2.4 GDS2333.0.2.4 0.62 agent control LTD4 infection uninfected delta pilD mutant GDS1956.0.2 GDS2200.0.2 0.62 disease state normal juvenile dermatomyositis disease state normal squamous cell carcinoma GDS715.2.5.18 GDS715.0.9.18 -0.62 agent negative control sulmazole agent none 5-fluorouridine GDS2367.0.2.3 GDS2057.0.1.4 0.62 agent vehicle tamoxifen agent control DHT GDS2341.0.2.4 GDS2216.0.1.5 0.62 agent untreated Type II IFN agent control LPS GDS1362.0.1 GDS1736.0.1 0.62 disease state non-failing heart non-ischemic cardiomyopathy agent control arachidonic acid GDS1312.0.1 GDS2635.0.3 0.62 disease state normal cancer disease state lobular control invasive ductal carcinoma GDS2737.0.1.3 GDS1312.0.1 0.62 disease state normal endometriosis disease state normal cancer GDS2737.0.1.3 GDS1375.0.2 0.62 disease state normal endometriosis disease state normal malignant melanoma GDS2255.3.4.0 GDS1850.0.1 0.62 agent untreated endotoxin disease state healthy carious GDS690.2.3.0 GDS1956.0.3 0.62 agent control flagellin disease state normal amyotophic lateral sclerosis GDS690.2.3.0 GDS1989.1.2.0 -0.62 agent control flagellin disease state normal benign nevus GDS2332.1.2 GDS1375.0.2 -0.62 infection wild type delta frpC/frpA mutant disease state normal malignant melanoma GDS1376.2.3.1 GDS1956.0.3 0.62 disease state normal thrombocythemia disease state normal amyotophic lateral sclerosis GDS1376.2.3.1 GDS690.2.3.0 0.62 disease state normal thrombocythemia agent control flagellin GDS2767.7.8.3 GDS1615.0.2 -0.62 agent water red wine disease state normal Crohn's disease GDS2767.5.8.0 GDS1428.0.1.10 0.62 agent water alcohol agent untreated Staphylococcus aureus GDS2767.5.8.0 GDS715.0.6.16 0.62 agent water alcohol agent none 16-ketoestradiol GDS2649.3.5.0 GDS2250.0.1 0.62 disease state uninfected chronic HIV infection disease state normal non-basal-like cancer GDS2649.2.5.1 GDS1989.1.5.0 0.62 disease state uninfected early HIV infection disease state normal vertical growth phase melanoma GDS2767.7.8.0 GDS1926.0.2.4 -0.62 agent water red wine agent control LTD4 GDS2767.7.8.0 GDS690.2.5.0 -0.62 agent water red wine agent control TNFa GDS2767.7.8.0 GDS651.0.1 0.62 agent water red wine disease state normal idiopathic dilated GDS1926.0.1.4 GDS484.0.1 -0.62 agent control thrombin disease state normal leiomyoma GDS1956.0.2 GDS2649.2.5.0 0.62 disease state normal juvenile dermatomyositis disease state uninfected early HIV infection GDS1850.0.1 GDS505.0.1 0.62 disease state healthy carious disease state normal RCC GDS1956.0.10 GDS505.0.1 0.62 disease state normal dysferlin mutation disease state normal RCC GDS715.0.14.18 GDS266.0.1.2 0.62 agent none R-(-)-apomorphine HCl disease state no atopy atopy GDS2332.0.2 GDS2214.0.1 0.61 infection uninfected delta frpC/frpA mutant agent control lipopolysaccharide GDS1259.0.1 GDS2418.0.1 0.61 disease state normal dermatomyositis disease state control vulvar intraepithelial neoplasia GDS2611.0.1.9 GDS2611.0.2.9 0.61 agent untreated keratinocyte growth factor agent untreated IL-1b GDS715.0.1.18 GDS1630.2.4.1 0.61 agent none positive control agent untreated atorvastatin GDS2643.0.3.5 GDS1736.0.1 0.61 disease state normal multiple myeloma agent control arachidonic acid GDS2643.0.3.5 GDS2643.0.2.4 0.61 disease state normal multiple myeloma disease state normal chronic lymphocytic leukemia GDS2643.0.3.5 GDS2142.0.1 -0.61 disease state normal multiple myeloma disease state normal mild cystic fibrosis GDS2250.0.2 GDS1685.0.1 0.61 disease state normal BRCA1-associated cancer disease state normal hereditary gingival fibromatosis GDS1050.2.3.0 GDS2021.0.2 -0.61 agent untreated valproic acid agent control nebivolol GDS1783.0.1 GDS2367.0.2.4 0.61 agent control thapsigargin agent vehicle tamoxifen GDS2643.0.1.5 GDS2255.3.4.0 -0.61 disease state normal Waldenstrom's macroglobulinemia agent untreated endotoxin GDS2367.0.1.3 GDS2200.0.2 0.61 agent vehicle estradiol disease state normal squamous cell carcinoma GDS2617.0.2 GDS1312.0.1 0.61 disease state normal tumorigenic cancer cell disease state normal cancer GDS2333.0.2.3 GDS2697.0.1 -0.61 infection uninfected delta pilD mutant disease state normal teratozoospermia GDS715.0.8.16 GDS1428.0.1.10 0.61 agent none 1,10-phenanthroline agent untreated Staphylococcus aureus GDS715.0.8.16 GDS2367.3.4.2 0.61 agent none 1,10-phenanthroline infection control adenovirus adenovirus carrying estrogen receptor beta GDS715.0.8.16 GDS1926.0.2.4 -0.61 agent none 1,10-phenanthroline agent control LTD4 GDS1331.0.1 GDS1956.0.1 0.61 disease state normal presymptomatic disease state normal acute quadriplegic myopathy GDS1331.0.1 GDS2643.0.3.5 0.61 disease state normal presymptomatic disease state normal multiple myeloma GDS1331.0.1 GDS1428.0.1.10 -0.61 disease state normal presymptomatic agent untreated Staphylococcus aureus GDS1331.0.1 GDS715.0.5.18 -0.61 disease state normal presymptomatic agent none sulmazole GDS715.0.15.18 GDS715.2.8.18 0.61 agent none cyclazosin HCl agent negative control 1,10-phenanthroline GDS1746.2.4.0 GDS1312.0.1 0.61 disease state normal basaloid disease state normal cancer GDS2341.0.1.5 GDS1321.0.1 0.61 agent untreated Type I IFN disease state normal Barrett's esophagus GDS2214.0.2 GDS1574.8.9.11 0.61 agent control HMGB1 agent control endotoxin GDS2250.0.1 GDS1375.0.1 0.61 disease state normal non-basal-like cancer disease state normal benign nevi GDS715.0.13.18 GDS715.0.1.18 0.61 agent none 8-(3-chlorostyryl) caffeine agent none positive control GDS2221.0.3 GDS2250.0.3 0.61 agent untreated lipopolysaccharide disease state normal basal-like cancer GDS1353.0.1.2 GDS2414.0.1.3 0.61 agent control dexamethasone agent control trophoblast conditioned medium GDS1447.0.1 GDS2332.0.2 0.61 agent control vanadium infection uninfected delta frpC/frpA mutant GDS715.2.8.18 GDS715.2.10.18 0.61 agent negative control 1,10-phenanthroline agent negative control pergolide methanesulfonate GDS1331.0.2 GDS1989.1.6.0 0.61 disease state normal symptomatic disease state normal metastatic growth phase melanoma GDS1331.0.2 GDS1362.0.2 0.61 disease state normal symptomatic disease state non-failing heart ischemic cardiomyopathy GDS1331.0.2 GDS715.2.9.18 0.61 disease state normal symptomatic agent negative control 5-fluorouridine GDS1331.0.2 GDS2367.3.4.1 -0.61 disease state normal symptomatic infection control adenovirus adenovirus carrying estrogen receptor beta GDS1331.0.2 GDS2697.0.1 -0.61 disease state normal symptomatic disease state normal teratozoospermia GDS1543.0.1 GDS1665.0.1 0.61 agent control tumor necrosis factor disease state normal papillary thyroid carcinoma GDS1543.0.1 GDS1405.0.1 -0.61 agent control tumor necrosis factor agent untreated DCI GDS1956.0.9 GDS1989.1.3.0 -0.61 disease state normal Calpain 3 mutation disease state normal atypical nevus GDS2057.0.2.4 GDS2397.0.1 -0.61 agent control RTI-018 disease state normal idiopathic myelofibrosis GDS2200.0.2 GDS1321.0.1 0.61 disease state normal squamous cell carcinoma disease state normal Barrett's esophagus GDS1956.0.2 GDS1989.1.2.0 -0.61 disease state normal juvenile dermatomyositis disease state normal benign nevus GDS1956.0.2 GDS2432.0.1 -0.61 disease state normal juvenile dermatomyositis disease state control pituitary adenoma predisposition GDS2332.0.3 GDS2221.1.2 0.61 infection uninfected delta pilD mutant agent vehicle galectin-1 GDS1850.0.1 GDS1989.1.4.0 0.61 disease state healthy carious disease state normal melanoma in situ GDS2367.0.2.3 GDS2635.0.3 0.61 agent vehicle tamoxifen disease state lobular control invasive ductal carcinoma GDS2057.0.1.4 GDS2250.0.3 0.61 agent control DHT disease state normal basal-like cancer GDS1362.0.1 GDS1630.2.4.0 -0.61 disease state non-failing heart non-ischemic cardiomyopathy agent untreated atorvastatin GDS1783.0.2 GDS2191.0.1 -0.61 agent control high potassium disease state control bipolar disorder GDS2221.0.2 GDS2200.0.2 0.61 agent untreated galectin-1 disease state normal squamous cell carcinoma GDS2332.1.2 GDS2414.0.1.3 0.61 infection wild type delta frpC/frpA mutant agent control trophoblast conditioned medium GDS715.0.12.18 GDS715.0.1.18 0.61 agent none 5-fluorouracil agent none positive control GDS2767.5.8.0 GDS2649.4.5.0 0.61 agent water alcohol disease state uninfected non-progressive HIV infection GDS2649.3.5.1 GDS2200.0.2 0.61 disease state uninfected chronic HIV infection disease state normal squamous cell carcinoma GDS2767.5.8.4 GDS1956.0.5 -0.61 agent water alcohol disease state normal fascioscapulohumeral muscular dystrophy GDS2767.6.8.0 GDS1956.0.5 -0.61 agent water grape juice disease state normal fascioscapulohumeral muscular dystrophy GDS2649.3.5.0 GDS1989.1.4.0 0.61 disease state uninfected chronic HIV infection disease state normal melanoma in situ GDS2767.7.8.0 GDS1956.0.2 -0.61 agent water red wine disease state normal juvenile dermatomyositis GDS2767.7.8.0 GDS690.2.3.0 -0.61 agent water red wine agent control flagellin GDS2767.7.8.0 GDS1956.0.1 -0.61 agent water red wine disease state normal acute quadriplegic myopathy GDS2767.7.8.0 GDS715.0.5.18 0.61 agent water red wine agent none sulmazole GDS715.0.8.16 GDS2649.4.5.1 0.61 agent none 1,10-phenanthroline disease state uninfected non-progressive HIV infection GDS2341.0.1.5 GDS2767.5.8.2 0.61 agent untreated Type I IFN agent water alcohol GDS2332.0.2 GDS2617.0.1 -0.60 infection uninfected delta frpC/frpA mutant disease state normal non-tumorigenic cancer cell GDS2635.0.2 GDS1989.1.7.0 0.60 disease state lobular control invasive lobular carcinoma disease state normal lymph node metastasis GDS2418.0.1 GDS2737.0.1.3 0.60 disease state control vulvar intraepithelial neoplasia disease state normal endometriosis GDS2418.0.1 GDS1439.0.1 0.60 disease state control vulvar intraepithelial neoplasia disease state benign primary GDS2643.0.3.5 GDS1333.0.1 -0.60 disease state normal multiple myeloma agent baseline oxandrolone GDS1574.8.9.12 GDS2414.0.1.4 0.60 agent control endotoxin agent control trophoblast conditioned medium GDS1574.8.9.12 GDS2221.1.2 0.60 agent control endotoxin agent vehicle galectin-1 GDS2250.0.3 GDS1220.0.1.3 0.60 disease state normal basal-like cancer disease state normal malignant pleural mesothelioma GDS2250.0.3 GDS1558.0.1.3 0.60 disease state normal basal-like cancer disease state no atrial fibrillation permanent atrial fibrillation GDS2250.0.3 GDS1630.2.4.1 -0.60 disease state normal basal-like cancer agent untreated atorvastatin GDS715.2.6.18 GDS715.2.13.18 0.60 agent negative control 16-ketoestradiol agent negative control 8-(3-chlorostyryl) caffeine GDS2200.0.1 GDS1259.0.1 0.60 disease state normal actinic keratosis disease state normal dermatomyositis GDS1783.0.1 GDS1956.0.6 0.60 agent control thapsigargin disease state normal Emery-Dreifuss muscular dystrophy GDS2643.0.1.5 GDS715.0.5.18 -0.60 disease state normal Waldenstrom's macroglobulinemia agent none sulmazole GDS2643.0.1.5 GDS715.2.5.18 -0.60 disease state normal Waldenstrom's macroglobulinemia agent negative control sulmazole GDS715.2.7.18 GDS715.2.10.18 0.60 agent negative control 4,5-dianilinophthalimide agent negative control pergolide methanesulfonate GDS2617.0.2 GDS2737.0.1.3 0.60 disease state normal tumorigenic cancer cell disease state normal endometriosis GDS2221.1.2 GDS2250.0.1 0.60 agent vehicle galectin-1 disease state normal non-basal-like cancer GDS2333.0.2.3 GDS1956.0.1 0.60 infection uninfected delta pilD mutant disease state normal acute quadriplegic myopathy GDS1956.0.11 GDS1956.0.4 0.60 disease state normal FKRP mutation disease state normal spastic paraplegia GDS715.0.6.18 GDS715.0.12.18 0.60 agent none 16-ketoestradiol agent none 5-fluorouracil GDS690.2.5.0 GDS1543.0.1 0.60 agent control TNFa agent control tumor necrosis factor GDS1375.0.2 GDS2635.0.3 0.60 disease state normal malignant melanoma disease state lobular control invasive ductal carcinoma GDS2333.1.2.4 GDS1313.0.1 -0.60 infection wild type delta pilD mutant agent control TGFb1 GDS2341.0.1.5 GDS2221.0.3 0.60 agent untreated Type I IFN agent untreated lipopolysaccharide GDS2367.3.4.2 GDS715.0.4.18 0.60 infection control adenovirus adenovirus carrying estrogen receptor beta agent none a-methyl-L-p-tyrosine GDS2367.3.4.2 GDS860.0.1 -0.60 infection control adenovirus adenovirus carrying estrogen receptor beta agent untreated endothelin-1 GDS690.2.4.1 GDS715.0.4.18 -0.60 agent control LTb agent none a-methyl-L-p-tyrosine GDS715.0.11.18 GDS715.0.8.18 0.60 agent none scopolamine methyl bromide agent none 1,10-phenanthroline GDS2341.0.2.5 GDS1989.1.4.0 0.60 agent untreated Type II IFN disease state normal melanoma in situ GDS1353.0.1.2 GDS1956.0.5 0.60 agent control dexamethasone disease state normal fascioscapulohumeral muscular dystrophy GDS1405.0.1 GDS1665.0.1 -0.60 agent untreated DCI disease state normal papillary thyroid carcinoma GDS1331.0.2 GDS1746.2.3.0 -0.60 disease state normal symptomatic disease state normal benign hyperplasia GDS1331.0.2 GDS715.0.5.18 -0.60 disease state normal symptomatic agent none sulmazole GDS1542.0.1 GDS2221.0.3 0.60 agent control tumor necrosis factor agent untreated lipopolysaccharide GDS1956.0.9 GDS1665.0.1 0.60 disease state normal Calpain 3 mutation disease state normal papillary thyroid carcinoma GDS715.2.11.18 GDS715.2.3.18 0.60 agent negative control scopolamine methyl bromide agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1989.1.6.0 GDS1321.0.1 0.60 disease state normal metastatic growth phase melanoma disease state normal Barrett's esophagus GDS715.2.3.18 GDS715.2.10.18 0.60 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control pergolide methanesulfonate GDS2697.0.1 GDS2852.0.1.5 -0.60 disease state normal teratozoospermia agent control IL-13 GDS2200.0.2 GDS2611.0.3.9 0.60 disease state normal squamous cell carcinoma agent untreated IFN-gamma GDS1956.0.2 GDS2341.0.2.4 0.60 disease state normal juvenile dermatomyositis agent untreated Type II IFN GDS1850.0.1 GDS2397.0.1 -0.60 disease state healthy carious disease state normal idiopathic myelofibrosis GDS2367.0.2.3 GDS860.0.1 0.60 agent vehicle tamoxifen agent untreated endothelin-1 GDS2221.1.3 GDS2200.0.1 0.60 agent vehicle lipopolysaccharide disease state normal actinic keratosis GDS2221.1.3 GDS1427.0.2 -0.60 agent vehicle lipopolysaccharide infection control v-Myb GDS1783.0.2 GDS1926.0.2.4 0.60 agent control high potassium agent control LTD4 GDS1783.0.2 GDS1989.1.3.0 -0.60 agent control high potassium disease state normal atypical nevus GDS1397.0.2 GDS2215.0.2 0.60 agent untreated TNF-alpha agent control cyfluthrin GDS1397.0.2 GDS2215.0.1 0.60 agent untreated TNF-alpha agent control chlorpyrifos GDS2367.3.4.0 GDS2191.0.1 0.60 infection control adenovirus adenovirus carrying estrogen receptor beta disease state control bipolar disorder GDS2341.0.1.4 GDS2362.6.7.2.5 -0.60 agent untreated Type I IFN agent untreated chloroguine treated GDS2333.1.2.3 GDS1783.0.2 0.60 infection wild type delta pilD mutant agent control high potassium GDS2333.1.2.3 GDS2191.0.1 -0.60 infection wild type delta pilD mutant disease state control bipolar disorder GDS1549.3.4.2 GDS2418.0.1 0.60 agent control estradiol disease state control vulvar intraepithelial neoplasia GDS484.0.1 GDS1312.0.1 0.60 disease state normal leiomyoma disease state normal cancer GDS2767.5.8.0 GDS1926.0.2.4 -0.60 agent water alcohol agent control LTD4 GDS2767.5.8.4 GDS715.2.9.18 -0.60 agent water alcohol agent negative control 5-fluorouridine GDS2767.5.8.4 GDS715.0.9.18 -0.60 agent water alcohol agent none 5-fluorouridine GDS2767.5.8.4 GDS1665.0.1 0.60 agent water alcohol disease state normal papillary thyroid carcinoma GDS2767.6.8.0 GDS2414.0.1.3 -0.60 agent water grape juice agent control trophoblast conditioned medium GDS2767.6.8.0 GDS1428.0.1.10 0.60 agent water grape juice agent untreated Staphylococcus aureus GDS2649.3.5.0 GDS1259.0.1 0.60 disease state uninfected chronic HIV infection disease state normal dermatomyositis GDS2649.2.5.1 GDS1375.0.1 0.60 disease state uninfected early HIV infection disease state normal benign nevi GDS2649.2.5.1 GDS1050.0.1.2 0.60 disease state uninfected early HIV infection disease state normal polycystic ovary syndrome GDS2767.7.8.0 GDS1746.2.3.0 0.60 agent water red wine disease state normal benign hyperplasia GDS1574.8.9.14 GDS266.0.1.4 -0.60 agent control endotoxin disease state no atopy atopy GDS1956.0.11 GDS505.0.1 0.60 disease state normal FKRP mutation disease state normal RCC GDS2341.0.3.4 GDS2649.2.5.1 0.60 agent untreated Types I and II IFNs disease state uninfected early HIV infection GDS1956.0.2 GDS1062.2.3.0 -0.60 disease state normal juvenile dermatomyositis disease state no metastasis metastasis GDS1259.0.1 GDS1321.0.2 0.59 disease state normal dermatomyositis disease state normal adenocarcinoma GDS2362.6.7.2.5 GDS1989.1.2.0 0.59 agent untreated chloroguine treated disease state normal benign nevus GDS2362.6.7.2.5 GDS2432.0.1 0.59 agent untreated chloroguine treated disease state control pituitary adenoma predisposition GDS2418.0.1 GDS2397.0.1 -0.59 disease state control vulvar intraepithelial neoplasia disease state normal idiopathic myelofibrosis GDS715.0.1.18 GDS715.2.6.18 0.59 agent none positive control agent negative control 16-ketoestradiol GDS2250.0.3 GDS2428.0.1.2 -0.59 disease state normal basal-like cancer agent untreated 5-aza-dC GDS2200.0.1 GDS2635.0.3 0.59 disease state normal actinic keratosis disease state lobular control invasive ductal carcinoma GDS1783.0.1 GDS2333.1.2.3 0.59 agent control thapsigargin infection wild type delta pilD mutant GDS2367.0.1.3 GDS1282.0.1 0.59 agent vehicle estradiol disease state control Wilms' tumor GDS1220.0.1.3 GDS1732.0.1 0.59 disease state normal malignant pleural mesothelioma disease state normal papillary thyroid cancer GDS2333.0.2.3 GDS1376.2.3.1 0.59 infection uninfected delta pilD mutant disease state normal thrombocythemia GDS1397.0.1 GDS1783.0.2 0.59 agent untreated HIV agent control high potassium GDS715.0.8.16 GDS690.2.3.0 -0.59 agent none 1,10-phenanthroline agent control flagellin GDS715.0.6.18 GDS715.2.13.18 -0.59 agent none 16-ketoestradiol agent negative control 8-(3-chlorostyryl) caffeine GDS2205.0.1 GDS1850.0.1 -0.59 disease state non-failing dilated cardiomyopathy disease state healthy carious GDS1746.2.4.0 GDS2609.0.1 -0.59 disease state normal basaloid disease state healthy control early onset colorectal cancer GDS715.0.6.16 GDS715.2.15.18 0.59 agent none 16-ketoestradiol agent negative control cyclazosin HCl GDS2250.0.1 GDS2744.0.1 -0.59 disease state normal non-basal-like cancer agent control dioxin GDS2250.0.1 GDS2428.0.1.2 -0.59 disease state normal non-basal-like cancer agent untreated 5-aza-dC GDS715.0.13.18 GDS715.2.15.18 -0.59 agent none 8-(3-chlorostyryl) caffeine agent negative control cyclazosin HCl GDS715.0.11.18 GDS715.0.15.18 0.59 agent none scopolamine methyl bromide agent none cyclazosin HCl GDS2341.0.2.5 GDS2221.1.2 0.59 agent untreated Type II IFN agent vehicle galectin-1 GDS1353.0.1.2 GDS1783.0.2 0.59 agent control dexamethasone agent control high potassium GDS1331.0.2 GDS1630.2.4.0 -0.59 disease state normal symptomatic agent untreated atorvastatin GDS1926.0.3.4 GDS715.2.7.18 0.59 agent control LTD4 and thrombin agent negative control 4,5-dianilinophthalimide GDS1926.0.3.4 GDS651.0.1 -0.59 agent control LTD4 and thrombin disease state normal idiopathic dilated GDS2697.0.1 GDS1428.0.1.10 0.59 disease state normal teratozoospermia agent untreated Staphylococcus aureus GDS2213.0.2 GDS1362.0.1 -0.59 agent untreated TSA disease state non-failing heart non-ischemic cardiomyopathy GDS2332.0.3 GDS1574.8.9.12 0.59 infection uninfected delta pilD mutant agent control endotoxin GDS1850.0.1 GDS1321.0.2 0.59 disease state healthy carious disease state normal adenocarcinoma GDS1850.0.1 GDS2200.0.2 0.59 disease state healthy carious disease state normal squamous cell carcinoma GDS1850.0.1 GDS1989.1.5.0 0.59 disease state healthy carious disease state normal vertical growth phase melanoma GDS715.2.5.18 GDS715.0.12.18 -0.59 agent negative control sulmazole agent none 5-fluorouracil GDS715.2.5.18 GDS715.2.9.18 -0.59 agent negative control sulmazole agent negative control 5-fluorouridine GDS2367.0.2.3 GDS1665.0.1 0.59 agent vehicle tamoxifen disease state normal papillary thyroid carcinoma GDS2057.0.1.4 GDS1630.2.4.1 -0.59 agent control DHT agent untreated atorvastatin GDS2221.1.3 GDS2250.0.2 0.59 agent vehicle lipopolysaccharide disease state normal BRCA1-associated cancer GDS1362.0.1 GDS2057.0.1.4 -0.59 disease state non-failing heart non-ischemic cardiomyopathy agent control DHT GDS2333.0.2.4 GDS2341.0.2.5 0.59 infection uninfected delta pilD mutant agent untreated Type II IFN GDS2333.0.2.4 GDS2341.0.3.5 0.59 infection uninfected delta pilD mutant agent untreated Types I and II IFNs GDS1956.0.1 GDS651.0.1 -0.59 disease state normal acute quadriplegic myopathy disease state normal idiopathic dilated GDS1312.0.1 GDS1732.0.1 0.59 disease state normal cancer disease state normal papillary thyroid cancer GDS1312.0.1 GDS2617.0.1 0.59 disease state normal cancer disease state normal non-tumorigenic cancer cell GDS2190.0.1 GDS2250.0.2 -0.59 disease state control bipolar disorder disease state normal BRCA1-associated cancer GDS1783.0.2 GDS2142.0.2 0.59 agent control high potassium disease state normal severe cystic fibrosis GDS1397.0.2 GDS2643.0.3.5 0.59 agent untreated TNF-alpha disease state normal multiple myeloma GDS1397.0.2 GDS715.0.6.16 -0.59 agent untreated TNF-alpha agent none 16-ketoestradiol GDS1397.0.2 GDS715.0.8.16 -0.59 agent untreated TNF-alpha agent none 1,10-phenanthroline GDS2737.0.1.3 GDS1549.3.4.2 0.59 disease state normal endometriosis agent control estradiol GDS2255.3.4.0 GDS2221.0.2 0.59 agent untreated endotoxin agent untreated galectin-1 GDS2255.3.4.0 GDS2118.0.3 -0.59 agent untreated endotoxin disease state normal refractory anemia with excess blasts GDS690.2.3.0 GDS1783.0.2 0.59 agent control flagellin agent control high potassium GDS2341.0.1.4 GDS2221.1.2 0.59 agent untreated Type I IFN agent vehicle galectin-1 GDS2341.0.1.4 GDS1447.0.1 -0.59 agent untreated Type I IFN agent control vanadium GDS2214.0.1 GDS2118.0.1 -0.59 agent control lipopolysaccharide disease state normal refractory anemia GDS2332.1.2 GDS1956.0.3 0.59 infection wild type delta frpC/frpA mutant disease state normal amyotophic lateral sclerosis GDS1376.2.3.1 GDS2643.0.1.5 0.59 disease state normal thrombocythemia disease state normal Waldenstrom's macroglobulinemia GDS1549.3.4.2 GDS2118.0.3 -0.59 agent control estradiol disease state normal refractory anemia with excess blasts GDS2767.7.8.0 GDS2649.4.5.0 0.59 agent water red wine disease state uninfected non-progressive HIV infection GDS2649.2.5.0 GDS1321.0.2 0.59 disease state uninfected early HIV infection disease state normal adenocarcinoma GDS2767.5.8.0 GDS2333.1.2.3 -0.59 agent water alcohol infection wild type delta pilD mutant GDS2767.5.8.0 GDS1630.2.4.0 0.59 agent water alcohol agent untreated atorvastatin GDS2767.5.8.4 GDS651.0.1 0.59 agent water alcohol disease state normal idiopathic dilated GDS2767.6.8.0 GDS2852.0.1.5 -0.59 agent water grape juice agent control IL-13 GDS2767.6.8.0 GDS715.0.9.18 -0.59 agent water grape juice agent none 5-fluorouridine GDS2767.6.8.0 GDS715.0.10.18 -0.59 agent water grape juice agent none pergolide methanesulfonate GDS2767.6.8.0 GDS2333.1.2.3 -0.59 agent water grape juice infection wild type delta pilD mutant GDS2767.6.8.0 GDS1665.0.1 0.59 agent water grape juice disease state normal papillary thyroid carcinoma GDS2649.2.5.1 GDS1480.0.1 -0.59 disease state uninfected early HIV infection disease state lean obese GDS2767.7.8.0 GDS2205.0.1 -0.59 agent water red wine disease state non-failing dilated cardiomyopathy GDS2767.7.8.0 GDS1630.2.4.0 0.59 agent water red wine agent untreated atorvastatin GDS2767.7.8.0 GDS1665.0.1 0.59 agent water red wine disease state normal papillary thyroid carcinoma GDS1615.0.1 GDS266.0.1.4 -0.59 disease state normal ulcerative colitis disease state no atopy atopy GDS2418.0.1 GDS505.0.1 0.59 disease state control vulvar intraepithelial neoplasia disease state normal RCC GDS2142.0.2 GDS505.0.1 -0.59 disease state normal severe cystic fibrosis disease state normal RCC GDS2362.6.7.2.5 GDS715.2.10.18 -0.58 agent untreated chloroguine treated agent negative control pergolide methanesulfonate GDS2215.0.2 GDS1397.0.1 0.58 agent control cyfluthrin agent untreated HIV GDS2200.0.1 GDS2250.0.3 0.58 disease state normal actinic keratosis disease state normal basal-like cancer GDS2414.0.1.3 GDS2362.6.7.2.5 -0.58 agent control trophoblast conditioned medium agent untreated chloroguine treated GDS1050.2.3.0 GDS2215.0.2 -0.58 agent untreated valproic acid agent control cyfluthrin GDS1050.2.3.0 GDS1375.0.2 -0.58 agent untreated valproic acid disease state normal malignant melanoma GDS1783.0.1 GDS1746.2.3.0 -0.58 agent control thapsigargin disease state normal benign hyperplasia GDS2643.0.1.5 GDS2153.0.1 0.58 disease state normal Waldenstrom's macroglobulinemia disease state normal dermatomyositis GDS2367.0.1.3 GDS1989.1.5.0 0.58 agent vehicle estradiol disease state normal vertical growth phase melanoma GDS2367.0.1.3 GDS1667.0.1 0.58 agent vehicle estradiol infection HPV negative HPV positive GDS2367.0.1.3 GDS2617.0.2 0.58 agent vehicle estradiol disease state normal tumorigenic cancer cell GDS2367.0.1.3 GDS2397.0.1 -0.58 agent vehicle estradiol disease state normal idiopathic myelofibrosis GDS715.2.4.18 GDS715.2.14.18 0.58 agent negative control a-methyl-L-p-tyrosine agent negative control R-(-)-apomorphine HCl GDS2221.1.2 GDS2200.0.1 0.58 agent vehicle galectin-1 disease state normal actinic keratosis GDS2221.1.2 GDS1989.1.5.0 0.58 agent vehicle galectin-1 disease state normal vertical growth phase melanoma GDS2333.0.2.3 GDS1220.0.1.3 0.58 infection uninfected delta pilD mutant disease state normal malignant pleural mesothelioma GDS2333.0.2.3 GDS2142.0.2 0.58 infection uninfected delta pilD mutant disease state normal severe cystic fibrosis GDS2333.0.2.3 GDS1736.0.1 0.58 infection uninfected delta pilD mutant agent control arachidonic acid GDS2333.0.2.3 GDS1956.0.6 0.58 infection uninfected delta pilD mutant disease state normal Emery-Dreifuss muscular dystrophy GDS2333.0.2.3 GDS1427.0.2 -0.58 infection uninfected delta pilD mutant infection control v-Myb GDS1956.0.11 GDS1321.0.2 0.58 disease state normal FKRP mutation disease state normal adenocarcinoma GDS1397.0.1 GDS715.0.15.18 -0.58 agent untreated HIV agent none cyclazosin HCl GDS715.0.8.16 GDS2362.6.7.2.5 0.58 agent none 1,10-phenanthroline agent untreated chloroguine treated GDS715.0.8.16 GDS690.2.5.0 -0.58 agent none 1,10-phenanthroline agent control TNFa GDS1956.0.6 GDS1989.1.3.0 -0.58 disease state normal Emery-Dreifuss muscular dystrophy disease state normal atypical nevus GDS1331.0.1 GDS651.0.1 -0.58 disease state normal presymptomatic disease state normal idiopathic dilated GDS1331.0.1 GDS715.0.6.16 -0.58 disease state normal presymptomatic agent none 16-ketoestradiol GDS1331.0.1 GDS1427.0.2 -0.58 disease state normal presymptomatic infection control v-Myb GDS1956.0.4 GDS1956.0.10 0.58 disease state normal spastic paraplegia disease state normal dysferlin mutation GDS690.2.5.0 GDS2414.0.1.3 0.58 agent control TNFa agent control trophoblast conditioned medium GDS2341.0.1.5 GDS1353.0.1.3 -0.58 agent untreated Type I IFN agent control dexamethasone GDS715.0.6.16 GDS2367.3.4.2 0.58 agent none 16-ketoestradiol infection control adenovirus adenovirus carrying estrogen receptor beta GDS715.0.5.18 GDS715.2.6.18 0.58 agent none sulmazole agent negative control 16-ketoestradiol GDS2341.0.3.4 GDS1667.0.1 0.58 agent untreated Types I and II IFNs infection HPV negative HPV positive GDS2617.0.1 GDS2118.0.2 0.58 disease state normal non-tumorigenic cancer cell disease state normal refractory anemia with ringed sideroblasts GDS2341.0.2.5 GDS2362.6.7.2.5 -0.58 agent untreated Type II IFN agent untreated chloroguine treated GDS1685.0.1 GDS1989.1.2.0 0.58 disease state normal hereditary gingival fibromatosis disease state normal benign nevus GDS2611.0.2.9 GDS2418.0.1 0.58 agent untreated IL-1b disease state control vulvar intraepithelial neoplasia GDS1542.0.1 GDS1850.0.1 0.58 agent control tumor necrosis factor disease state healthy carious GDS1956.0.9 GDS2609.0.1 0.58 disease state normal Calpain 3 mutation disease state healthy control early onset colorectal cancer GDS715.2.15.18 GDS715.0.4.18 0.58 agent negative control cyclazosin HCl agent none a-methyl-L-p-tyrosine GDS2643.0.1.4 GDS1971.0.1 0.58 disease state normal Waldenstrom's macroglobulinemia disease state healthy uncomplicated malaria GDS2332.0.3 GDS1665.0.1 0.58 infection uninfected delta pilD mutant disease state normal papillary thyroid carcinoma GDS2367.0.2.3 GDS1321.0.2 0.58 agent vehicle tamoxifen disease state normal adenocarcinoma GDS2221.1.3 GDS2200.0.2 0.58 agent vehicle lipopolysaccharide disease state normal squamous cell carcinoma GDS1362.0.1 GDS1746.2.4.0 -0.58 disease state non-failing heart non-ischemic cardiomyopathy disease state normal basaloid GDS2333.0.2.4 GDS1447.0.1 0.58 infection uninfected delta pilD mutant agent control vanadium GDS1956.0.5 GDS1989.1.2.0 -0.58 disease state normal fascioscapulohumeral muscular dystrophy disease state normal benign nevus GDS1783.0.2 GDS1956.0.6 0.58 agent control high potassium disease state normal Emery-Dreifuss muscular dystrophy GDS1783.0.2 GDS1630.2.4.0 -0.58 agent control high potassium agent untreated atorvastatin GDS2737.0.1.3 GDS1989.1.6.0 0.58 disease state normal endometriosis disease state normal metastatic growth phase melanoma GDS1558.0.1.3 GDS1313.0.1 0.58 disease state no atrial fibrillation permanent atrial fibrillation agent control TGFb1 GDS1282.0.1 GDS1989.1.5.0 0.58 disease state control Wilms' tumor disease state normal vertical growth phase melanoma GDS2333.1.2.3 GDS1956.0.2 0.58 infection wild type delta pilD mutant disease state normal juvenile dermatomyositis GDS715.2.13.18 GDS715.0.3.18 -0.58 agent negative control 8-(3-chlorostyryl) caffeine agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS715.0.12.18 GDS715.2.11.18 0.58 agent none 5-fluorouracil agent negative control scopolamine methyl bromide GDS1376.2.3.1 GDS1362.0.2 0.58 disease state normal thrombocythemia disease state non-failing heart ischemic cardiomyopathy GDS2649.3.5.1 GDS505.0.1 0.58 disease state uninfected chronic HIV infection disease state normal RCC GDS2767.5.8.0 GDS2118.0.2 0.58 agent water alcohol disease state normal refractory anemia with ringed sideroblasts GDS2767.5.8.4 GDS715.0.10.18 -0.58 agent water alcohol agent none pergolide methanesulfonate GDS2767.5.8.4 GDS1956.0.1 -0.58 agent water alcohol disease state normal acute quadriplegic myopathy GDS2767.6.8.0 GDS690.2.3.0 -0.58 agent water grape juice agent control flagellin GDS2767.6.8.0 GDS2737.0.1.4 0.58 agent water grape juice disease state normal endometriosis GDS2649.3.5.0 GDS2611.0.3.9 0.58 disease state uninfected chronic HIV infection agent untreated IFN-gamma GDS2649.2.5.1 GDS2635.0.2 0.58 disease state uninfected early HIV infection disease state lobular control invasive lobular carcinoma GDS715.1.2.18 GDS1615.0.2 0.58 agent negative control positive control disease state normal Crohn's disease GDS2767.7.8.0 GDS1353.0.1.2 -0.58 agent water red wine agent control dexamethasone GDS2200.0.1 GDS505.0.1 0.58 disease state normal actinic keratosis disease state normal RCC GDS2617.0.1 GDS484.0.1 0.58 disease state normal non-tumorigenic cancer cell disease state normal leiomyoma GDS1574.8.9.11 GDS715.1.2.18 0.58 agent control endotoxin agent negative control positive control GDS1331.0.2 GDS2649.4.5.0 -0.58 disease state normal symptomatic disease state uninfected non-progressive HIV infection GDS1971.0.2 GDS266.0.1.4 -0.58 disease state healthy complicated malaria disease state no atopy atopy GDS1615.0.1 GDS1971.0.2 0.57 disease state normal ulcerative colitis disease state healthy complicated malaria GDS1615.0.1 GDS2643.0.2.4 -0.57 disease state normal ulcerative colitis disease state normal chronic lymphocytic leukemia GDS1259.0.1 GDS2611.0.3.9 0.57 disease state normal dermatomyositis agent untreated IFN-gamma GDS715.0.8.18 GDS715.0.10.18 0.57 agent none 1,10-phenanthroline agent none pergolide methanesulfonate GDS1333.0.1 GDS715.0.8.16 0.57 agent baseline oxandrolone agent none 1,10-phenanthroline GDS1989.1.3.0 GDS1902.0.1.8.9 0.57 disease state normal atypical nevus agent none ethanol control GDS1553.0.1 GDS860.0.1 -0.57 agent untreated fullerene agent untreated endothelin-1 GDS2643.0.3.5 GDS2852.0.1.5 0.57 disease state normal multiple myeloma agent control IL-13 GDS2643.0.3.5 GDS1956.0.3 0.57 disease state normal multiple myeloma disease state normal amyotophic lateral sclerosis GDS1574.8.9.12 GDS2611.0.3.9 0.57 agent control endotoxin agent untreated IFN-gamma GDS2200.0.1 GDS1375.0.1 0.57 disease state normal actinic keratosis disease state normal benign nevi GDS1050.2.3.0 GDS2057.0.1.4 -0.57 agent untreated valproic acid agent control DHT GDS1783.0.1 GDS2153.0.1 0.57 agent control thapsigargin disease state normal dermatomyositis GDS2367.0.1.3 GDS2428.0.1.2 -0.57 agent vehicle estradiol agent untreated 5-aza-dC GDS2617.0.2 GDS1989.1.7.0 0.57 disease state normal tumorigenic cancer cell disease state normal lymph node metastasis GDS2333.0.2.3 GDS1956.0.2 0.57 infection uninfected delta pilD mutant disease state normal juvenile dermatomyositis GDS1956.0.11 GDS1321.0.1 0.57 disease state normal FKRP mutation disease state normal Barrett's esophagus GDS715.0.8.16 GDS1050.2.3.0 0.57 agent none 1,10-phenanthroline agent untreated valproic acid GDS1331.0.1 GDS2153.0.1 0.57 disease state normal presymptomatic disease state normal dermatomyositis GDS1331.0.1 GDS1783.0.2 0.57 disease state normal presymptomatic agent control high potassium GDS1331.0.1 GDS715.2.5.18 -0.57 disease state normal presymptomatic agent negative control sulmazole GDS1362.0.2 GDS1956.0.10 -0.57 disease state non-failing heart ischemic cardiomyopathy disease state normal dysferlin mutation GDS1667.0.1 GDS2617.0.1 0.57 infection HPV negative HPV positive disease state normal non-tumorigenic cancer cell GDS690.2.5.0 GDS2332.1.2 0.57 agent control TNFa infection wild type delta frpC/frpA mutant GDS690.2.5.0 GDS1956.0.5 0.57 agent control TNFa disease state normal fascioscapulohumeral muscular dystrophy GDS2367.3.4.2 GDS1989.1.6.0 -0.57 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal metastatic growth phase melanoma GDS2341.0.3.4 GDS1542.0.1 0.57 agent untreated Types I and II IFNs agent control tumor necrosis factor GDS690.2.4.1 GDS1783.0.2 0.57 agent control LTb agent control high potassium GDS715.0.11.18 GDS715.0.3.18 0.57 agent none scopolamine methyl bromide agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2617.0.1 GDS2200.0.2 0.57 disease state normal non-tumorigenic cancer cell disease state normal squamous cell carcinoma GDS2341.0.3.5 GDS2142.0.1 -0.57 agent untreated Types I and II IFNs disease state normal mild cystic fibrosis GDS2341.0.2.5 GDS2118.0.3 0.57 agent untreated Type II IFN disease state normal refractory anemia with excess blasts GDS2367.3.4.1 GDS1375.0.2 -0.57 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal malignant melanoma GDS1630.2.4.0 GDS2643.0.1.5 -0.57 agent untreated atorvastatin disease state normal Waldenstrom's macroglobulinemia GDS1353.0.1.2 GDS1783.0.1 0.57 agent control dexamethasone agent control thapsigargin GDS1447.0.1 GDS1926.0.3.4 0.57 agent control vanadium agent control LTD4 and thrombin GDS1331.0.2 GDS1427.0.2 -0.57 disease state normal symptomatic infection control v-Myb GDS1926.0.3.4 GDS2362.6.7.2.5 -0.57 agent control LTD4 and thrombin agent untreated chloroguine treated GDS1926.0.1.4 GDS715.2.7.18 0.57 agent control thrombin agent negative control 4,5-dianilinophthalimide GDS1956.0.9 GDS1956.0.4 0.57 disease state normal Calpain 3 mutation disease state normal spastic paraplegia GDS715.2.11.18 GDS715.0.6.18 -0.57 agent negative control scopolamine methyl bromide agent none 16-ketoestradiol GDS715.2.11.18 GDS715.0.7.18 -0.57 agent negative control scopolamine methyl bromide agent none 4,5-dianilinophthalimide GDS715.2.15.18 GDS715.0.12.18 -0.57 agent negative control cyclazosin HCl agent none 5-fluorouracil GDS2697.0.1 GDS715.0.6.16 0.57 disease state normal teratozoospermia agent none 16-ketoestradiol GDS1850.0.1 GDS1282.0.1 0.57 disease state healthy carious disease state control Wilms' tumor GDS1362.0.1 GDS715.2.5.18 -0.57 disease state non-failing heart non-ischemic cardiomyopathy agent negative control sulmazole GDS1362.0.1 GDS2118.0.3 -0.57 disease state non-failing heart non-ischemic cardiomyopathy disease state normal refractory anemia with excess blasts GDS1362.0.1 GDS2697.0.1 -0.57 disease state non-failing heart non-ischemic cardiomyopathy disease state normal teratozoospermia GDS2333.0.2.4 GDS2418.0.1 0.57 infection uninfected delta pilD mutant disease state control vulvar intraepithelial neoplasia GDS1312.0.1 GDS2609.0.1 -0.57 disease state normal cancer disease state healthy control early onset colorectal cancer GDS2737.0.1.3 GDS2250.0.2 0.57 disease state normal endometriosis disease state normal BRCA1-associated cancer GDS2737.0.1.3 GDS1439.0.1 0.57 disease state normal endometriosis disease state benign primary GDS2255.3.4.0 GDS2221.1.2 0.57 agent untreated endotoxin agent vehicle galectin-1 GDS690.2.3.0 GDS2153.0.1 0.57 agent control flagellin disease state normal dermatomyositis GDS2221.0.2 GDS2250.0.1 0.57 agent untreated galectin-1 disease state normal non-basal-like cancer GDS2142.0.1 GDS268.0.2 -0.57 disease state normal mild cystic fibrosis disease state non-obese morbidly obese GDS2367.3.4.0 GDS715.0.5.18 0.57 infection control adenovirus adenovirus carrying estrogen receptor beta agent none sulmazole GDS1282.0.1 GDS2250.0.1 0.57 disease state control Wilms' tumor disease state normal non-basal-like cancer GDS1282.0.1 GDS1989.1.7.0 0.57 disease state control Wilms' tumor disease state normal lymph node metastasis GDS2341.0.1.4 GDS2221.0.2 0.57 agent untreated Type I IFN agent untreated galectin-1 GDS2332.1.2 GDS2205.0.1 0.57 infection wild type delta frpC/frpA mutant disease state non-failing dilated cardiomyopathy GDS1376.2.3.1 GDS1956.0.1 0.57 disease state normal thrombocythemia disease state normal acute quadriplegic myopathy GDS2767.6.8.0 GDS2649.4.5.0 0.57 agent water grape juice disease state uninfected non-progressive HIV infection GDS505.0.1 GDS1989.1.3.0 -0.57 disease state normal RCC disease state normal atypical nevus GDS505.0.1 GDS2617.0.2 0.57 disease state normal RCC disease state normal tumorigenic cancer cell GDS505.0.1 GDS2609.0.1 0.57 disease state normal RCC disease state healthy control early onset colorectal cancer GDS505.0.1 GDS2153.0.1 0.57 disease state normal RCC disease state normal dermatomyositis GDS2767.6.8.0 GDS1926.0.2.4 -0.57 agent water grape juice agent control LTD4 GDS2767.6.8.0 GDS1630.2.4.0 0.57 agent water grape juice agent untreated atorvastatin GDS2649.3.5.0 GDS1971.0.2 0.57 disease state uninfected chronic HIV infection disease state healthy complicated malaria GDS2649.2.5.1 GDS2609.0.1 -0.57 disease state uninfected early HIV infection disease state healthy control early onset colorectal cancer GDS2649.2.5.1 GDS2057.0.1.4 0.57 disease state uninfected early HIV infection agent control DHT GDS2767.7.8.0 GDS2432.0.1 0.57 agent water red wine disease state control pituitary adenoma predisposition GDS2418.0.1 GDS715.1.2.18 -0.57 disease state control vulvar intraepithelial neoplasia agent negative control positive control GDS2418.0.1 GDS1062.2.3.0 -0.57 disease state control vulvar intraepithelial neoplasia disease state no metastasis metastasis GDS715.0.8.16 GDS2649.3.5.1 0.57 agent none 1,10-phenanthroline disease state uninfected chronic HIV infection GDS1615.0.1 GDS1392.0.1 0.56 disease state normal ulcerative colitis disease state normal rheumatoid arthritis, on methotrexate GDS651.0.1 GDS2153.0.1 -0.56 disease state normal idiopathic dilated disease state normal dermatomyositis GDS2362.6.7.2.5 GDS1615.0.1 -0.56 agent untreated chloroguine treated disease state normal ulcerative colitis GDS2362.6.7.2.5 GDS715.0.10.18 -0.56 agent untreated chloroguine treated agent none pergolide methanesulfonate GDS2191.0.1 GDS1956.0.4 0.56 disease state control bipolar disorder disease state normal spastic paraplegia GDS2418.0.1 GDS1685.0.1 0.56 disease state control vulvar intraepithelial neoplasia disease state normal hereditary gingival fibromatosis GDS2643.0.3.5 GDS690.2.3.0 0.56 disease state normal multiple myeloma agent control flagellin GDS2643.0.3.5 GDS810.0.3 -0.56 disease state normal multiple myeloma disease state control severe AD GDS2250.0.2 GDS1549.3.4.1 0.56 disease state normal BRCA1-associated cancer agent control estradiol GDS2414.0.1.3 GDS651.0.1 -0.56 agent control trophoblast conditioned medium disease state normal idiopathic dilated GDS1220.0.1.3 GDS2617.0.1 0.56 disease state normal malignant pleural mesothelioma disease state normal non-tumorigenic cancer cell GDS1736.0.1 GDS2341.0.2.4 -0.56 agent control arachidonic acid agent untreated Type II IFN GDS2221.1.2 GDS2250.0.3 0.56 agent vehicle galectin-1 disease state normal basal-like cancer GDS715.2.10.18 GDS715.2.6.18 0.56 agent negative control pergolide methanesulfonate agent negative control 16-ketoestradiol GDS2333.0.2.3 GDS2367.0.1.3 0.56 infection uninfected delta pilD mutant agent vehicle estradiol GDS2333.0.2.3 GDS715.0.10.18 0.56 infection uninfected delta pilD mutant agent none pergolide methanesulfonate GDS2333.0.2.3 GDS1333.0.1 -0.56 infection uninfected delta pilD mutant agent baseline oxandrolone GDS2333.0.2.3 GDS1989.1.2.0 -0.56 infection uninfected delta pilD mutant disease state normal benign nevus GDS1397.0.1 GDS2057.0.1.4 0.56 agent untreated HIV agent control DHT GDS715.0.8.16 GDS1220.0.1.3 -0.56 agent none 1,10-phenanthroline disease state normal malignant pleural mesothelioma GDS1331.0.1 GDS1956.0.2 0.56 disease state normal presymptomatic disease state normal juvenile dermatomyositis GDS1331.0.1 GDS2414.0.1.3 0.56 disease state normal presymptomatic agent control trophoblast conditioned medium GDS1331.0.1 GDS1630.2.4.0 -0.56 disease state normal presymptomatic agent untreated atorvastatin GDS1956.0.4 GDS2118.0.2 0.56 disease state normal spastic paraplegia disease state normal refractory anemia with ringed sideroblasts GDS1362.0.2 GDS1971.0.1 -0.56 disease state non-failing heart ischemic cardiomyopathy disease state healthy uncomplicated malaria GDS1667.0.1 GDS1321.0.1 -0.56 infection HPV negative HPV positive disease state normal Barrett's esophagus GDS1667.0.1 GDS2609.0.1 -0.56 infection HPV negative HPV positive disease state healthy control early onset colorectal cancer GDS715.0.6.18 GDS715.0.11.18 0.56 agent none 16-ketoestradiol agent none scopolamine methyl bromide GDS690.2.5.0 GDS2239.0.1 0.56 agent control TNFa agent control hepatitis C virus core protein GDS690.2.5.0 GDS2367.3.4.1 -0.56 agent control TNFa infection control adenovirus adenovirus carrying estrogen receptor beta GDS2021.0.1 GDS1746.2.4.0 -0.56 agent control metoprolol disease state normal basaloid GDS2737.0.1.2 GDS2414.0.1.4 0.56 disease state normal endometriosis agent control trophoblast conditioned medium GDS1989.1.4.0 GDS2418.0.1 0.56 disease state normal melanoma in situ disease state control vulvar intraepithelial neoplasia GDS2341.0.1.5 GDS1428.0.1.10 -0.56 agent untreated Type I IFN agent untreated Staphylococcus aureus GDS2367.3.4.2 GDS2609.0.1 0.56 infection control adenovirus adenovirus carrying estrogen receptor beta disease state healthy control early onset colorectal cancer GDS715.0.5.18 GDS715.0.14.18 0.56 agent none sulmazole agent none R-(-)-apomorphine HCl GDS715.0.13.18 GDS715.0.5.18 -0.56 agent none 8-(3-chlorostyryl) caffeine agent none sulmazole GDS690.2.3.1 GDS715.2.4.18 -0.56 agent control flagellin agent negative control a-methyl-L-p-tyrosine GDS2221.0.3 GDS2200.0.2 0.56 agent untreated lipopolysaccharide disease state normal squamous cell carcinoma GDS690.2.4.1 GDS2609.0.1 -0.56 agent control LTb disease state healthy control early onset colorectal cancer GDS1439.0.2 GDS1321.0.2 0.56 disease state benign metastatic disease state normal adenocarcinoma GDS1439.0.2 GDS1558.0.1.3 0.56 disease state benign metastatic disease state no atrial fibrillation permanent atrial fibrillation GDS1439.0.2 GDS2609.0.1 -0.56 disease state benign metastatic disease state healthy control early onset colorectal cancer GDS2617.0.1 GDS1926.0.1.4 -0.56 disease state normal non-tumorigenic cancer cell agent control thrombin GDS2617.0.1 GDS1926.0.2.4 -0.56 disease state normal non-tumorigenic cancer cell agent control LTD4 GDS2341.0.3.5 GDS1989.1.4.0 0.56 agent untreated Types I and II IFNs disease state normal melanoma in situ GDS2341.0.2.5 GDS1542.0.1 0.56 agent untreated Type II IFN agent control tumor necrosis factor GDS2307.0.2 GDS1543.0.1 0.56 agent untreated ox-LDL agent control tumor necrosis factor GDS1956.0.7 GDS289.0.1 -0.56 disease state normal Becker muscular dystrophy disease state control chronic obstructive pulmonary disease GDS1574.8.9.11 GDS715.0.8.16 0.56 agent control endotoxin agent none 1,10-phenanthroline GDS2611.0.2.9 GDS2200.0.1 0.56 agent untreated IL-1b disease state normal actinic keratosis GDS1331.0.2 GDS2432.0.1 -0.56 disease state normal symptomatic disease state control pituitary adenoma predisposition GDS2635.0.3 GDS1665.0.1 0.56 disease state lobular control invasive ductal carcinoma disease state normal papillary thyroid carcinoma GDS1926.0.3.4 GDS715.0.7.18 0.56 agent control LTD4 and thrombin agent none 4,5-dianilinophthalimide GDS1926.0.3.4 GDS2216.0.1.5 0.56 agent control LTD4 and thrombin agent control LPS GDS1926.0.3.4 GDS2250.0.3 -0.56 agent control LTD4 and thrombin disease state normal basal-like cancer GDS1926.0.2.4 GDS289.0.1 -0.56 agent control LTD4 disease state control chronic obstructive pulmonary disease GDS2697.0.1 GDS2367.3.4.0 0.56 disease state normal teratozoospermia infection control adenovirus adenovirus carrying estrogen receptor beta GDS1956.0.2 GDS2414.0.1.3 0.56 disease state normal juvenile dermatomyositis agent control trophoblast conditioned medium GDS2367.0.2.3 GDS1282.0.1 0.56 agent vehicle tamoxifen disease state control Wilms' tumor GDS2367.0.2.3 GDS1989.1.6.0 0.56 agent vehicle tamoxifen disease state normal metastatic growth phase melanoma GDS1956.0.5 GDS715.0.6.16 -0.56 disease state normal fascioscapulohumeral muscular dystrophy agent none 16-ketoestradiol GDS1783.0.2 GDS715.2.4.18 -0.56 agent control high potassium agent negative control a-methyl-L-p-tyrosine GDS1397.0.2 GDS715.0.4.18 -0.56 agent untreated TNF-alpha agent none a-methyl-L-p-tyrosine GDS1397.0.2 GDS1574.8.9.11 -0.56 agent untreated TNF-alpha agent control endotoxin GDS2737.0.1.3 GDS2635.0.3 0.56 disease state normal endometriosis disease state lobular control invasive ductal carcinoma GDS2737.0.1.3 GDS2057.0.1.4 0.56 disease state normal endometriosis agent control DHT GDS2737.0.1.3 GDS2397.0.1 -0.56 disease state normal endometriosis disease state normal idiopathic myelofibrosis GDS690.2.3.0 GDS2414.0.1.3 0.56 agent control flagellin agent control trophoblast conditioned medium GDS1428.0.1.10 GDS2118.0.3 -0.56 agent untreated Staphylococcus aureus disease state normal refractory anemia with excess blasts GDS1428.0.1.10 GDS2118.0.2 -0.56 agent untreated Staphylococcus aureus disease state normal refractory anemia with ringed sideroblasts GDS1282.0.1 GDS1665.0.1 0.56 disease state control Wilms' tumor disease state normal papillary thyroid carcinoma GDS1282.0.1 GDS1989.1.4.0 0.56 disease state control Wilms' tumor disease state normal melanoma in situ GDS1282.0.1 GDS1375.0.2 0.56 disease state control Wilms' tumor disease state normal malignant melanoma GDS2341.0.1.4 GDS2142.0.1 -0.56 agent untreated Type I IFN disease state normal mild cystic fibrosis GDS2214.0.1 GDS1615.0.2 0.56 agent control lipopolysaccharide disease state normal Crohn's disease GDS1376.2.3.1 GDS2367.3.4.1 -0.56 disease state normal thrombocythemia infection control adenovirus adenovirus carrying estrogen receptor beta GDS1549.3.4.2 GDS1630.2.4.1 -0.56 agent control estradiol agent untreated atorvastatin GDS2852.0.1.5 GDS1333.0.1 -0.56 agent control IL-13 agent baseline oxandrolone GDS2767.5.8.4 GDS2649.3.5.1 0.56 agent water alcohol disease state uninfected chronic HIV infection GDS2767.7.8.3 GDS2852.0.1.5 0.56 agent water red wine agent control IL-13 GDS484.0.1 GDS651.0.1 0.56 disease state normal leiomyoma disease state normal idiopathic dilated GDS2767.5.8.4 GDS690.2.4.1 -0.56 agent water alcohol agent control LTb GDS2767.6.8.0 GDS2643.0.2.4 -0.56 agent water grape juice disease state normal chronic lymphocytic leukemia GDS2767.6.8.0 GDS651.0.1 0.56 agent water grape juice disease state normal idiopathic dilated GDS2649.2.5.1 GDS2057.0.2.4 0.56 disease state uninfected early HIV infection agent control RTI-018 GDS2649.2.5.1 GDS1989.1.4.0 0.56 disease state uninfected early HIV infection disease state normal melanoma in situ GDS2767.7.8.0 GDS2084.0.1 -0.56 agent water red wine disease state control polycystic ovary syndrome GDS2767.7.8.0 GDS1333.0.1 0.56 agent water red wine agent baseline oxandrolone GDS2341.0.1.5 GDS2649.2.5.0 0.56 agent untreated Type I IFN disease state uninfected early HIV infection GDS1397.0.2 GDS1062.2.3.0 -0.56 agent untreated TNF-alpha disease state no metastasis metastasis GDS2852.0.1.5 GDS1062.2.3.0 -0.56 agent control IL-13 disease state no metastasis metastasis GDS1259.0.1 GDS2221.0.2 0.55 disease state normal dermatomyositis agent untreated galectin-1 GDS1259.0.1 GDS2221.0.3 0.55 disease state normal dermatomyositis agent untreated lipopolysaccharide GDS1259.0.1 GDS1989.1.3.0 -0.55 disease state normal dermatomyositis disease state normal atypical nevus GDS715.0.8.18 GDS715.0.13.18 0.55 agent none 1,10-phenanthroline agent none 8-(3-chlorostyryl) caffeine GDS2255.3.4.1 GDS1615.0.1 0.55 agent untreated endotoxin disease state normal ulcerative colitis GDS2418.0.1 GDS2428.0.1.2 -0.55 disease state control vulvar intraepithelial neoplasia agent untreated 5-aza-dC GDS2643.0.3.5 GDS1665.0.1 -0.55 disease state normal multiple myeloma disease state normal papillary thyroid carcinoma GDS715.0.10.18 GDS715.0.5.18 -0.55 agent none pergolide methanesulfonate agent none sulmazole GDS715.2.6.18 GDS715.2.12.18 0.55 agent negative control 16-ketoestradiol agent negative control 5-fluorouracil GDS2414.0.1.3 GDS1926.0.3.4 0.55 agent control trophoblast conditioned medium agent control LTD4 and thrombin GDS2414.0.1.3 GDS2142.0.1 -0.55 agent control trophoblast conditioned medium disease state normal mild cystic fibrosis GDS1783.0.1 GDS1333.0.1 -0.55 agent control thapsigargin agent baseline oxandrolone GDS2367.0.1.3 GDS2617.0.1 0.55 agent vehicle estradiol disease state normal non-tumorigenic cancer cell GDS2367.0.1.3 GDS1989.1.6.0 0.55 agent vehicle estradiol disease state normal metastatic growth phase melanoma GDS715.2.4.18 GDS715.2.9.18 -0.55 agent negative control a-methyl-L-p-tyrosine agent negative control 5-fluorouridine GDS2333.0.2.3 GDS1956.0.5 0.55 infection uninfected delta pilD mutant disease state normal fascioscapulohumeral muscular dystrophy GDS1397.0.1 GDS1783.0.1 0.55 agent untreated HIV agent control thapsigargin GDS715.0.8.16 GDS1375.0.1 -0.55 agent none 1,10-phenanthroline disease state normal benign nevi GDS715.0.8.16 GDS690.2.4.1 -0.55 agent none 1,10-phenanthroline agent control LTb GDS1574.8.9.10 GDS1375.0.1 0.55 agent control endotoxin disease state normal benign nevi GDS1331.0.1 GDS2367.3.4.2 -0.55 disease state normal presymptomatic infection control adenovirus adenovirus carrying estrogen receptor beta GDS1331.0.1 GDS715.0.4.18 -0.55 disease state normal presymptomatic agent none a-methyl-L-p-tyrosine GDS1331.0.1 GDS715.2.4.18 -0.55 disease state normal presymptomatic agent negative control a-methyl-L-p-tyrosine GDS1956.0.4 GDS1050.2.3.0 -0.55 disease state normal spastic paraplegia agent untreated valproic acid GDS1362.0.2 GDS2332.1.2 0.55 disease state non-failing heart ischemic cardiomyopathy infection wild type delta frpC/frpA mutant GDS690.2.5.0 GDS651.0.1 -0.55 agent control TNFa disease state normal idiopathic dilated GDS2021.0.1 GDS1956.0.5 0.55 agent control metoprolol disease state normal fascioscapulohumeral muscular dystrophy GDS2021.0.1 GDS1746.2.3.0 -0.55 agent control metoprolol disease state normal benign hyperplasia GDS1313.0.1 GDS651.0.2 -0.55 agent control TGFb1 disease state normal ischemic GDS2333.1.2.4 GDS1667.0.1 0.55 infection wild type delta pilD mutant infection HPV negative HPV positive GDS1746.2.4.0 GDS1989.1.5.0 -0.55 disease state normal basaloid disease state normal vertical growth phase melanoma GDS2341.0.1.5 GDS1427.0.2 -0.55 agent untreated Type I IFN infection control v-Myb GDS2214.0.2 GDS2118.0.1 -0.55 agent control HMGB1 disease state normal refractory anemia GDS2367.3.4.2 GDS2744.0.1 0.55 infection control adenovirus adenovirus carrying estrogen receptor beta agent control dioxin GDS2367.3.4.2 GDS1989.1.5.0 -0.55 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal vertical growth phase melanoma GDS2367.3.4.2 GDS715.0.10.18 -0.55 infection control adenovirus adenovirus carrying estrogen receptor beta agent none pergolide methanesulfonate GDS715.0.6.16 GDS715.2.4.18 0.55 agent none 16-ketoestradiol agent negative control a-methyl-L-p-tyrosine GDS2250.0.1 GDS2057.0.1.4 0.55 disease state normal non-basal-like cancer agent control DHT GDS2221.0.3 GDS1989.1.6.0 0.55 agent untreated lipopolysaccharide disease state normal metastatic growth phase melanoma GDS1989.1.7.0 GDS1321.0.1 0.55 disease state normal lymph node metastasis disease state normal Barrett's esophagus GDS1685.0.1 GDS1989.1.4.0 0.55 disease state normal hereditary gingival fibromatosis disease state normal melanoma in situ GDS1353.0.1.2 GDS1956.0.3 0.55 agent control dexamethasone disease state normal amyotophic lateral sclerosis GDS1353.0.1.2 GDS715.0.4.18 -0.55 agent control dexamethasone agent none a-methyl-L-p-tyrosine GDS2118.0.2 GDS2221.0.2 -0.55 disease state normal refractory anemia with ringed sideroblasts agent untreated galectin-1 GDS1574.8.9.11 GDS1333.0.1 0.55 agent control endotoxin agent baseline oxandrolone GDS1331.0.2 GDS2118.0.2 -0.55 disease state normal symptomatic disease state normal refractory anemia with ringed sideroblasts GDS1542.0.1 GDS2200.0.1 0.55 agent control tumor necrosis factor disease state normal actinic keratosis GDS1926.0.1.4 GDS1447.0.1 0.55 agent control thrombin agent control vanadium GDS1926.0.1.4 GDS715.0.7.18 0.55 agent control thrombin agent none 4,5-dianilinophthalimide GDS1926.0.1.4 GDS651.0.1 -0.55 agent control thrombin disease state normal idiopathic dilated GDS1543.0.1 GDS1989.1.4.0 0.55 agent control tumor necrosis factor disease state normal melanoma in situ GDS1543.0.1 GDS1574.8.9.12 0.55 agent control tumor necrosis factor agent control endotoxin GDS1543.0.1 GDS1362.0.2 -0.55 agent control tumor necrosis factor disease state non-failing heart ischemic cardiomyopathy GDS715.2.11.18 GDS715.2.7.18 0.55 agent negative control scopolamine methyl bromide agent negative control 4,5-dianilinophthalimide GDS1321.0.2 GDS1312.0.1 -0.55 disease state normal adenocarcinoma disease state normal cancer GDS2200.0.2 GDS1665.0.1 0.55 disease state normal squamous cell carcinoma disease state normal papillary thyroid carcinoma GDS1850.0.1 GDS1321.0.1 0.55 disease state healthy carious disease state normal Barrett's esophagus GDS2221.1.3 GDS1427.0.1 -0.55 agent vehicle lipopolysaccharide infection control c-Myb GDS1362.0.1 GDS1926.0.2.4 0.55 disease state non-failing heart non-ischemic cardiomyopathy agent control LTD4 GDS1312.0.1 GDS1282.0.1 0.55 disease state normal cancer disease state control Wilms' tumor GDS1312.0.1 GDS1989.1.6.0 0.55 disease state normal cancer disease state normal metastatic growth phase melanoma GDS1783.0.2 GDS1736.0.1 0.55 agent control high potassium agent control arachidonic acid GDS1783.0.2 GDS2367.3.4.1 -0.55 agent control high potassium infection control adenovirus adenovirus carrying estrogen receptor beta GDS1783.0.2 GDS2255.3.4.0 -0.55 agent control high potassium agent untreated endotoxin GDS1397.0.2 GDS2643.0.1.5 0.55 agent untreated TNF-alpha disease state normal Waldenstrom's macroglobulinemia GDS2255.3.4.0 GDS2617.0.1 -0.55 agent untreated endotoxin disease state normal non-tumorigenic cancer cell GDS1428.0.1.10 GDS715.0.6.16 0.55 agent untreated Staphylococcus aureus agent none 16-ketoestradiol GDS2367.3.4.0 GDS715.2.5.18 0.55 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control sulmazole GDS1439.0.1 GDS1989.1.7.0 0.55 disease state benign primary disease state normal lymph node metastasis GDS2333.1.2.3 GDS1630.2.4.0 -0.55 infection wild type delta pilD mutant agent untreated atorvastatin GDS2332.1.2 GDS885.0.1 -0.55 infection wild type delta frpC/frpA mutant agent control campthotecin GDS1376.2.3.1 GDS690.2.5.0 0.55 disease state normal thrombocythemia agent control TNFa GDS1376.2.3.1 GDS651.0.1 -0.55 disease state normal thrombocythemia disease state normal idiopathic dilated GDS1549.3.4.2 GDS1667.0.1 0.55 agent control estradiol infection HPV negative HPV positive GDS2767.7.8.0 GDS2649.3.5.1 0.55 agent water red wine disease state uninfected chronic HIV infection GDS484.0.1 GDS1321.0.1 -0.55 disease state normal leiomyoma disease state normal Barrett's esophagus GDS2649.3.5.1 GDS2418.0.1 0.55 disease state uninfected chronic HIV infection disease state control vulvar intraepithelial neoplasia GDS2767.5.8.0 GDS1850.0.1 0.55 agent water alcohol disease state healthy carious GDS2767.5.8.4 GDS2239.0.1 -0.55 agent water alcohol agent control hepatitis C virus core protein GDS2767.5.8.4 GDS2432.0.1 0.55 agent water alcohol disease state control pituitary adenoma predisposition GDS2767.6.8.0 GDS1989.1.3.0 0.55 agent water grape juice disease state normal atypical nevus GDS2767.6.8.0 GDS1333.0.1 0.55 agent water grape juice agent baseline oxandrolone GDS2649.3.5.0 GDS2200.0.1 0.55 disease state uninfected chronic HIV infection disease state normal actinic keratosis GDS2649.3.5.0 GDS1971.0.1 0.55 disease state uninfected chronic HIV infection disease state healthy uncomplicated malaria GDS715.1.2.18 GDS715.0.4.18 0.55 agent negative control positive control agent none a-methyl-L-p-tyrosine GDS2767.7.8.0 GDS1956.0.6 -0.55 agent water red wine disease state normal Emery-Dreifuss muscular dystrophy GDS2341.0.3.4 GDS2767.5.8.3 0.55 agent untreated Types I and II IFNs agent water alcohol GDS2367.0.2.3 GDS2649.3.5.1 0.55 agent vehicle tamoxifen disease state uninfected chronic HIV infection GDS1376.2.3.1 GDS2767.6.8.0 -0.55 disease state normal thrombocythemia agent water grape juice GDS651.0.1 GDS1050.2.3.0 0.54 disease state normal idiopathic dilated agent untreated valproic acid GDS2635.0.2 GDS1439.0.2 0.54 disease state lobular control invasive lobular carcinoma disease state benign metastatic GDS1333.0.1 GDS2250.0.1 0.54 agent baseline oxandrolone disease state normal non-basal-like cancer GDS2418.0.1 GDS860.0.1 0.54 disease state control vulvar intraepithelial neoplasia agent untreated endothelin-1 GDS1989.1.3.0 GDS2250.0.2 0.54 disease state normal atypical nevus disease state normal BRCA1-associated cancer GDS2643.0.3.5 GDS2215.0.1 0.54 disease state normal multiple myeloma agent control chlorpyrifos GDS2643.0.3.5 GDS2190.0.1 -0.54 disease state normal multiple myeloma disease state control bipolar disorder GDS2643.0.3.5 GDS715.2.4.18 -0.54 disease state normal multiple myeloma agent negative control a-methyl-L-p-tyrosine GDS2643.0.3.5 GDS715.0.4.18 -0.54 disease state normal multiple myeloma agent none a-methyl-L-p-tyrosine GDS2611.0.3.9 GDS1321.0.1 0.54 agent untreated IFN-gamma disease state normal Barrett's esophagus GDS2611.0.3.9 GDS1956.0.9 0.54 agent untreated IFN-gamma disease state normal Calpain 3 mutation GDS1574.8.9.12 GDS1428.0.4.10 0.54 agent control endotoxin agent untreated heat-killed Anaplasma phagocytophilum GDS1574.8.9.12 GDS1850.0.1 0.54 agent control endotoxin disease state healthy carious GDS1574.8.9.12 GDS1428.0.5.10 0.54 agent control endotoxin agent untreated Anaplasma phagocytophilum GDS2250.0.3 GDS715.2.9.18 0.54 disease state normal basal-like cancer agent negative control 5-fluorouridine GDS1783.0.1 GDS1558.0.1.3 -0.54 agent control thapsigargin disease state no atrial fibrillation permanent atrial fibrillation GDS1783.0.1 GDS2367.3.4.1 -0.54 agent control thapsigargin infection control adenovirus adenovirus carrying estrogen receptor beta GDS2367.0.1.3 GDS2057.0.1.4 0.54 agent vehicle estradiol agent control DHT GDS2367.0.1.3 GDS1989.1.7.0 0.54 agent vehicle estradiol disease state normal lymph node metastasis GDS1220.0.1.3 GDS2250.0.2 0.54 disease state normal malignant pleural mesothelioma disease state normal BRCA1-associated cancer GDS2333.0.2.3 GDS715.0.9.18 0.54 infection uninfected delta pilD mutant agent none 5-fluorouridine GDS1397.0.1 GDS2643.0.3.5 0.54 agent untreated HIV disease state normal multiple myeloma GDS1397.0.1 GDS715.0.4.18 -0.54 agent untreated HIV agent none a-methyl-L-p-tyrosine GDS1397.0.1 GDS715.2.4.18 -0.54 agent untreated HIV agent negative control a-methyl-L-p-tyrosine GDS1397.0.1 GDS1353.0.1.3 -0.54 agent untreated HIV agent control dexamethasone GDS715.0.8.16 GDS651.0.1 0.54 agent none 1,10-phenanthroline disease state normal idiopathic dilated GDS1956.0.6 GDS1375.0.1 -0.54 disease state normal Emery-Dreifuss muscular dystrophy disease state normal benign nevi GDS2142.0.2 GDS1926.0.2.4 0.54 disease state normal severe cystic fibrosis agent control LTD4 GDS1331.0.1 GDS715.0.9.18 0.54 disease state normal presymptomatic agent none 5-fluorouridine GDS1331.0.1 GDS2333.1.2.3 0.54 disease state normal presymptomatic infection wild type delta pilD mutant GDS1956.0.4 GDS2153.0.1 0.54 disease state normal spastic paraplegia disease state normal dermatomyositis GDS1956.0.4 GDS1956.0.7 0.54 disease state normal spastic paraplegia disease state normal Becker muscular dystrophy GDS1375.0.2 GDS1321.0.2 0.54 disease state normal malignant melanoma disease state normal adenocarcinoma GDS2341.0.1.5 GDS2200.0.2 0.54 agent untreated Type I IFN disease state normal squamous cell carcinoma GDS2214.0.2 GDS2221.0.3 0.54 agent control HMGB1 agent untreated lipopolysaccharide GDS2367.3.4.2 GDS2332.0.2 0.54 infection control adenovirus adenovirus carrying estrogen receptor beta infection uninfected delta frpC/frpA mutant GDS2367.3.4.2 GDS2333.1.2.4 -0.54 infection control adenovirus adenovirus carrying estrogen receptor beta infection wild type delta pilD mutant GDS715.0.6.16 GDS715.2.9.18 -0.54 agent none 16-ketoestradiol agent negative control 5-fluorouridine GDS715.0.6.16 GDS2643.0.3.5 -0.54 agent none 16-ketoestradiol disease state normal multiple myeloma GDS2118.0.1 GDS1392.0.1 0.54 disease state normal refractory anemia disease state normal rheumatoid arthritis, on methotrexate GDS2341.0.3.4 GDS2205.0.1 -0.54 agent untreated Types I and II IFNs disease state non-failing dilated cardiomyopathy GDS2221.0.3 GDS2200.0.1 0.54 agent untreated lipopolysaccharide disease state normal actinic keratosis GDS690.2.4.1 GDS2697.0.1 -0.54 agent control LTb disease state normal teratozoospermia GDS2367.3.4.1 GDS1989.1.7.0 -0.54 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal lymph node metastasis GDS1630.2.4.0 GDS690.2.4.1 -0.54 agent untreated atorvastatin agent control LTb GDS1405.0.1 GDS860.0.1 -0.54 agent untreated DCI agent untreated endothelin-1 GDS1574.8.9.11 GDS715.2.10.18 0.54 agent control endotoxin agent negative control pergolide methanesulfonate GDS1574.8.9.11 GDS715.0.1.18 0.54 agent control endotoxin agent none positive control GDS1331.0.2 GDS1257.0.2 0.54 disease state normal symptomatic disease state normal SCD steady state GDS1331.0.2 GDS715.2.11.18 -0.54 disease state normal symptomatic agent negative control scopolamine methyl bromide GDS1542.0.1 GDS2200.0.2 0.54 agent control tumor necrosis factor disease state normal squamous cell carcinoma GDS1926.0.3.4 GDS715.0.8.18 0.54 agent control LTD4 and thrombin agent none 1,10-phenanthroline GDS1926.0.3.4 GDS1732.0.1 -0.54 agent control LTD4 and thrombin disease state normal papillary thyroid cancer GDS1453.0.1 GDS2213.0.1 0.54 agent untreated camptothecin agent untreated 5-aza-dC GDS2216.0.1.5 GDS1989.1.6.0 0.54 agent control LPS disease state normal metastatic growth phase melanoma GDS1543.0.1 GDS885.0.1 0.54 agent control tumor necrosis factor agent control campthotecin GDS1543.0.1 GDS2617.0.1 -0.54 agent control tumor necrosis factor disease state normal non-tumorigenic cancer cell GDS1926.0.2.4 GDS2118.0.3 -0.54 agent control LTD4 disease state normal refractory anemia with excess blasts GDS715.0.7.16 GDS715.0.13.18 0.54 agent none 4,5-dianilinophthalimide agent none 8-(3-chlorostyryl) caffeine GDS1282.0.2 GDS1989.1.5.0 0.54 disease state control clear cell sarcoma of the kidney disease state normal vertical growth phase melanoma GDS737.0.1 GDS1956.0.2 0.54 disease state no or mild emphysema severe emphysema disease state normal juvenile dermatomyositis GDS1989.1.5.0 GDS1439.0.1 0.54 disease state normal vertical growth phase melanoma disease state benign primary GDS2221.1.3 GDS1989.1.6.0 0.54 agent vehicle lipopolysaccharide disease state normal metastatic growth phase melanoma GDS1362.0.1 GDS715.0.4.18 -0.54 disease state non-failing heart non-ischemic cardiomyopathy agent none a-methyl-L-p-tyrosine GDS1312.0.1 GDS1989.1.5.0 0.54 disease state normal cancer disease state normal vertical growth phase melanoma GDS1312.0.1 GDS1558.0.1.3 0.54 disease state normal cancer disease state no atrial fibrillation permanent atrial fibrillation GDS1312.0.1 GDS1989.1.3.0 0.54 disease state normal cancer disease state normal atypical nevus GDS2190.0.1 GDS1917.0.1 0.54 disease state control bipolar disorder disease state control schizophrenia GDS2190.0.1 GDS2250.0.3 -0.54 disease state control bipolar disorder disease state normal basal-like cancer GDS1783.0.2 GDS1667.0.1 0.54 agent control high potassium infection HPV negative HPV positive GDS1397.0.2 GDS715.2.4.18 -0.54 agent untreated TNF-alpha agent negative control a-methyl-L-p-tyrosine GDS2737.0.1.3 GDS1553.0.1 -0.54 disease state normal endometriosis agent untreated fullerene GDS2255.3.4.0 GDS2221.1.3 0.54 agent untreated endotoxin agent vehicle lipopolysaccharide GDS690.2.3.0 GDS1220.0.1.3 0.54 agent control flagellin disease state normal malignant pleural mesothelioma GDS690.2.3.0 GDS651.0.1 -0.54 agent control flagellin disease state normal idiopathic dilated GDS690.2.3.0 GDS715.0.4.18 -0.54 agent control flagellin agent none a-methyl-L-p-tyrosine GDS2221.0.2 GDS1989.1.5.0 0.54 agent untreated galectin-1 disease state normal vertical growth phase melanoma GDS2221.0.2 GDS2200.0.1 0.54 agent untreated galectin-1 disease state normal actinic keratosis GDS2705.0.1 GDS2023.0.1.2 0.54 agent control rosiglitazone infection vehicle control RSV GDS1376.2.3.1 GDS2153.0.1 0.54 disease state normal thrombocythemia disease state normal dermatomyositis GDS1376.2.3.1 GDS1956.0.6 0.54 disease state normal thrombocythemia disease state normal Emery-Dreifuss muscular dystrophy GDS1376.2.3.1 GDS2191.0.1 -0.54 disease state normal thrombocythemia disease state control bipolar disorder GDS484.0.1 GDS1989.1.2.0 0.54 disease state normal leiomyoma disease state normal benign nevus GDS2649.2.5.0 GDS2118.0.2 0.54 disease state uninfected early HIV infection disease state normal refractory anemia with ringed sideroblasts GDS2767.5.8.0 GDS1427.0.2 0.54 agent water alcohol infection control v-Myb GDS2767.5.8.0 GDS715.0.8.16 0.54 agent water alcohol agent none 1,10-phenanthroline GDS2767.5.8.4 GDS1989.1.2.0 0.54 agent water alcohol disease state normal benign nevus GDS2767.5.8.4 GDS1746.2.3.0 0.54 agent water alcohol disease state normal benign hyperplasia GDS2767.6.8.0 GDS1050.0.1.2 -0.54 agent water grape juice disease state normal polycystic ovary syndrome GDS2767.6.8.0 GDS2142.0.1 0.54 agent water grape juice disease state normal mild cystic fibrosis GDS2767.6.8.0 GDS2200.0.1 0.54 agent water grape juice disease state normal actinic keratosis GDS2649.3.5.0 GDS1956.0.2 0.54 disease state uninfected chronic HIV infection disease state normal juvenile dermatomyositis GDS2767.7.8.0 GDS1428.0.1.10 0.54 agent water red wine agent untreated Staphylococcus aureus GDS2767.7.8.0 GDS2737.0.1.4 0.54 agent water red wine disease state normal endometriosis GDS715.0.8.18 GDS266.0.1.4 -0.54 agent none 1,10-phenanthroline disease state no atopy atopy GDS2362.6.7.2.5 GDS266.0.1.4 0.54 agent untreated chloroguine treated disease state no atopy atopy GDS2215.0.2 GDS2649.4.5.1 0.54 agent control cyfluthrin disease state uninfected non-progressive HIV infection GDS2617.0.2 GDS715.1.2.18 -0.54 disease state normal tumorigenic cancer cell agent negative control positive control GDS1971.0.1 GDS266.0.1.4 -0.54 disease state healthy uncomplicated malaria disease state no atopy atopy GDS715.0.5.18 GDS2649.4.5.1 0.54 agent none sulmazole disease state uninfected non-progressive HIV infection GDS1989.1.7.0 GDS484.0.1 0.54 disease state normal lymph node metastasis disease state normal leiomyoma GDS2341.0.2.4 GDS2649.3.5.1 0.54 agent untreated Type II IFN disease state uninfected chronic HIV infection GDS1615.0.1 GDS715.2.14.18 0.53 disease state normal ulcerative colitis agent negative control R-(-)-apomorphine HCl GDS2332.0.2 GDS2221.0.2 0.53 infection uninfected delta frpC/frpA mutant agent untreated galectin-1 GDS2332.0.2 GDS2255.3.4.0 0.53 infection uninfected delta frpC/frpA mutant agent untreated endotoxin GDS651.0.1 GDS1956.0.2 -0.53 disease state normal idiopathic dilated disease state normal juvenile dermatomyositis GDS1259.0.1 GDS1543.0.1 0.53 disease state normal dermatomyositis agent control tumor necrosis factor GDS1333.0.1 GDS2250.0.2 0.53 agent baseline oxandrolone disease state normal BRCA1-associated cancer GDS1989.1.3.0 GDS2250.0.3 0.53 disease state normal atypical nevus disease state normal basal-like cancer GDS2643.0.3.5 GDS2200.0.1 -0.53 disease state normal multiple myeloma disease state normal actinic keratosis GDS2611.0.3.9 GDS1956.0.11 0.53 agent untreated IFN-gamma disease state normal FKRP mutation GDS2215.0.2 GDS2057.0.1.4 0.53 agent control cyfluthrin agent control DHT GDS2250.0.3 GDS2057.0.2.4 0.53 disease state normal basal-like cancer agent control RTI-018 GDS2250.0.3 GDS1326.2.3.1 -0.53 disease state normal basal-like cancer agent control E2 GDS2200.0.1 GDS1956.0.2 0.53 disease state normal actinic keratosis disease state normal juvenile dermatomyositis GDS1050.2.3.0 GDS1375.0.1 -0.53 agent untreated valproic acid disease state normal benign nevi GDS1783.0.1 GDS2341.0.3.5 0.53 agent control thapsigargin agent untreated Types I and II IFNs GDS1783.0.1 GDS2341.0.2.5 0.53 agent control thapsigargin agent untreated Type II IFN GDS1257.0.2 GDS2057.0.2.3 0.53 disease state normal SCD steady state agent control RTI-018 GDS2617.0.2 GDS1630.2.4.1 -0.53 disease state normal tumorigenic cancer cell agent untreated atorvastatin GDS1736.0.1 GDS2200.0.2 0.53 agent control arachidonic acid disease state normal squamous cell carcinoma GDS2221.1.2 GDS1989.1.7.0 0.53 agent vehicle galectin-1 disease state normal lymph node metastasis GDS2221.1.2 GDS1321.0.1 0.53 agent vehicle galectin-1 disease state normal Barrett's esophagus GDS2333.0.2.3 GDS2191.0.1 -0.53 infection uninfected delta pilD mutant disease state control bipolar disorder GDS1397.0.1 GDS2215.0.1 0.53 agent untreated HIV agent control chlorpyrifos GDS715.0.8.16 GDS1427.0.2 0.53 agent none 1,10-phenanthroline infection control v-Myb GDS715.0.8.16 GDS2737.0.1.2 0.53 agent none 1,10-phenanthroline disease state normal endometriosis GDS715.0.8.16 GDS2697.0.1 0.53 agent none 1,10-phenanthroline disease state normal teratozoospermia GDS715.0.8.16 GDS2084.0.1 -0.53 agent none 1,10-phenanthroline disease state control polycystic ovary syndrome GDS1956.0.6 GDS2250.0.3 -0.53 disease state normal Emery-Dreifuss muscular dystrophy disease state normal basal-like cancer GDS2142.0.2 GDS1665.0.1 -0.53 disease state normal severe cystic fibrosis disease state normal papillary thyroid carcinoma GDS715.2.9.18 GDS715.2.15.18 0.53 agent negative control 5-fluorouridine agent negative control cyclazosin HCl GDS1331.0.1 GDS2084.0.1 0.53 disease state normal presymptomatic disease state control polycystic ovary syndrome GDS1331.0.1 GDS2332.1.2 0.53 disease state normal presymptomatic infection wild type delta frpC/frpA mutant GDS1331.0.1 GDS2118.0.2 -0.53 disease state normal presymptomatic disease state normal refractory anemia with ringed sideroblasts GDS1331.0.1 GDS1956.0.4 -0.53 disease state normal presymptomatic disease state normal spastic paraplegia GDS1956.0.4 GDS715.2.15.18 -0.53 disease state normal spastic paraplegia agent negative control cyclazosin HCl GDS1362.0.2 GDS1615.0.2 -0.53 disease state non-failing heart ischemic cardiomyopathy disease state normal Crohn's disease GDS1746.2.3.0 GDS737.0.1 -0.53 disease state normal benign hyperplasia disease state no or mild emphysema severe emphysema GDS690.2.5.0 GDS1956.0.2 0.53 agent control TNFa disease state normal juvenile dermatomyositis GDS2021.0.1 GDS1956.0.1 0.53 agent control metoprolol disease state normal acute quadriplegic myopathy GDS1375.0.2 GDS1312.0.1 0.53 disease state normal malignant melanoma disease state normal cancer GDS1989.1.4.0 GDS2307.0.1 -0.53 disease state normal melanoma in situ agent untreated LDL GDS715.0.15.18 GDS715.0.10.18 0.53 agent none cyclazosin HCl agent none pergolide methanesulfonate GDS2367.3.4.2 GDS1220.0.1.3 -0.53 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal malignant pleural mesothelioma GDS2367.3.4.2 GDS1282.0.1 -0.53 infection control adenovirus adenovirus carrying estrogen receptor beta disease state control Wilms' tumor GDS2250.0.1 GDS2307.0.1 0.53 disease state normal non-basal-like cancer agent untreated LDL GDS2250.0.1 GDS2057.0.2.4 0.53 disease state normal non-basal-like cancer agent control RTI-018 GDS715.0.5.18 GDS715.2.8.18 0.53 agent none sulmazole agent negative control 1,10-phenanthroline GDS2341.0.3.4 GDS2250.0.3 0.53 agent untreated Types I and II IFNs disease state normal basal-like cancer GDS2341.0.3.4 GDS1313.0.1 -0.53 agent untreated Types I and II IFNs agent control TGFb1 GDS715.0.13.18 GDS715.2.8.18 -0.53 agent none 8-(3-chlorostyryl) caffeine agent negative control 1,10-phenanthroline GDS690.2.4.1 GDS2367.0.1.3 0.53 agent control LTb agent vehicle estradiol GDS1439.0.2 GDS2057.0.1.4 0.53 disease state benign metastatic agent control DHT GDS1353.0.1.2 GDS715.0.10.18 0.53 agent control dexamethasone agent none pergolide methanesulfonate GDS2118.0.2 GDS2362.6.7.2.5 0.53 disease state normal refractory anemia with ringed sideroblasts agent untreated chloroguine treated GDS1574.8.9.11 GDS1220.0.1.3 -0.53 agent control endotoxin disease state normal malignant pleural mesothelioma GDS1331.0.2 GDS2142.0.1 -0.53 disease state normal symptomatic disease state normal mild cystic fibrosis GDS2216.0.1.5 GDS2611.0.3.9 0.53 agent control LPS agent untreated IFN-gamma GDS1543.0.1 GDS2611.0.3.9 0.53 agent control tumor necrosis factor agent untreated IFN-gamma GDS1926.0.2.4 GDS1956.0.5 0.53 agent control LTD4 disease state normal fascioscapulohumeral muscular dystrophy GDS715.2.3.18 GDS715.2.12.18 0.53 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 5-fluorouracil GDS2643.0.1.4 GDS1615.0.2 0.53 disease state normal Waldenstrom's macroglobulinemia disease state normal Crohn's disease GDS1956.0.2 GDS2221.0.2 0.53 disease state normal juvenile dermatomyositis agent untreated galectin-1 GDS737.0.1 GDS1956.0.5 0.53 disease state no or mild emphysema severe emphysema disease state normal fascioscapulohumeral muscular dystrophy GDS2332.0.3 GDS2118.0.1 -0.53 infection uninfected delta pilD mutant disease state normal refractory anemia GDS2332.0.3 GDS1405.0.1 -0.53 infection uninfected delta pilD mutant agent untreated DCI GDS1850.0.1 GDS2418.0.1 0.53 disease state healthy carious disease state control vulvar intraepithelial neoplasia GDS1850.0.1 GDS1732.0.1 0.53 disease state healthy carious disease state normal papillary thyroid cancer GDS1375.0.1 GDS2617.0.2 0.53 disease state normal benign nevi disease state normal tumorigenic cancer cell GDS2221.1.3 GDS1989.1.7.0 0.53 agent vehicle lipopolysaccharide disease state normal lymph node metastasis GDS2221.1.3 GDS1321.0.1 0.53 agent vehicle lipopolysaccharide disease state normal Barrett's esophagus GDS1362.0.1 GDS2643.0.3.5 0.53 disease state non-failing heart non-ischemic cardiomyopathy disease state normal multiple myeloma GDS1362.0.1 GDS1220.0.1.3 0.53 disease state non-failing heart non-ischemic cardiomyopathy disease state normal malignant pleural mesothelioma GDS1362.0.1 GDS715.2.4.18 -0.53 disease state non-failing heart non-ischemic cardiomyopathy agent negative control a-methyl-L-p-tyrosine GDS1362.0.1 GDS810.0.3 -0.53 disease state non-failing heart non-ischemic cardiomyopathy disease state control severe AD GDS1362.0.1 GDS1746.2.3.0 -0.53 disease state non-failing heart non-ischemic cardiomyopathy disease state normal benign hyperplasia GDS1956.0.5 GDS715.0.9.18 0.53 disease state normal fascioscapulohumeral muscular dystrophy agent none 5-fluorouridine GDS1956.0.5 GDS1989.1.3.0 -0.53 disease state normal fascioscapulohumeral muscular dystrophy disease state normal atypical nevus GDS1956.0.5 GDS810.0.1 -0.53 disease state normal fascioscapulohumeral muscular dystrophy disease state control incipient AD GDS2190.0.1 GDS2250.0.1 -0.53 disease state control bipolar disorder disease state normal non-basal-like cancer GDS1397.0.2 GDS715.2.15.18 -0.53 agent untreated TNF-alpha agent negative control cyclazosin HCl GDS268.0.2 GDS1956.0.3 0.53 disease state non-obese morbidly obese disease state normal amyotophic lateral sclerosis GDS2154.0.1 GDS1333.0.1 0.53 disease state healthy inflammatory dilated cardiomyopathy agent baseline oxandrolone GDS2737.0.1.3 GDS1375.0.1 0.53 disease state normal endometriosis disease state normal benign nevi GDS690.2.3.0 GDS2333.1.2.3 0.53 agent control flagellin infection wild type delta pilD mutant GDS690.2.3.0 GDS2643.0.1.5 0.53 agent control flagellin disease state normal Waldenstrom's macroglobulinemia GDS690.2.3.0 GDS1989.1.3.0 -0.53 agent control flagellin disease state normal atypical nevus GDS2705.0.1 GDS1926.0.1.4 0.53 agent control rosiglitazone agent control thrombin GDS1428.0.1.10 GDS2084.0.1 -0.53 agent untreated Staphylococcus aureus disease state control polycystic ovary syndrome GDS1558.0.1.3 GDS1665.0.1 0.53 disease state no atrial fibrillation permanent atrial fibrillation disease state normal papillary thyroid carcinoma GDS1282.0.1 GDS1989.1.6.0 0.53 disease state control Wilms' tumor disease state normal metastatic growth phase melanoma GDS2333.1.2.3 GDS715.2.5.18 -0.53 infection wild type delta pilD mutant agent negative control sulmazole GDS1376.2.3.1 GDS1331.0.2 0.53 disease state normal thrombocythemia disease state normal symptomatic GDS1376.2.3.1 GDS1850.0.1 -0.53 disease state normal thrombocythemia disease state healthy carious GDS2852.0.1.5 GDS1989.1.2.0 -0.53 agent control IL-13 disease state normal benign nevus GDS2767.6.8.0 GDS1062.2.3.0 0.53 agent water grape juice disease state no metastasis metastasis GDS2649.2.5.1 GDS484.0.1 0.53 disease state uninfected early HIV infection disease state normal leiomyoma GDS2767.5.8.2 GDS1574.8.9.13 0.53 agent water alcohol agent control endotoxin GDS484.0.1 GDS1926.0.2.4 -0.53 disease state normal leiomyoma agent control LTD4 GDS2649.3.5.1 GDS2635.0.3 0.53 disease state uninfected chronic HIV infection disease state lobular control invasive ductal carcinoma GDS2649.3.5.1 GDS2250.0.2 0.53 disease state uninfected chronic HIV infection disease state normal BRCA1-associated cancer GDS2767.5.8.4 GDS2737.0.1.4 0.53 agent water alcohol disease state normal endometriosis GDS2767.6.8.0 GDS1956.0.1 -0.53 agent water grape juice disease state normal acute quadriplegic myopathy GDS2767.6.8.0 GDS690.2.4.1 -0.53 agent water grape juice agent control LTb GDS2767.6.8.0 GDS1427.0.2 0.53 agent water grape juice infection control v-Myb GDS2767.6.8.0 GDS1746.2.3.0 0.53 agent water grape juice disease state normal benign hyperplasia GDS2649.3.5.0 GDS2221.0.2 0.53 disease state uninfected chronic HIV infection agent untreated galectin-1 GDS2649.3.5.0 GDS2118.0.1 0.53 disease state uninfected chronic HIV infection disease state normal refractory anemia GDS2649.2.5.1 GDS1685.0.1 0.53 disease state uninfected early HIV infection disease state normal hereditary gingival fibromatosis GDS2767.7.8.0 GDS2142.0.2 -0.53 agent water red wine disease state normal severe cystic fibrosis GDS2767.7.8.0 GDS2367.0.1.3 -0.53 agent water red wine agent vehicle estradiol GDS2767.7.8.0 GDS1312.0.1 0.53 agent water red wine disease state normal cancer GDS2362.6.7.2.5 GDS2767.5.8.2 -0.53 agent untreated chloroguine treated agent water alcohol GDS715.2.14.18 GDS266.0.1.2 0.53 agent negative control R-(-)-apomorphine HCl disease state no atopy atopy GDS2250.0.3 GDS715.1.2.18 -0.53 disease state normal basal-like cancer agent negative control positive control GDS2250.0.3 GDS484.0.1 0.53 disease state normal basal-like cancer disease state normal leiomyoma GDS2250.0.1 GDS484.0.1 0.53 disease state normal non-basal-like cancer disease state normal leiomyoma GDS1989.1.6.0 GDS505.0.1 0.53 disease state normal metastatic growth phase melanoma disease state normal RCC GDS1362.0.1 GDS2649.4.5.0 -0.53 disease state non-failing heart non-ischemic cardiomyopathy disease state uninfected non-progressive HIV infection GDS2737.0.1.3 GDS715.1.2.18 -0.53 disease state normal endometriosis agent negative control positive control GDS1615.0.1 GDS715.2.8.18 0.52 disease state normal ulcerative colitis agent negative control 1,10-phenanthroline GDS1259.0.1 GDS2341.0.3.5 0.52 disease state normal dermatomyositis agent untreated Types I and II IFNs GDS1259.0.1 GDS2635.0.3 0.52 disease state normal dermatomyositis disease state lobular control invasive ductal carcinoma GDS2362.6.7.2.5 GDS1427.0.2 0.52 agent untreated chloroguine treated infection control v-Myb GDS2191.0.1 GDS1353.0.1.2 -0.52 disease state control bipolar disorder agent control dexamethasone GDS2643.0.3.5 GDS690.2.5.0 0.52 disease state normal multiple myeloma agent control TNFa GDS2643.0.3.5 GDS1427.0.2 -0.52 disease state normal multiple myeloma infection control v-Myb GDS715.0.10.18 GDS1574.8.9.12 0.52 agent none pergolide methanesulfonate agent control endotoxin GDS2250.0.2 GDS1558.0.1.3 0.52 disease state normal BRCA1-associated cancer disease state no atrial fibrillation permanent atrial fibrillation GDS2250.0.2 GDS1630.2.4.1 -0.52 disease state normal BRCA1-associated cancer agent untreated atorvastatin GDS2250.0.3 GDS2307.0.1 0.52 disease state normal basal-like cancer agent untreated LDL GDS2250.0.3 GDS2609.0.1 -0.52 disease state normal basal-like cancer disease state healthy control early onset colorectal cancer GDS2414.0.1.3 GDS1926.0.2.4 0.52 agent control trophoblast conditioned medium agent control LTD4 GDS2414.0.1.3 GDS2021.0.1 0.52 agent control trophoblast conditioned medium agent control metoprolol GDS1783.0.1 GDS1736.0.1 0.52 agent control thapsigargin agent control arachidonic acid GDS1783.0.1 GDS2367.0.1.3 0.52 agent control thapsigargin agent vehicle estradiol GDS1783.0.1 GDS690.2.4.1 0.52 agent control thapsigargin agent control LTb GDS1783.0.1 GDS2021.0.1 0.52 agent control thapsigargin agent control metoprolol GDS2643.0.1.5 GDS715.2.8.18 -0.52 disease state normal Waldenstrom's macroglobulinemia agent negative control 1,10-phenanthroline GDS2367.0.1.3 GDS1321.0.2 0.52 agent vehicle estradiol disease state normal adenocarcinoma GDS2367.0.1.3 GDS1326.2.3.1 -0.52 agent vehicle estradiol agent control E2 GDS1220.0.1.3 GDS1989.1.5.0 0.52 disease state normal malignant pleural mesothelioma disease state normal vertical growth phase melanoma GDS1736.0.1 GDS1543.0.1 0.52 agent control arachidonic acid agent control tumor necrosis factor GDS715.0.1.16 GDS1331.0.2 0.52 agent none positive control disease state normal symptomatic GDS2221.1.2 GDS2418.0.1 0.52 agent vehicle galectin-1 disease state control vulvar intraepithelial neoplasia GDS2221.1.2 GDS2250.0.2 0.52 agent vehicle galectin-1 disease state normal BRCA1-associated cancer GDS2221.1.2 GDS1428.0.5.10 0.52 agent vehicle galectin-1 agent untreated Anaplasma phagocytophilum GDS2333.0.2.3 GDS715.2.9.18 0.52 infection uninfected delta pilD mutant agent negative control 5-fluorouridine GDS2333.0.2.3 GDS651.0.1 -0.52 infection uninfected delta pilD mutant disease state normal idiopathic dilated GDS1397.0.1 GDS1574.8.9.11 -0.52 agent untreated HIV agent control endotoxin GDS1397.0.1 GDS651.0.1 -0.52 agent untreated HIV disease state normal idiopathic dilated GDS1397.0.1 GDS715.0.8.16 -0.52 agent untreated HIV agent none 1,10-phenanthroline GDS715.0.8.16 GDS1956.0.1 -0.52 agent none 1,10-phenanthroline disease state normal acute quadriplegic myopathy GDS1956.0.6 GDS737.0.1 0.52 disease state normal Emery-Dreifuss muscular dystrophy disease state no or mild emphysema severe emphysema GDS1956.0.6 GDS2250.0.1 -0.52 disease state normal Emery-Dreifuss muscular dystrophy disease state normal non-basal-like cancer GDS2705.0.3 GDS2428.0.1.4 0.52 agent control rosiglitazone plus carboplatin agent untreated 5-aza-dC GDS2142.0.2 GDS1989.1.4.0 -0.52 disease state normal severe cystic fibrosis disease state normal melanoma in situ GDS2397.0.1 GDS715.0.4.18 0.52 disease state normal idiopathic myelofibrosis agent none a-methyl-L-p-tyrosine GDS1362.0.2 GDS2191.0.1 -0.52 disease state non-failing heart ischemic cardiomyopathy disease state control bipolar disorder GDS2118.0.3 GDS1392.0.1 0.52 disease state normal refractory anemia with excess blasts disease state normal rheumatoid arthritis, on methotrexate GDS2205.0.1 GDS651.0.1 0.52 disease state non-failing dilated cardiomyopathy disease state normal idiopathic dilated GDS2205.0.1 GDS2154.0.1 0.52 disease state non-failing dilated cardiomyopathy disease state healthy inflammatory dilated cardiomyopathy GDS1746.2.4.0 GDS1665.0.1 0.52 disease state normal basaloid disease state normal papillary thyroid carcinoma GDS1746.2.4.0 GDS1321.0.2 -0.52 disease state normal basaloid disease state normal adenocarcinoma GDS715.0.7.18 GDS1321.0.1 0.52 agent none 4,5-dianilinophthalimide disease state normal Barrett's esophagus GDS2118.0.1 GDS2250.0.3 0.52 disease state normal refractory anemia disease state normal basal-like cancer GDS2118.0.1 GDS2617.0.2 0.52 disease state normal refractory anemia disease state normal tumorigenic cancer cell GDS715.0.9.18 GDS1956.0.2 0.52 agent none 5-fluorouridine disease state normal juvenile dermatomyositis GDS715.0.3.18 GDS715.2.10.18 0.52 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control pergolide methanesulfonate GDS2221.0.3 GDS1428.0.5.10 0.52 agent untreated lipopolysaccharide agent untreated Anaplasma phagocytophilum GDS690.2.4.1 GDS1397.0.1 0.52 agent control LTb agent untreated HIV GDS1439.0.2 GDS2428.0.1.2 -0.52 disease state benign metastatic agent untreated 5-aza-dC GDS2341.0.3.5 GDS2362.6.7.2.5 -0.52 agent untreated Types I and II IFNs agent untreated chloroguine treated GDS2341.0.2.5 GDS1282.0.2 0.52 agent untreated Type II IFN disease state control clear cell sarcoma of the kidney GDS2414.0.1.4 GDS1850.0.1 0.52 agent control trophoblast conditioned medium disease state healthy carious GDS2414.0.1.4 GDS651.0.2 -0.52 agent control trophoblast conditioned medium disease state normal ischemic GDS1630.2.4.0 GDS1926.0.2.4 -0.52 agent untreated atorvastatin agent control LTD4 GDS1630.2.4.0 GDS1956.0.3 -0.52 agent untreated atorvastatin disease state normal amyotophic lateral sclerosis GDS1405.0.1 GDS1732.0.1 -0.52 agent untreated DCI disease state normal papillary thyroid cancer GDS1447.0.1 GDS1574.8.9.11 0.52 agent control vanadium agent control endotoxin GDS1447.0.1 GDS2617.0.1 -0.52 agent control vanadium disease state normal non-tumorigenic cancer cell GDS1956.0.7 GDS1321.0.1 0.52 disease state normal Becker muscular dystrophy disease state normal Barrett's esophagus GDS2118.0.2 GDS2221.0.3 -0.52 disease state normal refractory anemia with ringed sideroblasts agent untreated lipopolysaccharide GDS1331.0.2 GDS2333.1.2.3 0.52 disease state normal symptomatic infection wild type delta pilD mutant GDS1331.0.2 GDS1665.0.1 -0.52 disease state normal symptomatic disease state normal papillary thyroid carcinoma GDS1989.1.2.0 GDS2250.0.3 0.52 disease state normal benign nevus disease state normal basal-like cancer GDS1926.0.3.4 GDS2617.0.2 -0.52 agent control LTD4 and thrombin disease state normal tumorigenic cancer cell GDS1926.0.3.4 GDS1439.0.2 -0.52 agent control LTD4 and thrombin disease state benign metastatic GDS1326.2.3.0 GDS715.2.7.18 0.52 agent control E2 agent negative control 4,5-dianilinophthalimide GDS2215.0.1 GDS1553.0.1 0.52 agent control chlorpyrifos agent untreated fullerene GDS1543.0.1 GDS1427.0.2 -0.52 agent control tumor necrosis factor infection control v-Myb GDS1956.0.9 GDS2617.0.2 0.52 disease state normal Calpain 3 mutation disease state normal tumorigenic cancer cell GDS2697.0.1 GDS1427.0.2 0.52 disease state normal teratozoospermia infection control v-Myb GDS2697.0.1 GDS1926.0.2.4 -0.52 disease state normal teratozoospermia agent control LTD4 GDS2697.0.1 GDS2215.0.1 -0.52 disease state normal teratozoospermia agent control chlorpyrifos GDS2643.0.1.4 GDS2118.0.3 -0.52 disease state normal Waldenstrom's macroglobulinemia disease state normal refractory anemia with excess blasts GDS1956.0.2 GDS2635.0.3 0.52 disease state normal juvenile dermatomyositis disease state lobular control invasive ductal carcinoma GDS1956.0.2 GDS2221.0.3 0.52 disease state normal juvenile dermatomyositis agent untreated lipopolysaccharide GDS1956.0.2 GDS1543.0.1 0.52 disease state normal juvenile dermatomyositis agent control tumor necrosis factor GDS2332.0.3 GDS2617.0.2 -0.52 infection uninfected delta pilD mutant disease state normal tumorigenic cancer cell GDS1989.1.5.0 GDS2341.0.1.4 0.52 disease state normal vertical growth phase melanoma agent untreated Type I IFN GDS2057.0.1.4 GDS1312.0.1 0.52 agent control DHT disease state normal cancer GDS2221.1.3 GDS1989.1.5.0 0.52 agent vehicle lipopolysaccharide disease state normal vertical growth phase melanoma GDS2221.1.3 GDS1428.0.5.10 0.52 agent vehicle lipopolysaccharide agent untreated Anaplasma phagocytophilum GDS2333.0.2.4 GDS1313.0.1 0.52 infection uninfected delta pilD mutant agent control TGFb1 GDS2333.0.2.4 GDS1926.0.1.4 0.52 infection uninfected delta pilD mutant agent control thrombin GDS1783.0.2 GDS1956.0.8 0.52 agent control high potassium disease state normal Duchenne muscular dystrophy GDS1783.0.2 GDS2852.0.1.5 0.52 agent control high potassium agent control IL-13 GDS268.0.2 GDS1956.0.5 0.52 disease state non-obese morbidly obese disease state normal fascioscapulohumeral muscular dystrophy GDS2737.0.1.3 GDS1665.0.1 0.52 disease state normal endometriosis disease state normal papillary thyroid carcinoma GDS2737.0.1.3 GDS651.0.2 0.52 disease state normal endometriosis disease state normal ischemic GDS690.2.3.0 GDS2239.0.1 0.52 agent control flagellin agent control hepatitis C virus core protein GDS690.2.3.0 GDS1736.0.1 0.52 agent control flagellin agent control arachidonic acid GDS2221.0.2 GDS1428.0.5.10 0.52 agent untreated galectin-1 agent untreated Anaplasma phagocytophilum GDS2221.0.2 GDS1989.1.7.0 0.52 agent untreated galectin-1 disease state normal lymph node metastasis GDS2705.0.2 GDS2341.0.1.4 -0.52 agent control carboplatin agent untreated Type I IFN GDS1428.0.1.10 GDS715.2.4.18 0.52 agent untreated Staphylococcus aureus agent negative control a-methyl-L-p-tyrosine GDS1439.0.1 GDS2635.0.3 0.52 disease state benign primary disease state lobular control invasive ductal carcinoma GDS2333.1.2.3 GDS2643.0.1.5 0.52 infection wild type delta pilD mutant disease state normal Waldenstrom's macroglobulinemia GDS2333.1.2.3 GDS1850.0.1 -0.52 infection wild type delta pilD mutant disease state healthy carious GDS2214.0.1 GDS2221.1.2 0.52 agent control lipopolysaccharide agent vehicle galectin-1 GDS2214.0.1 GDS1428.0.3.10 -0.52 agent control lipopolysaccharide agent untreated HL60 cell lysate GDS1630.2.3.1 GDS1902.0.1.8.9 -0.52 agent untreated mevalonate agent none ethanol control GDS1549.3.4.2 GDS1375.0.2 0.52 agent control estradiol disease state normal malignant melanoma GDS2852.0.1.5 GDS2153.0.1 0.52 agent control IL-13 disease state normal dermatomyositis GDS2649.4.5.0 GDS266.0.1.2 -0.52 disease state uninfected non-progressive HIV infection disease state no atopy atopy GDS2767.7.8.3 GDS1615.0.1 -0.52 agent water red wine disease state normal ulcerative colitis GDS484.0.1 GDS289.0.1 0.52 disease state normal leiomyoma disease state control chronic obstructive pulmonary disease GDS2649.3.5.1 GDS2221.1.3 0.52 disease state uninfected chronic HIV infection agent vehicle lipopolysaccharide GDS2767.5.8.0 GDS2205.0.1 -0.52 agent water alcohol disease state non-failing dilated cardiomyopathy GDS2767.5.8.4 GDS1956.0.2 -0.52 agent water alcohol disease state normal juvenile dermatomyositis GDS2767.5.8.4 GDS2852.0.1.5 -0.52 agent water alcohol agent control IL-13 GDS2767.6.8.0 GDS690.2.5.0 -0.52 agent water grape juice agent control TNFa GDS2767.6.8.0 GDS715.2.9.18 -0.52 agent water grape juice agent negative control 5-fluorouridine GDS2767.6.8.0 GDS715.0.6.16 0.52 agent water grape juice agent none 16-ketoestradiol GDS2649.2.5.1 GDS1439.0.1 0.52 disease state uninfected early HIV infection disease state benign primary GDS2767.7.8.0 GDS715.2.11.18 0.52 agent water red wine agent negative control scopolamine methyl bromide GDS1615.0.2 GDS2649.2.5.0 -0.52 disease state normal Crohn's disease disease state uninfected early HIV infection GDS1397.0.1 GDS1062.2.3.0 -0.52 agent untreated HIV disease state no metastasis metastasis GDS2414.0.1.4 GDS484.0.1 -0.52 agent control trophoblast conditioned medium disease state normal leiomyoma GDS2697.0.1 GDS1062.2.3.0 0.52 disease state normal teratozoospermia disease state no metastasis metastasis GDS1615.0.1 GDS715.2.7.18 0.51 disease state normal ulcerative colitis agent negative control 4,5-dianilinophthalimide GDS2635.0.2 GDS2737.0.1.3 0.51 disease state lobular control invasive lobular carcinoma disease state normal endometriosis GDS2362.6.7.2.5 GDS715.0.1.16 -0.51 agent untreated chloroguine treated agent none positive control GDS1333.0.1 GDS2737.0.1.2 0.51 agent baseline oxandrolone disease state normal endometriosis GDS1333.0.1 GDS1956.0.5 -0.51 agent baseline oxandrolone disease state normal fascioscapulohumeral muscular dystrophy GDS2418.0.1 GDS1326.2.3.1 -0.51 disease state control vulvar intraepithelial neoplasia agent control E2 GDS2643.0.3.5 GDS2737.0.1.4 -0.51 disease state normal multiple myeloma disease state normal endometriosis GDS2611.0.3.9 GDS2414.0.1.4 0.51 agent untreated IFN-gamma agent control trophoblast conditioned medium GDS2250.0.3 GDS2333.1.2.4 0.51 disease state normal basal-like cancer infection wild type delta pilD mutant GDS2250.0.3 GDS715.0.9.18 0.51 disease state normal basal-like cancer agent none 5-fluorouridine GDS2200.0.1 GDS2617.0.2 0.51 disease state normal actinic keratosis disease state normal tumorigenic cancer cell GDS1615.0.2 GDS715.0.7.18 0.51 disease state normal Crohn's disease agent none 4,5-dianilinophthalimide GDS1050.2.3.0 GDS1926.0.2.4 -0.51 agent untreated valproic acid agent control LTD4 GDS1783.0.1 GDS2852.0.1.5 0.51 agent control thapsigargin agent control IL-13 GDS1783.0.1 GDS690.2.5.0 0.51 agent control thapsigargin agent control TNFa GDS1783.0.1 GDS2191.0.1 -0.51 agent control thapsigargin disease state control bipolar disorder GDS1783.0.1 GDS1427.0.2 -0.51 agent control thapsigargin infection control v-Myb GDS1783.0.1 GDS2697.0.1 -0.51 agent control thapsigargin disease state normal teratozoospermia GDS1326.2.3.1 GDS1989.1.6.0 -0.51 agent control E2 disease state normal metastatic growth phase melanoma GDS2617.0.2 GDS1989.1.5.0 0.51 disease state normal tumorigenic cancer cell disease state normal vertical growth phase melanoma GDS2221.1.2 GDS1989.1.6.0 0.51 agent vehicle galectin-1 disease state normal metastatic growth phase melanoma GDS2333.0.2.3 GDS1989.1.3.0 -0.51 infection uninfected delta pilD mutant disease state normal atypical nevus GDS2428.0.1.2 GDS2057.0.1.4 -0.51 agent untreated 5-aza-dC agent control DHT GDS1956.0.6 GDS1375.0.2 -0.51 disease state normal Emery-Dreifuss muscular dystrophy disease state normal malignant melanoma GDS2142.0.2 GDS2737.0.1.4 -0.51 disease state normal severe cystic fibrosis disease state normal endometriosis GDS1331.0.1 GDS2142.0.1 -0.51 disease state normal presymptomatic disease state normal mild cystic fibrosis GDS1362.0.2 GDS2643.0.1.5 0.51 disease state non-failing heart ischemic cardiomyopathy disease state normal Waldenstrom's macroglobulinemia GDS690.2.5.0 GDS1736.0.1 0.51 agent control TNFa agent control arachidonic acid GDS1375.0.2 GDS1989.1.3.0 0.51 disease state normal malignant melanoma disease state normal atypical nevus GDS2333.1.2.4 GDS1926.0.1.4 -0.51 infection wild type delta pilD mutant agent control thrombin GDS1746.2.4.0 GDS1282.0.2 -0.51 disease state normal basaloid disease state control clear cell sarcoma of the kidney GDS1746.2.4.0 GDS1783.0.1 -0.51 disease state normal basaloid agent control thapsigargin GDS1746.2.4.0 GDS1783.0.2 -0.51 disease state normal basaloid agent control high potassium GDS2341.0.1.5 GDS1220.0.1.3 0.51 agent untreated Type I IFN disease state normal malignant pleural mesothelioma GDS2341.0.1.5 GDS1321.0.2 0.51 agent untreated Type I IFN disease state normal adenocarcinoma GDS1971.0.1 GDS2362.6.7.2.5 -0.51 disease state healthy uncomplicated malaria agent untreated chloroguine treated GDS2214.0.2 GDS2216.0.1.5 0.51 agent control HMGB1 agent control LPS GDS715.0.7.18 GDS1312.0.1 -0.51 agent none 4,5-dianilinophthalimide disease state normal cancer GDS2367.3.4.2 GDS715.2.15.18 0.51 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control cyclazosin HCl GDS2367.3.4.2 GDS2611.0.1.9 -0.51 infection control adenovirus adenovirus carrying estrogen receptor beta agent untreated keratinocyte growth factor GDS2250.0.1 GDS2643.0.1.5 0.51 disease state normal non-basal-like cancer disease state normal Waldenstrom's macroglobulinemia GDS2341.0.3.4 GDS1312.0.1 -0.51 agent untreated Types I and II IFNs disease state normal cancer GDS715.0.3.18 GDS715.2.11.18 -0.51 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control scopolamine methyl bromide GDS2221.0.3 GDS1989.1.5.0 0.51 agent untreated lipopolysaccharide disease state normal vertical growth phase melanoma GDS690.2.4.1 GDS1331.0.2 0.51 agent control LTb disease state normal symptomatic GDS690.2.4.1 GDS715.2.4.18 -0.51 agent control LTb agent negative control a-methyl-L-p-tyrosine GDS1439.0.2 GDS1685.0.1 0.51 disease state benign metastatic disease state normal hereditary gingival fibromatosis GDS1439.0.2 GDS737.0.1 -0.51 disease state benign metastatic disease state no or mild emphysema severe emphysema GDS2341.0.3.5 GDS1282.0.2 0.51 agent untreated Types I and II IFNs disease state control clear cell sarcoma of the kidney GDS2341.0.3.5 GDS2200.0.2 0.51 agent untreated Types I and II IFNs disease state normal squamous cell carcinoma GDS1989.1.7.0 GDS2307.0.1 -0.51 disease state normal lymph node metastasis agent untreated LDL GDS1630.2.4.0 GDS1220.0.1.3 -0.51 agent untreated atorvastatin disease state normal malignant pleural mesothelioma GDS1405.0.1 GDS2418.0.1 -0.51 agent untreated DCI disease state control vulvar intraepithelial neoplasia GDS1956.0.7 GDS1783.0.2 0.51 disease state normal Becker muscular dystrophy agent control high potassium GDS1331.0.2 GDS2367.0.1.3 0.51 disease state normal symptomatic agent vehicle estradiol GDS1331.0.2 GDS715.0.14.18 0.51 disease state normal symptomatic agent none R-(-)-apomorphine HCl GDS1926.0.3.4 GDS1259.0.1 0.51 agent control LTD4 and thrombin disease state normal dermatomyositis GDS1926.0.3.4 GDS1783.0.1 0.51 agent control LTD4 and thrombin agent control thapsigargin GDS1326.2.3.0 GDS2705.0.2 0.51 agent control E2 agent control carboplatin GDS1732.0.1 GDS2617.0.2 0.51 disease state normal papillary thyroid cancer disease state normal tumorigenic cancer cell GDS1926.0.2.4 GDS1362.0.2 0.51 agent control LTD4 disease state non-failing heart ischemic cardiomyopathy GDS1574.8.9.15 GDS715.2.15.18 0.51 agent control endotoxin agent negative control cyclazosin HCl GDS1956.0.9 GDS1282.0.1 0.51 disease state normal Calpain 3 mutation disease state control Wilms' tumor GDS2057.0.2.4 GDS1667.0.1 0.51 agent control RTI-018 infection HPV negative HPV positive GDS2057.0.2.4 GDS2418.0.1 0.51 agent control RTI-018 disease state control vulvar intraepithelial neoplasia GDS2057.0.2.4 GDS1375.0.2 0.51 agent control RTI-018 disease state normal malignant melanoma GDS2057.0.2.4 GDS2200.0.2 0.51 agent control RTI-018 disease state normal squamous cell carcinoma GDS715.2.3.18 GDS715.2.13.18 0.51 agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent negative control 8-(3-chlorostyryl) caffeine GDS1321.0.2 GDS1375.0.1 -0.51 disease state normal adenocarcinoma disease state normal benign nevi GDS2697.0.1 GDS2255.3.4.0 0.51 disease state normal teratozoospermia agent untreated endotoxin GDS2643.0.1.4 GDS1574.8.9.11 0.51 disease state normal Waldenstrom's macroglobulinemia agent control endotoxin GDS2200.0.2 GDS1282.0.1 0.51 disease state normal squamous cell carcinoma disease state control Wilms' tumor GDS1282.0.2 GDS1989.1.7.0 0.51 disease state control clear cell sarcoma of the kidney disease state normal lymph node metastasis GDS1956.0.2 GDS268.0.2 0.51 disease state normal juvenile dermatomyositis disease state non-obese morbidly obese GDS737.0.1 GDS1746.2.4.0 -0.51 disease state no or mild emphysema severe emphysema disease state normal basaloid GDS2332.0.3 GDS2021.0.1 0.51 infection uninfected delta pilD mutant agent control metoprolol GDS2332.0.3 GDS1428.0.1.10 0.51 infection uninfected delta pilD mutant agent untreated Staphylococcus aureus GDS1850.0.1 GDS1375.0.1 0.51 disease state healthy carious disease state normal benign nevi GDS1617.0.2 GDS2367.0.2.4 0.51 agent control 50uM zinc agent vehicle tamoxifen GDS2367.0.2.3 GDS2332.0.3 -0.51 agent vehicle tamoxifen infection uninfected delta pilD mutant GDS2057.0.1.4 GDS2418.0.1 0.51 agent control DHT disease state control vulvar intraepithelial neoplasia GDS2057.0.1.4 GDS1667.0.1 0.51 agent control DHT infection HPV negative HPV positive GDS2057.0.1.4 GDS1956.0.3 -0.51 agent control DHT disease state normal amyotophic lateral sclerosis GDS1375.0.1 GDS2617.0.1 0.51 disease state normal benign nevi disease state normal non-tumorigenic cancer cell GDS1362.0.1 GDS1257.0.2 0.51 disease state non-failing heart non-ischemic cardiomyopathy disease state normal SCD steady state GDS1362.0.1 GDS1989.1.4.0 -0.51 disease state non-failing heart non-ischemic cardiomyopathy disease state normal melanoma in situ GDS1956.0.5 GDS1312.0.1 -0.51 disease state normal fascioscapulohumeral muscular dystrophy disease state normal cancer GDS1783.0.2 GDS2239.0.1 0.51 agent control high potassium agent control hepatitis C virus core protein GDS1397.0.2 GDS715.2.9.18 0.51 agent untreated TNF-alpha agent negative control 5-fluorouridine GDS2737.0.1.3 GDS1989.1.4.0 0.51 disease state normal endometriosis disease state normal melanoma in situ GDS690.2.3.0 GDS1956.0.1 0.51 agent control flagellin disease state normal acute quadriplegic myopathy GDS690.2.3.0 GDS1783.0.1 0.51 agent control flagellin agent control thapsigargin GDS690.2.3.0 GDS1617.0.5 -0.51 agent control flagellin agent control MGd/50uM zinc GDS690.2.3.0 GDS2191.0.1 -0.51 agent control flagellin disease state control bipolar disorder GDS1428.0.1.10 GDS2432.0.1 0.51 agent untreated Staphylococcus aureus disease state control pituitary adenoma predisposition GDS1428.0.1.10 GDS1397.0.1 -0.51 agent untreated Staphylococcus aureus agent untreated HIV GDS1558.0.1.3 GDS1321.0.1 0.51 disease state no atrial fibrillation permanent atrial fibrillation disease state normal Barrett's esophagus GDS1558.0.1.3 GDS2154.0.1 0.51 disease state no atrial fibrillation permanent atrial fibrillation disease state healthy inflammatory dilated cardiomyopathy GDS2333.1.2.3 GDS2205.0.1 0.51 infection wild type delta pilD mutant disease state non-failing dilated cardiomyopathy GDS2333.1.2.3 GDS2414.0.1.3 0.51 infection wild type delta pilD mutant agent control trophoblast conditioned medium GDS2333.1.2.3 GDS2153.0.1 0.51 infection wild type delta pilD mutant disease state normal dermatomyositis GDS1956.0.10 GDS1665.0.1 0.51 disease state normal dysferlin mutation disease state normal papillary thyroid carcinoma GDS2332.1.2 GDS2153.0.1 0.51 infection wild type delta frpC/frpA mutant disease state normal dermatomyositis GDS2332.1.2 GDS1665.0.1 -0.51 infection wild type delta frpC/frpA mutant disease state normal papillary thyroid carcinoma GDS1956.0.3 GDS2142.0.2 0.51 disease state normal amyotophic lateral sclerosis disease state normal severe cystic fibrosis GDS1376.2.3.1 GDS690.2.4.1 0.51 disease state normal thrombocythemia agent control LTb GDS1376.2.3.1 GDS715.2.4.18 -0.51 disease state normal thrombocythemia agent negative control a-methyl-L-p-tyrosine GDS1376.2.3.1 GDS715.0.6.16 -0.51 disease state normal thrombocythemia agent none 16-ketoestradiol GDS1549.3.4.2 GDS2428.0.1.2 -0.51 agent control estradiol agent untreated 5-aza-dC GDS2649.2.5.0 GDS1062.2.3.0 -0.51 disease state uninfected early HIV infection disease state no metastasis metastasis GDS2767.7.8.3 GDS690.2.4.1 0.51 agent water red wine agent control LTb GDS505.0.1 GDS1321.0.2 0.51 disease state normal RCC disease state normal adenocarcinoma GDS484.0.1 GDS2362.6.7.2.5 0.51 disease state normal leiomyoma agent untreated chloroguine treated GDS2649.3.5.1 GDS1375.0.2 0.51 disease state uninfected chronic HIV infection disease state normal malignant melanoma GDS2767.5.8.0 GDS1989.1.3.0 0.51 agent water alcohol disease state normal atypical nevus GDS2767.5.8.4 GDS715.2.10.18 -0.51 agent water alcohol agent negative control pergolide methanesulfonate GDS2767.5.8.4 GDS2142.0.1 0.51 agent water alcohol disease state normal mild cystic fibrosis GDS2767.5.8.4 GDS810.0.3 0.51 agent water alcohol disease state control severe AD GDS2767.6.8.0 GDS1956.0.2 -0.51 agent water grape juice disease state normal juvenile dermatomyositis GDS2767.6.8.0 GDS1353.0.1.2 -0.51 agent water grape juice agent control dexamethasone GDS2767.6.8.0 GDS2142.0.2 -0.51 agent water grape juice disease state normal severe cystic fibrosis GDS2767.6.8.0 GDS810.0.3 0.51 agent water grape juice disease state control severe AD GDS2767.6.8.0 GDS715.2.11.18 0.51 agent water grape juice agent negative control scopolamine methyl bromide GDS2767.6.8.0 GDS715.0.8.16 0.51 agent water grape juice agent none 1,10-phenanthroline GDS2649.3.5.0 GDS2221.1.2 0.51 disease state uninfected chronic HIV infection agent vehicle galectin-1 GDS2649.2.5.1 GDS1553.0.1 -0.51 disease state uninfected early HIV infection agent untreated fullerene GDS2649.2.5.1 GDS860.0.1 0.51 disease state uninfected early HIV infection agent untreated endothelin-1 GDS2649.2.5.1 GDS2307.0.1 0.51 disease state uninfected early HIV infection agent untreated LDL GDS715.1.2.18 GDS1375.0.1 -0.51 agent negative control positive control disease state normal benign nevi GDS2767.7.8.0 GDS1376.2.3.1 -0.51 agent water red wine disease state normal thrombocythemia GDS2767.7.8.0 GDS715.0.9.18 -0.51 agent water red wine agent none 5-fluorouridine GDS2767.7.8.0 GDS715.0.8.16 0.51 agent water red wine agent none 1,10-phenanthroline GDS2255.3.4.1 GDS266.0.1.4 -0.51 agent untreated endotoxin disease state no atopy atopy GDS2084.0.1 GDS505.0.1 -0.51 disease state control polycystic ovary syndrome disease state normal RCC GDS2250.0.1 GDS715.1.2.18 -0.51 disease state normal non-basal-like cancer agent negative control positive control GDS1685.0.1 GDS484.0.1 0.51 disease state normal hereditary gingival fibromatosis disease state normal leiomyoma GDS1850.0.1 GDS2649.2.5.1 0.51 disease state healthy carious disease state uninfected early HIV infection GDS1783.0.2 GDS1062.2.3.0 -0.51 agent control high potassium disease state no metastasis metastasis GDS2341.0.1.4 GDS505.0.1 0.51 agent untreated Type I IFN disease state normal RCC GDS1615.0.1 GDS1665.0.1 0.50 disease state normal ulcerative colitis disease state normal papillary thyroid carcinoma GDS2332.0.2 GDS2221.0.3 0.50 infection uninfected delta frpC/frpA mutant agent untreated lipopolysaccharide GDS2332.0.2 GDS2214.0.2 0.50 infection uninfected delta frpC/frpA mutant agent control HMGB1 GDS2635.0.2 GDS1321.0.2 0.50 disease state lobular control invasive lobular carcinoma disease state normal adenocarcinoma GDS1259.0.1 GDS2617.0.2 0.50 disease state normal dermatomyositis disease state normal tumorigenic cancer cell GDS1259.0.1 GDS715.0.12.18 0.50 disease state normal dermatomyositis agent none 5-fluorouracil GDS1333.0.1 GDS690.2.4.1 -0.50 agent baseline oxandrolone agent control LTb GDS1333.0.1 GDS1926.0.2.4 -0.50 agent baseline oxandrolone agent control LTD4 GDS1989.1.3.0 GDS1917.0.1 0.50 disease state normal atypical nevus disease state control schizophrenia GDS715.0.1.18 GDS2213.0.1 0.50 agent none positive control agent untreated 5-aza-dC GDS715.0.1.18 GDS1375.0.1 -0.50 agent none positive control disease state normal benign nevi GDS2643.0.3.5 GDS715.0.9.18 0.50 disease state normal multiple myeloma agent none 5-fluorouridine GDS2643.0.3.5 GDS1427.0.1 -0.50 disease state normal multiple myeloma infection control c-Myb GDS2643.0.3.5 GDS2362.6.7.2.5 -0.50 disease state normal multiple myeloma agent untreated chloroguine treated GDS2215.0.2 GDS1326.2.3.0 -0.50 agent control cyfluthrin agent control E2 GDS715.0.10.18 GDS2255.3.4.0 -0.50 agent none pergolide methanesulfonate agent untreated endotoxin GDS2250.0.2 GDS1989.1.2.0 0.50 disease state normal BRCA1-associated cancer disease state normal benign nevus GDS2250.0.3 GDS2643.0.1.5 0.50 disease state normal basal-like cancer disease state normal Waldenstrom's macroglobulinemia GDS2250.0.3 GDS1746.2.3.0 0.50 disease state normal basal-like cancer disease state normal benign hyperplasia GDS2250.0.3 GDS715.0.1.18 -0.50 disease state normal basal-like cancer agent none positive control GDS2200.0.1 GDS2250.0.1 0.50 disease state normal actinic keratosis disease state normal non-basal-like cancer GDS1615.0.2 GDS715.2.3.18 0.50 disease state normal Crohn's disease agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1615.0.2 GDS715.2.7.18 0.50 disease state normal Crohn's disease agent negative control 4,5-dianilinophthalimide GDS1615.0.2 GDS715.0.8.18 0.50 disease state normal Crohn's disease agent none 1,10-phenanthroline GDS2414.0.1.3 GDS1956.0.6 0.50 agent control trophoblast conditioned medium disease state normal Emery-Dreifuss muscular dystrophy GDS1050.2.3.0 GDS715.0.4.18 0.50 agent untreated valproic acid agent none a-methyl-L-p-tyrosine GDS2609.0.1 GDS1989.1.3.0 -0.50 disease state healthy control early onset colorectal cancer disease state normal atypical nevus GDS2617.0.2 GDS715.0.1.18 -0.50 disease state normal tumorigenic cancer cell agent none positive control GDS2057.0.2.3 GDS651.0.1 -0.50 agent control RTI-018 disease state normal idiopathic dilated GDS2333.0.2.3 GDS2239.0.1 0.50 infection uninfected delta pilD mutant agent control hepatitis C virus core protein GDS1397.0.1 GDS1956.0.2 0.50 agent untreated HIV disease state normal juvenile dermatomyositis GDS2397.0.1 GDS1989.1.6.0 -0.50 disease state normal idiopathic myelofibrosis disease state normal metastatic growth phase melanoma GDS1574.8.9.10 GDS2021.0.2 0.50 agent control endotoxin agent control nebivolol GDS1630.2.4.1 GDS1375.0.2 -0.50 agent untreated atorvastatin disease state normal malignant melanoma GDS715.2.9.18 GDS715.0.7.18 0.50 agent negative control 5-fluorouridine agent none 4,5-dianilinophthalimide GDS1331.0.1 GDS1376.2.3.1 0.50 disease state normal presymptomatic disease state normal thrombocythemia GDS1331.0.1 GDS1971.0.1 -0.50 disease state normal presymptomatic disease state healthy uncomplicated malaria GDS1956.0.4 GDS2215.0.2 0.50 disease state normal spastic paraplegia agent control cyfluthrin GDS1956.0.4 GDS1282.0.1 0.50 disease state normal spastic paraplegia disease state control Wilms' tumor GDS1362.0.2 GDS1956.0.4 -0.50 disease state non-failing heart ischemic cardiomyopathy disease state normal spastic paraplegia GDS1667.0.1 GDS1956.0.9 -0.50 infection HPV negative HPV positive disease state normal Calpain 3 mutation GDS690.2.5.0 GDS1783.0.2 0.50 agent control TNFa agent control high potassium GDS2021.0.1 GDS1926.0.2.4 0.50 agent control metoprolol agent control LTD4 GDS2216.0.2.5 GDS1617.0.3 0.50 agent control CyP agent control MGd GDS2193.0.1 GDS715.0.7.18 0.50 agent control Sox4 RNAi agent none 4,5-dianilinophthalimide GDS2341.0.1.5 GDS1956.0.11 0.50 agent untreated Type I IFN disease state normal FKRP mutation GDS2341.0.1.5 GDS2635.0.3 0.50 agent untreated Type I IFN disease state lobular control invasive ductal carcinoma GDS2341.0.1.5 GDS2021.0.2 0.50 agent untreated Type I IFN agent control nebivolol GDS2341.0.1.5 GDS1427.0.1 -0.50 agent untreated Type I IFN infection control c-Myb GDS1971.0.1 GDS1542.0.1 0.50 disease state healthy uncomplicated malaria agent control tumor necrosis factor GDS1971.0.1 GDS2414.0.1.4 0.50 disease state healthy uncomplicated malaria agent control trophoblast conditioned medium GDS1971.0.1 GDS1397.0.1 -0.50 disease state healthy uncomplicated malaria agent untreated HIV GDS2367.3.4.2 GDS1257.0.1 0.50 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal SCD with acute chest syndrome GDS2367.3.4.2 GDS885.0.1 0.50 infection control adenovirus adenovirus carrying estrogen receptor beta agent control campthotecin GDS715.0.5.18 GDS715.0.12.18 0.50 agent none sulmazole agent none 5-fluorouracil GDS2341.0.3.4 GDS1850.0.1 0.50 agent untreated Types I and II IFNs disease state healthy carious GDS2221.0.3 GDS1989.1.7.0 0.50 agent untreated lipopolysaccharide disease state normal lymph node metastasis GDS690.2.4.1 GDS715.2.9.18 0.50 agent control LTb agent negative control 5-fluorouridine GDS690.2.4.1 GDS2367.0.2.3 0.50 agent control LTb agent vehicle tamoxifen GDS715.0.11.18 GDS2021.0.1 -0.50 agent none scopolamine methyl bromide agent control metoprolol GDS2617.0.1 GDS1989.1.7.0 0.50 disease state normal non-tumorigenic cancer cell disease state normal lymph node metastasis GDS2341.0.3.5 GDS1050.0.1.2 0.50 agent untreated Types I and II IFNs disease state normal polycystic ovary syndrome GDS2341.0.3.5 GDS1427.0.1 -0.50 agent untreated Types I and II IFNs infection control c-Myb GDS2341.0.2.5 GDS2307.0.2 0.50 agent untreated Type II IFN agent untreated ox-LDL GDS2414.0.1.4 GDS1989.1.4.0 0.50 agent control trophoblast conditioned medium disease state normal melanoma in situ GDS1630.2.4.0 GDS2332.1.2 -0.50 agent untreated atorvastatin infection wild type delta frpC/frpA mutant GDS2118.0.2 GDS1971.0.1 0.50 disease state normal refractory anemia with ringed sideroblasts disease state healthy uncomplicated malaria GDS1331.0.2 GDS1989.1.3.0 -0.50 disease state normal symptomatic disease state normal atypical nevus GDS1926.0.3.4 GDS715.2.8.18 0.50 agent control LTD4 and thrombin agent negative control 1,10-phenanthroline GDS2216.0.1.5 GDS715.2.4.18 0.50 agent control LPS agent negative control a-methyl-L-p-tyrosine GDS2216.0.1.5 GDS2367.3.4.2 0.50 agent control LPS infection control adenovirus adenovirus carrying estrogen receptor beta GDS2216.0.1.5 GDS1615.0.2 0.50 agent control LPS disease state normal Crohn's disease GDS2216.0.1.5 GDS715.0.4.18 0.50 agent control LPS agent none a-methyl-L-p-tyrosine GDS1926.0.2.4 GDS1956.0.1 0.50 agent control LTD4 disease state normal acute quadriplegic myopathy GDS1926.0.2.4 GDS2737.0.1.3 -0.50 agent control LTD4 disease state normal endometriosis GDS1956.0.9 GDS1321.0.1 0.50 disease state normal Calpain 3 mutation disease state normal Barrett's esophagus GDS1574.8.9.13 GDS715.0.7.18 0.50 agent control endotoxin agent none 4,5-dianilinophthalimide GDS1956.0.2 GDS1989.1.5.0 0.50 disease state normal juvenile dermatomyositis disease state normal vertical growth phase melanoma GDS1956.0.2 GDS2635.0.2 0.50 disease state normal juvenile dermatomyositis disease state lobular control invasive lobular carcinoma GDS1956.0.2 GDS2617.0.2 0.50 disease state normal juvenile dermatomyositis disease state normal tumorigenic cancer cell GDS1956.0.2 GDS2190.0.1 -0.50 disease state normal juvenile dermatomyositis disease state control bipolar disorder GDS1956.0.2 GDS715.0.6.16 -0.50 disease state normal juvenile dermatomyositis agent none 16-ketoestradiol GDS2332.0.3 GDS2205.0.1 -0.50 infection uninfected delta pilD mutant disease state non-failing dilated cardiomyopathy GDS1971.0.2 GDS2362.6.7.2.5 -0.50 disease state healthy complicated malaria agent untreated chloroguine treated GDS2367.0.2.3 GDS1989.1.4.0 0.50 agent vehicle tamoxifen disease state normal melanoma in situ GDS2057.0.1.4 GDS2200.0.2 0.50 agent control DHT disease state normal squamous cell carcinoma GDS1362.0.1 GDS2214.0.1 -0.50 disease state non-failing heart non-ischemic cardiomyopathy agent control lipopolysaccharide GDS1783.0.2 GDS1574.8.9.11 -0.50 agent control high potassium agent control endotoxin GDS1783.0.2 GDS1428.0.1.10 -0.50 agent control high potassium agent untreated Staphylococcus aureus GDS2737.0.1.3 GDS1558.0.1.3 0.50 disease state normal endometriosis disease state no atrial fibrillation permanent atrial fibrillation GDS2737.0.1.3 GDS1630.2.4.1 -0.50 disease state normal endometriosis agent untreated atorvastatin GDS2255.3.4.0 GDS2205.0.1 -0.50 agent untreated endotoxin disease state non-failing dilated cardiomyopathy GDS690.2.3.0 GDS1850.0.1 -0.50 agent control flagellin disease state healthy carious GDS690.2.3.0 GDS1630.2.4.0 -0.50 agent control flagellin agent untreated atorvastatin GDS2142.0.1 GDS2362.6.7.2.5 0.50 disease state normal mild cystic fibrosis agent untreated chloroguine treated GDS2705.0.2 GDS2341.0.2.5 -0.50 agent control carboplatin agent untreated Type II IFN GDS2341.0.1.4 GDS2333.1.2.4 0.50 agent untreated Type I IFN infection wild type delta pilD mutant GDS2333.1.2.3 GDS1956.0.1 0.50 infection wild type delta pilD mutant disease state normal acute quadriplegic myopathy GDS2333.1.2.3 GDS2118.0.2 -0.50 infection wild type delta pilD mutant disease state normal refractory anemia with ringed sideroblasts GDS1956.0.10 GDS289.0.1 -0.50 disease state normal dysferlin mutation disease state control chronic obstructive pulmonary disease GDS1630.2.3.1 GDS715.0.15.18 -0.50 agent untreated mevalonate agent none cyclazosin HCl GDS2332.1.2 GDS1050.0.1.2 0.50 infection wild type delta frpC/frpA mutant disease state normal polycystic ovary syndrome GDS1956.0.3 GDS2154.0.1 0.50 disease state normal amyotophic lateral sclerosis disease state healthy inflammatory dilated cardiomyopathy GDS1376.2.3.1 GDS1956.0.2 0.50 disease state normal thrombocythemia disease state normal juvenile dermatomyositis GDS1376.2.3.1 GDS2414.0.1.3 0.50 disease state normal thrombocythemia agent control trophoblast conditioned medium GDS1376.2.3.1 GDS1989.1.2.0 -0.50 disease state normal thrombocythemia disease state normal benign nevus GDS810.0.1 GDS1917.0.1 -0.50 disease state control incipient AD disease state control schizophrenia GDS2852.0.1.5 GDS2215.0.1 0.50 agent control IL-13 agent control chlorpyrifos GDS2767.6.8.0 GDS266.0.1.2 -0.50 agent water grape juice disease state no atopy atopy GDS2767.7.8.3 GDS1558.0.1.3 -0.50 agent water red wine disease state no atrial fibrillation permanent atrial fibrillation GDS484.0.1 GDS2341.0.3.5 -0.50 disease state normal leiomyoma agent untreated Types I and II IFNs GDS2649.3.5.1 GDS1989.1.5.0 0.50 disease state uninfected chronic HIV infection disease state normal vertical growth phase melanoma GDS266.0.1.2 GDS715.0.15.18 0.50 disease state no atopy atopy agent none cyclazosin HCl GDS266.0.1.4 GDS715.2.7.18 -0.50 disease state no atopy atopy agent negative control 4,5-dianilinophthalimide GDS2767.5.8.4 GDS1956.0.6 -0.50 agent water alcohol disease state normal Emery-Dreifuss muscular dystrophy GDS2767.5.8.4 GDS1736.0.1 -0.50 agent water alcohol agent control arachidonic acid GDS2767.6.8.0 GDS2239.0.1 -0.50 agent water grape juice agent control hepatitis C virus core protein GDS2767.6.8.0 GDS2216.0.3.5 -0.50 agent water grape juice agent control CyP plus LPS GDS2649.3.5.0 GDS2255.3.4.1 0.50 disease state uninfected chronic HIV infection agent untreated endotoxin GDS2649.2.5.1 GDS2332.0.3 -0.50 disease state uninfected early HIV infection infection uninfected delta pilD mutant GDS2649.4.5.0 GDS2432.0.1 0.50 disease state uninfected non-progressive HIV infection disease state control pituitary adenoma predisposition GDS2767.7.8.0 GDS2142.0.1 0.50 agent water red wine disease state normal mild cystic fibrosis GDS1615.0.1 GDS715.1.2.18 0.50 disease state normal ulcerative colitis agent negative control positive control GDS1259.0.1 GDS2649.2.5.0 0.50 disease state normal dermatomyositis disease state uninfected early HIV infection GDS2333.0.2.3 GDS266.0.1.2 0.50 infection uninfected delta pilD mutant disease state no atopy atopy GDS2341.0.1.5 GDS1062.2.3.0 -0.50 agent untreated Type I IFN disease state no metastasis metastasis GDS2341.0.2.5 GDS2649.2.5.0 0.50 agent untreated Type II IFN disease state uninfected early HIV infection GDS2200.0.2 GDS1062.2.3.0 -0.50 disease state normal squamous cell carcinoma disease state no metastasis metastasis GDS1615.0.1 GDS1956.0.10 0.49 disease state normal ulcerative colitis disease state normal dysferlin mutation GDS1615.0.1 GDS1850.0.1 0.49 disease state normal ulcerative colitis disease state healthy carious GDS2332.0.2 GDS2205.0.1 -0.49 infection uninfected delta frpC/frpA mutant disease state non-failing dilated cardiomyopathy GDS2611.0.1.9 GDS1746.2.4.0 0.49 agent untreated keratinocyte growth factor disease state normal basaloid GDS2362.6.7.2.5 GDS715.0.7.18 -0.49 agent untreated chloroguine treated agent none 4,5-dianilinophthalimide GDS1333.0.1 GDS1397.0.1 -0.49 agent baseline oxandrolone agent untreated HIV GDS2418.0.1 GDS715.0.1.18 -0.49 disease state control vulvar intraepithelial neoplasia agent none positive control GDS2643.0.3.5 GDS1362.0.2 0.49 disease state normal multiple myeloma disease state non-failing heart ischemic cardiomyopathy GDS2643.0.3.5 GDS715.2.9.18 0.49 disease state normal multiple myeloma agent negative control 5-fluorouridine GDS2643.0.3.5 GDS2332.1.2 0.49 disease state normal multiple myeloma infection wild type delta frpC/frpA mutant GDS2643.0.3.5 GDS2332.0.2 0.49 disease state normal multiple myeloma infection uninfected delta frpC/frpA mutant GDS2643.0.3.5 GDS2239.0.1 0.49 disease state normal multiple myeloma agent control hepatitis C virus core protein GDS2611.0.3.9 GDS1732.0.1 0.49 agent untreated IFN-gamma disease state normal papillary thyroid cancer GDS715.0.10.18 GDS1428.0.1.10 -0.49 agent none pergolide methanesulfonate agent untreated Staphylococcus aureus GDS1574.8.9.12 GDS2142.0.2 -0.49 agent control endotoxin disease state normal severe cystic fibrosis GDS1574.8.9.12 GDS2215.0.1 -0.49 agent control endotoxin agent control chlorpyrifos GDS2200.0.1 GDS1989.1.3.0 -0.49 disease state normal actinic keratosis disease state normal atypical nevus GDS2744.0.1 GDS1237.0.1 0.49 agent control dioxin infection control Anaplasma phagocytophilum GDS2414.0.1.3 GDS1956.0.1 0.49 agent control trophoblast conditioned medium disease state normal acute quadriplegic myopathy GDS2414.0.1.3 GDS2432.0.1 -0.49 agent control trophoblast conditioned medium disease state control pituitary adenoma predisposition GDS2414.0.1.3 GDS1989.1.3.0 -0.49 agent control trophoblast conditioned medium disease state normal atypical nevus GDS2414.0.1.3 GDS2617.0.1 -0.49 agent control trophoblast conditioned medium disease state normal non-tumorigenic cancer cell GDS1050.2.3.0 GDS715.2.4.18 0.49 agent untreated valproic acid agent negative control a-methyl-L-p-tyrosine GDS1783.0.1 GDS715.0.10.18 0.49 agent control thapsigargin agent none pergolide methanesulfonate GDS1783.0.1 GDS2215.0.1 0.49 agent control thapsigargin agent control chlorpyrifos GDS1783.0.1 GDS1574.8.9.11 -0.49 agent control thapsigargin agent control endotoxin GDS1783.0.1 GDS715.2.4.18 -0.49 agent control thapsigargin agent negative control a-methyl-L-p-tyrosine GDS2643.0.1.5 GDS1428.0.1.10 -0.49 disease state normal Waldenstrom's macroglobulinemia agent untreated Staphylococcus aureus GDS2367.0.1.3 GDS2635.0.3 0.49 agent vehicle estradiol disease state lobular control invasive ductal carcinoma GDS2609.0.1 GDS1375.0.1 -0.49 disease state healthy control early onset colorectal cancer disease state normal benign nevi GDS2609.0.1 GDS1321.0.2 -0.49 disease state healthy control early onset colorectal cancer disease state normal adenocarcinoma GDS1220.0.1.3 GDS690.2.5.0 0.49 disease state normal malignant pleural mesothelioma agent control TNFa GDS1220.0.1.3 GDS1050.2.3.0 -0.49 disease state normal malignant pleural mesothelioma agent untreated valproic acid GDS715.2.4.18 GDS2021.0.2 -0.49 agent negative control a-methyl-L-p-tyrosine agent control nebivolol GDS2333.0.2.3 GDS2432.0.1 -0.49 infection uninfected delta pilD mutant disease state control pituitary adenoma predisposition GDS1630.2.3.0 GDS1926.0.2.4 0.49 agent untreated mevalonate agent control LTD4 GDS715.0.8.16 GDS2341.0.2.4 -0.49 agent none 1,10-phenanthroline agent untreated Type II IFN GDS715.0.8.16 GDS1375.0.2 -0.49 agent none 1,10-phenanthroline disease state normal malignant melanoma GDS1956.0.6 GDS2084.0.1 0.49 disease state normal Emery-Dreifuss muscular dystrophy disease state control polycystic ovary syndrome GDS2705.0.3 GDS715.0.3.16 0.49 agent control rosiglitazone plus carboplatin agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1665.0.1 GDS1321.0.1 0.49 disease state normal papillary thyroid carcinoma disease state normal Barrett's esophagus GDS1665.0.1 GDS2418.0.1 0.49 disease state normal papillary thyroid carcinoma disease state control vulvar intraepithelial neoplasia GDS715.2.9.18 GDS715.0.8.18 0.49 agent negative control 5-fluorouridine agent none 1,10-phenanthroline GDS1331.0.1 GDS690.2.3.0 0.49 disease state normal presymptomatic agent control flagellin GDS1331.0.1 GDS1333.0.1 -0.49 disease state normal presymptomatic agent baseline oxandrolone GDS2118.0.3 GDS2609.0.1 -0.49 disease state normal refractory anemia with excess blasts disease state healthy control early onset colorectal cancer GDS690.2.5.0 GDS2118.0.2 -0.49 agent control TNFa disease state normal refractory anemia with ringed sideroblasts GDS2021.0.1 GDS715.0.1.16 0.49 agent control metoprolol agent none positive control GDS2021.0.1 GDS715.2.13.18 0.49 agent control metoprolol agent negative control 8-(3-chlorostyryl) caffeine GDS2333.1.2.4 GDS2118.0.1 0.49 infection wild type delta pilD mutant disease state normal refractory anemia GDS2250.0.1 GDS715.0.1.18 -0.49 disease state normal non-basal-like cancer agent none positive control GDS2213.0.1 GDS2307.0.2 -0.49 agent untreated 5-aza-dC agent untreated ox-LDL GDS2341.0.3.4 GDS2250.0.1 0.49 agent untreated Types I and II IFNs disease state normal non-basal-like cancer GDS2341.0.3.4 GDS2142.0.2 -0.49 agent untreated Types I and II IFNs disease state normal severe cystic fibrosis GDS690.2.3.1 GDS2697.0.1 -0.49 agent control flagellin disease state normal teratozoospermia GDS690.2.4.1 GDS715.0.9.18 0.49 agent control LTb agent none 5-fluorouridine GDS2617.0.1 GDS1362.0.1 -0.49 disease state normal non-tumorigenic cancer cell disease state non-failing heart non-ischemic cardiomyopathy GDS2617.0.1 GDS1956.0.6 -0.49 disease state normal non-tumorigenic cancer cell disease state normal Emery-Dreifuss muscular dystrophy GDS2341.0.2.5 GDS1427.0.2 -0.49 agent untreated Type II IFN infection control v-Myb GDS1428.0.5.10 GDS715.2.15.18 0.49 agent untreated Anaplasma phagocytophilum agent negative control cyclazosin HCl GDS1428.0.5.10 GDS1971.0.1 0.49 agent untreated Anaplasma phagocytophilum disease state healthy uncomplicated malaria GDS1630.2.4.0 GDS1850.0.1 0.49 agent untreated atorvastatin disease state healthy carious GDS1630.2.4.0 GDS715.0.4.18 0.49 agent untreated atorvastatin agent none a-methyl-L-p-tyrosine GDS1630.2.4.0 GDS2142.0.2 -0.49 agent untreated atorvastatin disease state normal severe cystic fibrosis GDS1353.0.1.2 GDS1850.0.1 -0.49 agent control dexamethasone disease state healthy carious GDS1956.0.7 GDS268.0.1 -0.49 disease state normal Becker muscular dystrophy disease state non-obese obese GDS2118.0.2 GDS2432.0.1 0.49 disease state normal refractory anemia with ringed sideroblasts disease state control pituitary adenoma predisposition GDS2118.0.2 GDS2617.0.2 0.49 disease state normal refractory anemia with ringed sideroblasts disease state normal tumorigenic cancer cell GDS1331.0.2 GDS715.2.10.18 0.49 disease state normal symptomatic agent negative control pergolide methanesulfonate GDS1331.0.2 GDS2084.0.1 0.49 disease state normal symptomatic disease state control polycystic ovary syndrome GDS1331.0.2 GDS810.0.3 -0.49 disease state normal symptomatic disease state control severe AD GDS1989.1.2.0 GDS1956.0.1 -0.49 disease state normal benign nevus disease state normal acute quadriplegic myopathy GDS1326.2.3.0 GDS1237.0.1 -0.49 agent control E2 infection control Anaplasma phagocytophilum GDS1326.2.3.0 GDS2021.0.1 -0.49 agent control E2 agent control metoprolol GDS2215.0.1 GDS2057.0.1.4 0.49 agent control chlorpyrifos agent control DHT GDS1926.0.1.4 GDS2737.0.1.3 -0.49 agent control thrombin disease state normal endometriosis GDS1926.0.1.4 GDS1746.2.4.0 -0.49 agent control thrombin disease state normal basaloid GDS1926.0.1.4 GDS2118.0.2 -0.49 agent control thrombin disease state normal refractory anemia with ringed sideroblasts GDS1732.0.1 GDS2200.0.2 0.49 disease state normal papillary thyroid cancer disease state normal squamous cell carcinoma GDS1543.0.1 GDS2250.0.3 0.49 agent control tumor necrosis factor disease state normal basal-like cancer GDS1956.0.9 GDS1392.0.1 0.49 disease state normal Calpain 3 mutation disease state normal rheumatoid arthritis, on methotrexate GDS2023.0.1.2 GDS2307.0.1 -0.49 infection vehicle control RSV agent untreated LDL GDS1956.0.2 GDS2418.0.1 0.49 disease state normal juvenile dermatomyositis disease state control vulvar intraepithelial neoplasia GDS1956.0.2 GDS1392.0.1 0.49 disease state normal juvenile dermatomyositis disease state normal rheumatoid arthritis, on methotrexate GDS1956.0.2 GDS1353.0.1.3 -0.49 disease state normal juvenile dermatomyositis agent control dexamethasone GDS2213.0.2 GDS1783.0.1 -0.49 agent untreated TSA agent control thapsigargin GDS715.2.5.18 GDS715.0.1.16 -0.49 agent negative control sulmazole agent none positive control GDS1617.0.2 GDS715.2.4.18 0.49 agent control 50uM zinc agent negative control a-methyl-L-p-tyrosine GDS1971.0.2 GDS2118.0.2 0.49 disease state healthy complicated malaria disease state normal refractory anemia with ringed sideroblasts GDS2367.0.2.3 GDS2213.0.2 0.49 agent vehicle tamoxifen agent untreated TSA GDS2057.0.1.4 GDS1989.1.4.0 0.49 agent control DHT disease state normal melanoma in situ GDS2221.1.3 GDS2418.0.1 0.49 agent vehicle lipopolysaccharide disease state control vulvar intraepithelial neoplasia GDS2341.0.2.4 GDS2118.0.2 0.49 agent untreated Type II IFN disease state normal refractory anemia with ringed sideroblasts GDS2341.0.2.4 GDS2118.0.1 0.49 agent untreated Type II IFN disease state normal refractory anemia GDS1362.0.1 GDS1956.0.8 0.49 disease state non-failing heart non-ischemic cardiomyopathy disease state normal Duchenne muscular dystrophy GDS1956.0.1 GDS1427.0.2 -0.49 disease state normal acute quadriplegic myopathy infection control v-Myb GDS1956.0.5 GDS1685.0.1 -0.49 disease state normal fascioscapulohumeral muscular dystrophy disease state normal hereditary gingival fibromatosis GDS1783.0.2 GDS2205.0.1 0.49 agent control high potassium disease state non-failing dilated cardiomyopathy GDS1783.0.2 GDS2643.0.2.4 0.49 agent control high potassium disease state normal chronic lymphocytic leukemia GDS1397.0.2 GDS715.0.9.18 0.49 agent untreated TNF-alpha agent none 5-fluorouridine GDS1397.0.2 GDS2057.0.1.4 0.49 agent untreated TNF-alpha agent control DHT GDS1397.0.2 GDS715.2.14.18 -0.49 agent untreated TNF-alpha agent negative control R-(-)-apomorphine HCl GDS268.0.2 GDS1259.0.1 0.49 disease state non-obese morbidly obese disease state normal dermatomyositis GDS2154.0.1 GDS1956.0.4 -0.49 disease state healthy inflammatory dilated cardiomyopathy disease state normal spastic paraplegia GDS2737.0.1.3 GDS1971.0.2 0.49 disease state normal endometriosis disease state healthy complicated malaria GDS690.2.3.0 GDS1956.0.6 0.49 agent control flagellin disease state normal Emery-Dreifuss muscular dystrophy GDS2221.0.2 GDS1850.0.1 0.49 agent untreated galectin-1 disease state healthy carious GDS2221.0.2 GDS2250.0.2 0.49 agent untreated galectin-1 disease state normal BRCA1-associated cancer GDS2221.0.2 GDS2250.0.3 0.49 agent untreated galectin-1 disease state normal basal-like cancer GDS1428.0.1.10 GDS2216.0.1.5 0.49 agent untreated Staphylococcus aureus agent control LPS GDS1558.0.1.3 GDS1321.0.2 0.49 disease state no atrial fibrillation permanent atrial fibrillation disease state normal adenocarcinoma GDS690.2.5.1 GDS1630.2.5.0 0.49 agent control TNFa agent untreated atorvastatin and mevalonate GDS2333.1.2.3 GDS1736.0.1 0.49 infection wild type delta pilD mutant agent control arachidonic acid GDS2333.1.2.3 GDS715.2.4.18 -0.49 infection wild type delta pilD mutant agent negative control a-methyl-L-p-tyrosine GDS2214.0.1 GDS2643.0.1.4 0.49 agent control lipopolysaccharide disease state normal Waldenstrom's macroglobulinemia GDS2332.1.2 GDS1257.0.2 0.49 infection wild type delta frpC/frpA mutant disease state normal SCD steady state GDS2332.1.2 GDS1375.0.1 -0.49 infection wild type delta frpC/frpA mutant disease state normal benign nevi GDS1956.0.3 GDS1257.0.2 0.49 disease state normal amyotophic lateral sclerosis disease state normal SCD steady state GDS1956.0.3 GDS651.0.2 0.49 disease state normal amyotophic lateral sclerosis disease state normal ischemic GDS1376.2.3.1 GDS1665.0.1 -0.49 disease state normal thrombocythemia disease state normal papillary thyroid carcinoma GDS715.0.14.18 GDS1615.0.1 0.49 agent none R-(-)-apomorphine HCl disease state normal ulcerative colitis GDS2767.5.8.4 GDS266.0.1.2 -0.49 agent water alcohol disease state no atopy atopy GDS2767.7.8.3 GDS2643.0.2.4 0.49 agent water red wine disease state normal chronic lymphocytic leukemia GDS505.0.1 GDS1989.1.2.0 -0.49 disease state normal RCC disease state normal benign nevus GDS505.0.1 GDS1956.0.7 0.49 disease state normal RCC disease state normal Becker muscular dystrophy GDS484.0.1 GDS1956.0.5 -0.49 disease state normal leiomyoma disease state normal fascioscapulohumeral muscular dystrophy GDS2649.3.5.1 GDS2414.0.1.4 0.49 disease state uninfected chronic HIV infection agent control trophoblast conditioned medium GDS2767.6.8.2 GDS2255.3.4.0 0.49 agent water grape juice agent untreated endotoxin GDS2767.6.8.0 GDS2214.0.2 -0.49 agent water grape juice agent control HMGB1 GDS2767.6.8.0 GDS2205.0.1 -0.49 agent water grape juice disease state non-failing dilated cardiomyopathy GDS2767.6.8.0 GDS715.0.12.18 -0.49 agent water grape juice agent none 5-fluorouracil GDS2767.6.8.0 GDS2432.0.1 0.49 agent water grape juice disease state control pituitary adenoma predisposition GDS715.1.2.18 GDS2213.0.1 0.49 agent negative control positive control agent untreated 5-aza-dC GDS2767.7.8.0 GDS1220.0.1.3 -0.49 agent water red wine disease state normal malignant pleural mesothelioma GDS2767.7.8.0 GDS2214.0.2 -0.49 agent water red wine agent control HMGB1 GDS2250.0.2 GDS505.0.1 0.49 disease state normal BRCA1-associated cancer disease state normal RCC GDS2617.0.2 GDS484.0.1 0.49 disease state normal tumorigenic cancer cell disease state normal leiomyoma GDS715.0.7.18 GDS266.0.1.4 -0.49 agent none 4,5-dianilinophthalimide disease state no atopy atopy GDS715.0.6.16 GDS2649.4.5.1 0.49 agent none 16-ketoestradiol disease state uninfected non-progressive HIV infection GDS2341.0.3.4 GDS1062.2.3.0 -0.49 agent untreated Types I and II IFNs disease state no metastasis metastasis GDS2635.0.3 GDS505.0.1 0.49 disease state lobular control invasive ductal carcinoma disease state normal RCC GDS2216.0.1.5 GDS2649.3.5.0 0.49 agent control LPS disease state uninfected chronic HIV infection GDS2057.0.2.4 GDS715.1.2.18 -0.49 agent control RTI-018 agent negative control positive control GDS1615.0.1 GDS715.0.8.18 0.48 disease state normal ulcerative colitis agent none 1,10-phenanthroline GDS1615.0.1 GDS1956.0.9 0.48 disease state normal ulcerative colitis disease state normal Calpain 3 mutation GDS1615.0.1 GDS1397.0.1 -0.48 disease state normal ulcerative colitis agent untreated HIV GDS2332.0.2 GDS1667.0.1 -0.48 infection uninfected delta frpC/frpA mutant infection HPV negative HPV positive GDS651.0.1 GDS2737.0.1.2 0.48 disease state normal idiopathic dilated disease state normal endometriosis GDS651.0.1 GDS1736.0.1 -0.48 disease state normal idiopathic dilated agent control arachidonic acid GDS2635.0.2 GDS1375.0.2 0.48 disease state lobular control invasive lobular carcinoma disease state normal malignant melanoma GDS2635.0.2 GDS2418.0.1 0.48 disease state lobular control invasive lobular carcinoma disease state control vulvar intraepithelial neoplasia GDS1259.0.1 GDS1989.1.5.0 0.48 disease state normal dermatomyositis disease state normal vertical growth phase melanoma GDS715.0.8.18 GDS2414.0.1.4 0.48 agent none 1,10-phenanthroline agent control trophoblast conditioned medium GDS2362.6.7.2.5 GDS715.2.9.18 -0.48 agent untreated chloroguine treated agent negative control 5-fluorouridine GDS1333.0.1 GDS2250.0.3 0.48 agent baseline oxandrolone disease state normal basal-like cancer GDS2191.0.1 GDS715.2.5.18 0.48 disease state control bipolar disorder agent negative control sulmazole GDS2191.0.1 GDS715.2.3.18 0.48 disease state control bipolar disorder agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1989.1.3.0 GDS2250.0.1 0.48 disease state normal atypical nevus disease state normal non-basal-like cancer GDS1989.1.3.0 GDS2023.0.1.2 0.48 disease state normal atypical nevus infection vehicle control RSV GDS715.0.1.18 GDS1615.0.1 0.48 agent none positive control disease state normal ulcerative colitis GDS715.0.1.18 GDS1375.0.2 -0.48 agent none positive control disease state normal malignant melanoma GDS2643.0.3.5 GDS715.0.5.18 -0.48 disease state normal multiple myeloma agent none sulmazole GDS2215.0.2 GDS268.0.2 -0.48 agent control cyfluthrin disease state non-obese morbidly obese GDS2250.0.2 GDS1667.0.1 0.48 disease state normal BRCA1-associated cancer infection HPV negative HPV positive GDS2250.0.3 GDS2611.0.1.9 0.48 disease state normal basal-like cancer agent untreated keratinocyte growth factor GDS2250.0.3 GDS2744.0.1 -0.48 disease state normal basal-like cancer agent control dioxin GDS1615.0.2 GDS715.2.8.18 0.48 disease state normal Crohn's disease agent negative control 1,10-phenanthroline GDS2414.0.1.3 GDS2307.0.2 0.48 agent control trophoblast conditioned medium agent untreated ox-LDL GDS2414.0.1.3 GDS2057.0.2.3 0.48 agent control trophoblast conditioned medium agent control RTI-018 GDS1353.0.1.3 GDS1480.0.1 -0.48 agent control dexamethasone disease state lean obese GDS1783.0.1 GDS715.0.9.18 0.48 agent control thapsigargin agent none 5-fluorouridine GDS1783.0.1 GDS2737.0.1.4 -0.48 agent control thapsigargin disease state normal endometriosis GDS2617.0.2 GDS1989.1.6.0 0.48 disease state normal tumorigenic cancer cell disease state normal metastatic growth phase melanoma GDS2617.0.2 GDS1321.0.2 0.48 disease state normal tumorigenic cancer cell disease state normal adenocarcinoma GDS715.2.4.18 GDS715.0.3.16 -0.48 agent negative control a-methyl-L-p-tyrosine agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1736.0.1 GDS715.0.7.18 0.48 agent control arachidonic acid agent none 4,5-dianilinophthalimide GDS2333.0.2.3 GDS1257.0.2 0.48 infection uninfected delta pilD mutant disease state normal SCD steady state GDS1321.0.1 GDS1375.0.1 -0.48 disease state normal Barrett's esophagus disease state normal benign nevi GDS1956.0.11 GDS1282.0.1 0.48 disease state normal FKRP mutation disease state control Wilms' tumor GDS715.0.8.16 GDS1783.0.1 -0.48 agent none 1,10-phenanthroline agent control thapsigargin GDS715.0.8.16 GDS2635.0.3 -0.48 agent none 1,10-phenanthroline disease state lobular control invasive ductal carcinoma GDS715.0.8.16 GDS2341.0.1.4 -0.48 agent none 1,10-phenanthroline agent untreated Type I IFN GDS2142.0.2 GDS2609.0.1 -0.48 disease state normal severe cystic fibrosis disease state healthy control early onset colorectal cancer GDS2142.0.2 GDS2697.0.1 -0.48 disease state normal severe cystic fibrosis disease state normal teratozoospermia GDS1384.0.1 GDS2744.0.1 -0.48 agent control c-Myb agent control dioxin GDS1331.0.1 GDS2239.0.1 0.48 disease state normal presymptomatic agent control hepatitis C virus core protein GDS1331.0.1 GDS715.0.10.18 0.48 disease state normal presymptomatic agent none pergolide methanesulfonate GDS1331.0.1 GDS2205.0.1 0.48 disease state normal presymptomatic disease state non-failing dilated cardiomyopathy GDS1331.0.1 GDS1428.0.2.10 0.48 disease state normal presymptomatic agent untreated heat-killed HL60 cell lysate GDS1331.0.1 GDS1574.8.9.11 -0.48 disease state normal presymptomatic agent control endotoxin GDS1331.0.1 GDS715.0.8.16 -0.48 disease state normal presymptomatic agent none 1,10-phenanthroline GDS1331.0.1 GDS2697.0.1 -0.48 disease state normal presymptomatic disease state normal teratozoospermia GDS1956.0.4 GDS2332.1.3 -0.48 disease state normal spastic paraplegia infection wild type delta pilD mutant GDS2118.0.3 GDS2617.0.2 0.48 disease state normal refractory anemia with excess blasts disease state normal tumorigenic cancer cell GDS2118.0.3 GDS1665.0.1 -0.48 disease state normal refractory anemia with excess blasts disease state normal papillary thyroid carcinoma GDS690.2.5.0 GDS2333.1.2.4 0.48 agent control TNFa infection wild type delta pilD mutant GDS690.2.5.0 GDS2118.0.3 -0.48 agent control TNFa disease state normal refractory anemia with excess blasts GDS2021.0.1 GDS715.0.7.16 0.48 agent control metoprolol agent none 4,5-dianilinophthalimide GDS715.0.15.18 GDS715.2.3.18 0.48 agent none cyclazosin HCl agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1746.2.4.0 GDS1956.0.5 -0.48 disease state normal basaloid disease state normal fascioscapulohumeral muscular dystrophy GDS268.0.1 GDS1259.0.1 0.48 disease state non-obese obese disease state normal dermatomyositis GDS2341.0.1.5 GDS1428.0.2.10 0.48 agent untreated Type I IFN agent untreated heat-killed HL60 cell lysate GDS2341.0.1.5 GDS2643.0.3.5 0.48 agent untreated Type I IFN disease state normal multiple myeloma GDS2341.0.1.5 GDS2255.3.4.0 -0.48 agent untreated Type I IFN agent untreated endotoxin GDS2214.0.2 GDS2221.1.2 0.48 agent control HMGB1 agent vehicle galectin-1 GDS2367.3.4.2 GDS1558.0.1.3 -0.48 infection control adenovirus adenovirus carrying estrogen receptor beta disease state no atrial fibrillation permanent atrial fibrillation GDS2367.3.4.2 GDS715.2.10.18 -0.48 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control pergolide methanesulfonate GDS2250.0.1 GDS2239.0.1 0.48 disease state normal non-basal-like cancer agent control hepatitis C virus core protein GDS2250.0.1 GDS715.0.9.18 0.48 disease state normal non-basal-like cancer agent none 5-fluorouridine GDS2250.0.1 GDS1732.0.1 0.48 disease state normal non-basal-like cancer disease state normal papillary thyroid cancer GDS1956.0.8 GDS2617.0.2 0.48 disease state normal Duchenne muscular dystrophy disease state normal tumorigenic cancer cell GDS715.0.5.18 GDS1956.0.5 -0.48 agent none sulmazole disease state normal fascioscapulohumeral muscular dystrophy GDS2341.0.3.4 GDS2635.0.3 0.48 agent untreated Types I and II IFNs disease state lobular control invasive ductal carcinoma GDS715.0.13.18 GDS2255.3.4.0 -0.48 agent none 8-(3-chlorostyryl) caffeine agent untreated endotoxin GDS1439.0.2 GDS1630.2.4.1 -0.48 disease state benign metastatic agent untreated atorvastatin GDS2617.0.1 GDS1989.1.4.0 0.48 disease state normal non-tumorigenic cancer cell disease state normal melanoma in situ GDS1630.2.4.0 GDS1362.0.2 -0.48 agent untreated atorvastatin disease state non-failing heart ischemic cardiomyopathy GDS1630.2.4.0 GDS1956.0.1 -0.48 agent untreated atorvastatin disease state normal acute quadriplegic myopathy GDS1630.2.4.0 GDS690.2.5.0 -0.48 agent untreated atorvastatin agent control TNFa GDS1353.0.1.2 GDS715.2.10.18 0.48 agent control dexamethasone agent negative control pergolide methanesulfonate GDS1353.0.1.2 GDS2697.0.1 -0.48 agent control dexamethasone disease state normal teratozoospermia GDS1353.0.1.2 GDS715.2.3.18 -0.48 agent control dexamethasone agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1353.0.1.2 GDS1746.2.3.0 -0.48 agent control dexamethasone disease state normal benign hyperplasia GDS1956.0.7 GDS1321.0.2 0.48 disease state normal Becker muscular dystrophy disease state normal adenocarcinoma GDS1574.8.9.11 GDS715.2.3.18 0.48 agent control endotoxin agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS1574.8.9.11 GDS1956.0.3 -0.48 agent control endotoxin disease state normal amyotophic lateral sclerosis GDS1331.0.2 GDS1956.0.1 0.48 disease state normal symptomatic disease state normal acute quadriplegic myopathy GDS1331.0.2 GDS715.0.7.16 0.48 disease state normal symptomatic agent none 4,5-dianilinophthalimide GDS1331.0.2 GDS651.0.1 -0.48 disease state normal symptomatic disease state normal idiopathic dilated GDS1617.0.5 GDS2333.0.2.4 0.48 agent control MGd/50uM zinc infection uninfected delta pilD mutant GDS1926.0.3.4 GDS1956.0.5 0.48 agent control LTD4 and thrombin disease state normal fascioscapulohumeral muscular dystrophy GDS1326.2.3.0 GDS715.2.13.18 0.48 agent control E2 agent negative control 8-(3-chlorostyryl) caffeine GDS1926.0.1.4 GDS1732.0.1 -0.48 agent control thrombin disease state normal papillary thyroid cancer GDS1630.2.5.1 GDS1926.0.1.4 0.48 agent untreated atorvastatin and mevalonate agent control thrombin GDS2216.0.1.5 GDS1971.0.1 0.48 agent control LPS disease state healthy uncomplicated malaria GDS1543.0.1 GDS715.2.7.18 0.48 agent control tumor necrosis factor agent negative control 4,5-dianilinophthalimide GDS1543.0.1 GDS2617.0.2 -0.48 agent control tumor necrosis factor disease state normal tumorigenic cancer cell GDS1926.0.2.4 GDS715.0.7.18 0.48 agent control LTD4 agent none 4,5-dianilinophthalimide GDS1926.0.2.4 GDS715.2.7.18 0.48 agent control LTD4 agent negative control 4,5-dianilinophthalimide GDS1956.0.9 GDS2635.0.2 0.48 disease state normal Calpain 3 mutation disease state lobular control invasive lobular carcinoma GDS2428.0.1.4 GDS2021.0.2 0.48 agent untreated 5-aza-dC agent control nebivolol GDS2697.0.1 GDS1427.0.1 0.48 disease state normal teratozoospermia infection control c-Myb GDS2643.0.1.4 GDS2118.0.1 -0.48 disease state normal Waldenstrom's macroglobulinemia disease state normal refractory anemia GDS1956.0.2 GDS1447.0.1 -0.48 disease state normal juvenile dermatomyositis agent control vanadium GDS1956.0.2 GDS1615.0.2 -0.48 disease state normal juvenile dermatomyositis disease state normal Crohn's disease GDS737.0.1 GDS2611.0.2.9 -0.48 disease state no or mild emphysema severe emphysema agent untreated IL-1b GDS2332.0.3 GDS1428.0.5.10 0.48 infection uninfected delta pilD mutant agent untreated Anaplasma phagocytophilum GDS1989.1.5.0 GDS1667.0.1 -0.48 disease state normal vertical growth phase melanoma infection HPV negative HPV positive GDS1850.0.1 GDS1480.0.1 0.48 disease state healthy carious disease state lean obese GDS1850.0.1 GDS1989.1.7.0 0.48 disease state healthy carious disease state normal lymph node metastasis GDS715.2.5.18 GDS1926.0.3.4 -0.48 agent negative control sulmazole agent control LTD4 and thrombin GDS1617.0.2 GDS1841.0.1 -0.48 agent control 50uM zinc agent empty vector wild-type surfactant protein C GDS2367.0.2.3 GDS1558.0.1.3 0.48 agent vehicle tamoxifen disease state no atrial fibrillation permanent atrial fibrillation GDS2367.0.2.3 GDS715.2.9.18 0.48 agent vehicle tamoxifen agent negative control 5-fluorouridine GDS2057.0.1.4 GDS1956.0.5 -0.48 agent control DHT disease state normal fascioscapulohumeral muscular dystrophy GDS2341.0.2.4 GDS1667.0.1 0.48 agent untreated Type II IFN infection HPV negative HPV positive GDS1362.0.1 GDS2023.0.1.2 -0.48 disease state non-failing heart non-ischemic cardiomyopathy infection vehicle control RSV GDS1362.0.1 GDS2432.0.1 -0.48 disease state non-failing heart non-ischemic cardiomyopathy disease state control pituitary adenoma predisposition GDS1956.0.1 GDS1989.1.3.0 -0.48 disease state normal acute quadriplegic myopathy disease state normal atypical nevus GDS1956.0.5 GDS715.2.9.18 0.48 disease state normal fascioscapulohumeral muscular dystrophy agent negative control 5-fluorouridine GDS1956.0.5 GDS2250.0.1 -0.48 disease state normal fascioscapulohumeral muscular dystrophy disease state normal non-basal-like cancer GDS1312.0.1 GDS2367.3.4.2 -0.48 disease state normal cancer infection control adenovirus adenovirus carrying estrogen receptor beta GDS1783.0.2 GDS715.0.7.16 0.48 agent control high potassium agent none 4,5-dianilinophthalimide GDS1783.0.2 GDS715.0.10.18 0.48 agent control high potassium agent none pergolide methanesulfonate GDS1783.0.2 GDS2744.0.1 -0.48 agent control high potassium agent control dioxin GDS1783.0.2 GDS715.2.5.18 -0.48 agent control high potassium agent negative control sulmazole GDS1397.0.2 GDS715.0.15.18 -0.48 agent untreated TNF-alpha agent none cyclazosin HCl GDS2737.0.1.3 GDS2118.0.3 -0.48 disease state normal endometriosis disease state normal refractory anemia with excess blasts GDS690.2.3.0 GDS1926.0.2.4 0.48 agent control flagellin agent control LTD4 GDS2221.0.2 GDS2418.0.1 0.48 agent untreated galectin-1 disease state control vulvar intraepithelial neoplasia GDS2221.0.2 GDS1989.1.6.0 0.48 agent untreated galectin-1 disease state normal metastatic growth phase melanoma GDS2221.0.2 GDS1405.0.1 -0.48 agent untreated galectin-1 agent untreated DCI GDS2142.0.1 GDS1956.0.5 -0.48 disease state normal mild cystic fibrosis disease state normal fascioscapulohumeral muscular dystrophy GDS1428.0.1.10 GDS715.0.4.18 0.48 agent untreated Staphylococcus aureus agent none a-methyl-L-p-tyrosine GDS2367.3.4.0 GDS1050.0.1.2 -0.48 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal polycystic ovary syndrome GDS690.2.5.1 GDS2332.0.2 0.48 agent control TNFa infection uninfected delta frpC/frpA mutant GDS690.2.5.1 GDS1574.8.9.12 0.48 agent control TNFa agent control endotoxin GDS2341.0.1.4 GDS1989.1.3.0 -0.48 agent untreated Type I IFN disease state normal atypical nevus GDS1439.0.1 GDS1989.1.6.0 0.48 disease state benign primary disease state normal metastatic growth phase melanoma GDS2333.1.2.3 GDS2239.0.1 0.48 infection wild type delta pilD mutant agent control hepatitis C virus core protein GDS2333.1.2.3 GDS2643.0.3.5 0.48 infection wild type delta pilD mutant disease state normal multiple myeloma GDS2333.1.2.3 GDS1956.0.5 0.48 infection wild type delta pilD mutant disease state normal fascioscapulohumeral muscular dystrophy GDS2333.1.2.3 GDS715.0.4.18 -0.48 infection wild type delta pilD mutant agent none a-methyl-L-p-tyrosine GDS2333.1.2.3 GDS1665.0.1 -0.48 infection wild type delta pilD mutant disease state normal papillary thyroid carcinoma GDS2214.0.1 GDS1971.0.2 0.48 agent control lipopolysaccharide disease state healthy complicated malaria GDS2214.0.1 GDS2617.0.1 -0.48 agent control lipopolysaccharide disease state normal non-tumorigenic cancer cell GDS1630.2.3.1 GDS2057.0.1.3 -0.48 agent untreated mevalonate agent control DHT GDS2332.1.2 GDS2118.0.3 -0.48 infection wild type delta frpC/frpA mutant disease state normal refractory anemia with excess blasts GDS1376.2.3.1 GDS1736.0.1 0.48 disease state normal thrombocythemia agent control arachidonic acid GDS1549.3.4.2 GDS2617.0.1 0.48 agent control estradiol disease state normal non-tumorigenic cancer cell GDS1549.3.4.2 GDS860.0.1 0.48 agent control estradiol agent untreated endothelin-1 GDS2852.0.1.5 GDS2643.0.1.5 0.48 agent control IL-13 disease state normal Waldenstrom's macroglobulinemia GDS2852.0.1.5 GDS1989.1.3.0 -0.48 agent control IL-13 disease state normal atypical nevus GDS484.0.1 GDS266.0.1.2 -0.48 disease state normal leiomyoma disease state no atopy atopy GDS2767.7.8.3 GDS1050.0.1.2 0.48 agent water red wine disease state normal polycystic ovary syndrome GDS2649.2.5.0 GDS2332.0.2 -0.48 disease state uninfected early HIV infection infection uninfected delta frpC/frpA mutant GDS2649.2.5.0 GDS1574.8.9.10 0.48 disease state uninfected early HIV infection agent control endotoxin GDS2649.3.5.1 GDS2397.0.1 -0.48 disease state uninfected chronic HIV infection disease state normal idiopathic myelofibrosis GDS2767.5.8.0 GDS1392.0.2 -0.48 agent water alcohol disease state normal myelodysplastic syndrome GDS266.0.1.2 GDS715.2.15.18 0.48 disease state no atopy atopy agent negative control cyclazosin HCl GDS2767.5.8.4 GDS1220.0.1.3 -0.48 agent water alcohol disease state normal malignant pleural mesothelioma GDS2767.6.8.0 GDS1667.0.1 -0.48 agent water grape juice infection HPV negative HPV positive GDS2767.6.8.0 GDS1574.8.9.11 0.48 agent water grape juice agent control endotoxin GDS2767.7.8.0 GDS715.0.7.16 -0.48 agent water red wine agent none 4,5-dianilinophthalimide GDS1617.0.4 GDS715.1.2.18 0.48 agent control MGd/25uM zinc agent negative control positive control GDS715.2.5.18 GDS2649.4.5.1 0.48 agent negative control sulmazole disease state uninfected non-progressive HIV infection GDS2221.1.3 GDS2649.2.5.1 0.48 agent vehicle lipopolysaccharide disease state uninfected early HIV infection GDS2221.0.2 GDS505.0.1 0.48 agent untreated galectin-1 disease state normal RCC GDS1549.3.4.2 GDS484.0.1 0.48 agent control estradiol disease state normal leiomyoma GDS1615.0.1 GDS715.2.3.18 0.47 disease state normal ulcerative colitis agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2332.0.2 GDS2221.1.2 0.47 infection uninfected delta frpC/frpA mutant agent vehicle galectin-1 GDS2332.0.2 GDS1850.0.1 0.47 infection uninfected delta frpC/frpA mutant disease state healthy carious GDS651.0.1 GDS715.0.4.18 0.47 disease state normal idiopathic dilated agent none a-methyl-L-p-tyrosine GDS2635.0.2 GDS1989.1.6.0 0.47 disease state lobular control invasive lobular carcinoma disease state normal metastatic growth phase melanoma GDS2635.0.2 GDS1989.1.5.0 0.47 disease state lobular control invasive lobular carcinoma disease state normal vertical growth phase melanoma GDS1259.0.1 GDS715.0.7.18 0.47 disease state normal dermatomyositis agent none 4,5-dianilinophthalimide GDS1259.0.1 GDS2362.6.7.2.5 -0.47 disease state normal dermatomyositis agent untreated chloroguine treated GDS2362.6.7.2.5 GDS1989.1.3.0 0.47 agent untreated chloroguine treated disease state normal atypical nevus GDS1333.0.1 GDS1353.0.1.3 0.47 agent baseline oxandrolone agent control dexamethasone GDS1333.0.1 GDS715.0.6.16 0.47 agent baseline oxandrolone agent none 16-ketoestradiol GDS2418.0.1 GDS1480.0.1 -0.47 disease state control vulvar intraepithelial neoplasia disease state lean obese GDS2643.0.3.5 GDS1392.0.2 0.47 disease state normal multiple myeloma disease state normal myelodysplastic syndrome GDS2643.0.3.5 GDS1237.0.1 -0.47 disease state normal multiple myeloma infection control Anaplasma phagocytophilum GDS2250.0.2 GDS1746.2.3.0 0.47 disease state normal BRCA1-associated cancer disease state normal benign hyperplasia GDS2250.0.2 GDS1282.0.1 0.47 disease state normal BRCA1-associated cancer disease state control Wilms' tumor GDS2250.0.2 GDS1257.0.1 -0.47 disease state normal BRCA1-associated cancer disease state normal SCD with acute chest syndrome GDS1574.8.9.12 GDS715.0.15.18 0.47 agent control endotoxin agent none cyclazosin HCl GDS1574.8.9.12 GDS2200.0.2 0.47 agent control endotoxin disease state normal squamous cell carcinoma GDS2250.0.3 GDS1405.0.1 -0.47 disease state normal basal-like cancer agent untreated DCI GDS1615.0.2 GDS715.0.3.18 0.47 disease state normal Crohn's disease agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS2414.0.1.3 GDS715.0.7.18 0.47 agent control trophoblast conditioned medium agent none 4,5-dianilinophthalimide GDS2414.0.1.3 GDS1989.1.6.0 0.47 agent control trophoblast conditioned medium disease state normal metastatic growth phase melanoma GDS2414.0.1.3 GDS1989.1.2.0 -0.47 agent control trophoblast conditioned medium disease state normal benign nevus GDS1050.2.3.0 GDS1384.0.1 -0.47 agent untreated valproic acid agent control c-Myb GDS1050.2.3.0 GDS2341.0.1.5 -0.47 agent untreated valproic acid agent untreated Type I IFN GDS1353.0.1.3 GDS1326.2.3.1 0.47 agent control dexamethasone agent control E2 GDS1783.0.1 GDS2239.0.1 0.47 agent control thapsigargin agent control hepatitis C virus core protein GDS1783.0.1 GDS2205.0.1 0.47 agent control thapsigargin disease state non-failing dilated cardiomyopathy GDS1257.0.2 GDS1926.0.2.4 0.47 disease state normal SCD steady state agent control LTD4 GDS1257.0.2 GDS2414.0.1.3 0.47 disease state normal SCD steady state agent control trophoblast conditioned medium GDS2609.0.1 GDS1989.1.4.0 -0.47 disease state healthy control early onset colorectal cancer disease state normal melanoma in situ GDS1220.0.1.3 GDS2418.0.1 0.47 disease state normal malignant pleural mesothelioma disease state control vulvar intraepithelial neoplasia GDS1220.0.1.3 GDS1989.1.7.0 0.47 disease state normal malignant pleural mesothelioma disease state normal lymph node metastasis GDS2617.0.2 GDS1558.0.1.3 0.47 disease state normal tumorigenic cancer cell disease state no atrial fibrillation permanent atrial fibrillation GDS1736.0.1 GDS1321.0.1 0.47 agent control arachidonic acid disease state normal Barrett's esophagus GDS715.0.1.16 GDS1428.0.1.10 -0.47 agent none positive control agent untreated Staphylococcus aureus GDS2428.0.1.3 GDS690.2.5.1 0.47 agent untreated 5-aza-dC agent control TNFa GDS1321.0.1 GDS2737.0.1.4 0.47 disease state normal Barrett's esophagus disease state normal endometriosis GDS2428.0.1.2 GDS1685.0.1 -0.47 agent untreated 5-aza-dC disease state normal hereditary gingival fibromatosis GDS1397.0.1 GDS715.0.6.16 -0.47 agent untreated HIV agent none 16-ketoestradiol GDS715.0.8.16 GDS2367.0.1.3 -0.47 agent none 1,10-phenanthroline agent vehicle estradiol GDS1956.0.6 GDS2737.0.1.4 -0.47 disease state normal Emery-Dreifuss muscular dystrophy disease state normal endometriosis GDS2705.0.3 GDS1617.0.1 -0.47 agent control rosiglitazone plus carboplatin agent control 25uM zinc GDS2142.0.2 GDS2215.0.1 0.47 disease state normal severe cystic fibrosis agent control chlorpyrifos GDS2397.0.1 GDS1989.1.4.0 -0.47 disease state normal idiopathic myelofibrosis disease state normal melanoma in situ GDS1630.2.4.1 GDS2397.0.1 0.47 agent untreated atorvastatin disease state normal idiopathic myelofibrosis GDS1331.0.1 GDS715.2.9.18 0.47 disease state normal presymptomatic agent negative control 5-fluorouridine GDS1956.0.4 GDS715.0.15.18 -0.47 disease state normal spastic paraplegia agent none cyclazosin HCl GDS1362.0.2 GDS1989.1.4.0 -0.47 disease state non-failing heart ischemic cardiomyopathy disease state normal melanoma in situ GDS2118.0.3 GDS715.0.14.18 -0.47 disease state normal refractory anemia with excess blasts agent none R-(-)-apomorphine HCl GDS690.2.5.0 GDS1321.0.2 0.47 agent control TNFa disease state normal adenocarcinoma GDS2205.0.1 GDS1989.1.4.0 -0.47 disease state non-failing dilated cardiomyopathy disease state normal melanoma in situ GDS1375.0.2 GDS1665.0.1 0.47 disease state normal malignant melanoma disease state normal papillary thyroid carcinoma GDS1989.1.4.0 GDS2428.0.1.2 0.47 disease state normal melanoma in situ agent untreated 5-aza-dC GDS1746.2.4.0 GDS2611.0.2.9 0.47 disease state normal basaloid agent untreated IL-1b GDS2341.0.1.5 GDS1667.0.1 0.47 agent untreated Type I IFN infection HPV negative HPV positive GDS1971.0.1 GDS2118.0.1 0.47 disease state healthy uncomplicated malaria disease state normal refractory anemia GDS2367.3.4.2 GDS1375.0.1 -0.47 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal benign nevi GDS715.0.6.16 GDS1428.0.5.10 0.47 agent none 16-ketoestradiol agent untreated Anaplasma phagocytophilum GDS2250.0.1 GDS715.2.9.18 0.47 disease state normal non-basal-like cancer agent negative control 5-fluorouridine GDS715.0.5.18 GDS715.2.7.18 0.47 agent none sulmazole agent negative control 4,5-dianilinophthalimide GDS2341.0.3.4 GDS2118.0.2 0.47 agent untreated Types I and II IFNs disease state normal refractory anemia with ringed sideroblasts GDS715.0.9.18 GDS715.2.3.18 0.47 agent none 5-fluorouridine agent negative control erythro-9-(2-hydroxy-3-nonyl)adenine HCl GDS690.2.4.1 GDS2142.0.1 -0.47 agent control LTb disease state normal mild cystic fibrosis GDS690.2.4.1 GDS1574.8.9.11 -0.47 agent control LTb agent control endotoxin GDS690.2.4.1 GDS715.0.6.16 -0.47 agent control LTb agent none 16-ketoestradiol GDS1439.0.2 GDS1480.0.1 -0.47 disease state benign metastatic disease state lean obese GDS2341.0.3.5 GDS1427.0.2 -0.47 agent untreated Types I and II IFNs infection control v-Myb GDS2341.0.2.5 GDS2635.0.3 0.47 agent untreated Type II IFN disease state lobular control invasive ductal carcinoma GDS2341.0.2.5 GDS1050.0.1.2 0.47 agent untreated Type II IFN disease state normal polycystic ovary syndrome GDS1428.0.5.10 GDS715.2.11.18 0.47 agent untreated Anaplasma phagocytophilum agent negative control scopolamine methyl bromide GDS2367.3.4.1 GDS1615.0.2 0.47 infection control adenovirus adenovirus carrying estrogen receptor beta disease state normal Crohn's disease GDS1685.0.1 GDS2200.0.1 0.47 disease state normal hereditary gingival fibromatosis disease state normal actinic keratosis GDS1630.2.4.0 GDS2191.0.1 0.47 agent untreated atorvastatin disease state control bipolar disorder GDS1353.0.1.2 GDS2643.0.3.5 0.47 agent control dexamethasone disease state normal multiple myeloma GDS1353.0.1.2 GDS715.2.4.18 -0.47 agent control dexamethasone agent negative control a-methyl-L-p-tyrosine GDS1353.0.1.2 GDS715.0.5.18 -0.47 agent control dexamethasone agent none sulmazole GDS1447.0.1 GDS2221.0.2 0.47 agent control vanadium agent untreated galectin-1 GDS2118.0.2 GDS1282.0.2 -0.47 disease state normal refractory anemia with ringed sideroblasts disease state control clear cell sarcoma of the kidney GDS1574.8.9.11 GDS715.2.7.18 0.47 agent control endotoxin agent negative control 4,5-dianilinophthalimide GDS1574.8.9.11 GDS2617.0.2 -0.47 agent control endotoxin disease state normal tumorigenic cancer cell GDS1331.0.2 GDS1736.0.1 0.47 disease state normal symptomatic agent control arachidonic acid GDS1331.0.2 GDS715.0.8.16 -0.47 disease state normal symptomatic agent none 1,10-phenanthroline GDS2635.0.3 GDS860.0.1 0.47 disease state lobular control invasive ductal carcinoma agent untreated endothelin-1 GDS1542.0.1 GDS2362.6.7.2.5 -0.47 agent control tumor necrosis factor agent untreated chloroguine treated GDS860.0.1 GDS2705.0.3 0.47 agent untreated endothelin-1 agent control rosiglitazone plus carboplatin GDS1926.0.3.4 GDS2214.0.1 0.47 agent control LTD4 and thrombin agent control lipopolysaccharide GDS1926.0.3.4 GDS2432.0.1 -0.47 agent control LTD4 and thrombin disease state control pituitary adenoma predisposition GDS1326.2.3.0 GDS268.0.1 0.47 agent control E2 disease state non-obese obese GDS2215.0.1 GDS2428.0.1.2 -0.47 agent control chlorpyrifos agent untreated 5-aza-dC GDS1926.0.1.4 GDS1312.0.1 -0.47 agent control thrombin disease state normal cancer GDS2216.0.1.5 GDS2200.0.1 0.47 agent control LPS disease state normal actinic keratosis GDS2216.0.1.5 GDS1989.1.4.0 0.47 agent control LPS disease state normal melanoma in situ GDS2216.0.1.5 GDS715.0.6.16 0.47 agent control LPS agent none 16-ketoestradiol GDS2216.0.1.5 GDS1397.0.1 -0.47 agent control LPS agent untreated HIV GDS1926.0.2.4 GDS2643.0.3.5 0.47 agent control LTD4 disease state normal multiple myeloma GDS1926.0.2.4 GDS2250.0.1 -0.47 agent control LTD4 disease state normal non-basal-like cancer GDS1926.0.2.4 GDS1427.0.2 -0.47 agent control LTD4 infection control v-Myb GDS1926.0.2.4 GDS2250.0.3 -0.47 agent control LTD4 disease state normal basal-like cancer GDS2021.0.2 GDS1375.0.1 0.47 agent control nebivolol disease state normal benign nevi GDS2021.0.2 GDS1746.2.4.0 -0.47 agent control nebivolol disease state normal basaloid GDS715.2.11.18 GDS1926.0.2.4 -0.47 agent negative control scopolamine methyl bromide agent control LTD4 GDS1321.0.2 GDS2221.0.3 0.47 disease state normal adenocarcinoma agent untreated lipopolysaccharide GDS2697.0.1 GDS715.2.4.18 0.47 disease state normal teratozoospermia agent negative control a-methyl-L-p-tyrosine GDS2200.0.2 GDS1439.0.1 0.47 disease state normal squamous cell carcinoma disease state benign primary GDS2200.0.2 GDS1321.0.2 0.47 disease state normal squamous cell carcinoma disease state normal adenocarcinoma GDS1282.0.2 GDS1989.1.2.0 0.47 disease state control clear cell sarcoma of the kidney disease state normal benign nevus GDS1282.0.2 GDS1480.0.1 -0.47 disease state control clear cell sarcoma of the kidney disease state lean obese GDS1956.0.2 GDS810.0.1 -0.47 disease state normal juvenile dermatomyositis disease state control incipient AD GDS1956.0.2 GDS1427.0.2 -0.47 disease state normal juvenile dermatomyositis infection control v-Myb GDS2332.0.3 GDS1615.0.2 0.47 infection uninfected delta pilD mutant disease state normal Crohn's disease GDS2332.0.3 GDS715.2.14.18 0.47 infection uninfected delta pilD mutant agent negative control R-(-)-apomorphine HCl GDS1850.0.1 GDS2737.0.1.4 0.47 disease state healthy carious disease state normal endometriosis GDS1617.0.2 GDS715.2.15.18 0.47 agent control 50uM zinc agent negative control cyclazosin HCl GDS1617.0.2 GDS2332.1.3 0.47 agent control 50uM zinc infection wild type delta pilD mutant GDS2367.0.2.3 GDS1971.0.1 0.47 agent vehicle tamoxifen disease state healthy uncomplicated malaria GDS2367.0.2.3 GDS2332.0.2 -0.47 agent vehicle tamoxifen infection uninfected delta frpC/frpA mutant GDS2057.0.1.4 GDS1375.0.1 0.47 agent control DHT disease state normal benign nevi GDS1375.0.1 GDS2153.0.1 -0.47 disease state normal benign nevi disease state normal dermatomyositis GDS2221.1.3 GDS2611.0.3.9 0.47 agent vehicle lipopolysaccharide agent untreated IFN-gamma GDS2221.1.3 GDS1989.1.4.0 0.47 agent vehicle lipopolysaccharide disease state normal melanoma in situ GDS2341.0.2.4 GDS2205.0.1 -0.47 agent untreated Type II IFN disease state non-failing dilated cardiomyopathy GDS1362.0.1 GDS651.0.2 0.47 disease state non-failing heart non-ischemic cardiomyopathy disease state normal ischemic GDS1362.0.1 GDS1333.0.1 -0.47 disease state non-failing heart non-ischemic cardiomyopathy agent baseline oxandrolone GDS1362.0.1 GDS1971.0.1 -0.47 disease state non-failing heart non-ischemic cardiomyopathy disease state healthy uncomplicated malaria GDS2333.0.2.4 GDS2737.0.1.3 -0.47 infection uninfected delta pilD mutant disease state normal endometriosis GDS1956.0.5 GDS2142.0.2 0.47 disease state normal fascioscapulohumeral muscular dystrophy disease state normal severe cystic fibrosis GDS1956.0.5 GDS1375.0.2 -0.47 disease state normal fascioscapulohumeral muscular dystrophy disease state normal malignant melanoma GDS1312.0.1 GDS1362.0.2 -0.47 disease state normal cancer disease state non-failing heart ischemic cardiomyopathy GDS2190.0.1 GDS2418.0.1 -0.47 disease state control bipolar disorder disease state control vulvar intraepithelial neoplasia GDS1783.0.2 GDS2021.0.1 0.47 agent control high potassium agent control metoprolol GDS1783.0.2 GDS715.0.6.16 -0.47 agent control high potassium agent none 16-ketoestradiol GDS1783.0.2 GDS715.0.4.18 -0.47 agent control high potassium agent none a-methyl-L-p-tyrosine GDS1397.0.2 GDS1783.0.1 0.47 agent untreated TNF-alpha agent control thapsigargin GDS1397.0.2 GDS690.2.4.1 0.47 agent untreated TNF-alpha agent control LTb GDS1397.0.2 GDS1615.0.2 -0.47 agent untreated TNF-alpha disease state normal Crohn's disease GDS2154.0.1 GDS2084.0.1 -0.47 disease state healthy inflammatory dilated cardiomyopathy disease state control polycystic ovary syndrome GDS2255.3.4.0 GDS1362.0.2 -0.47 agent untreated endotoxin disease state non-failing heart ischemic cardiomyopathy GDS2255.3.4.0 GDS2643.0.2.4 -0.47 agent untreated endotoxin disease state normal chronic lymphocytic leukemia GDS2142.0.1 GDS1259.0.1 -0.47 disease state normal mild cystic fibrosis disease state normal dermatomyositis GDS1428.0.1.10 GDS715.2.8.18 0.47 agent untreated Staphylococcus aureus agent negative control 1,10-phenanthroline GDS1428.0.1.10 GDS2617.0.1 -0.47 agent untreated Staphylococcus aureus disease state normal non-tumorigenic cancer cell GDS1428.0.1.10 GDS2617.0.2 -0.47 agent untreated Staphylococcus aureus disease state normal tumorigenic cancer cell GDS2367.3.4.0 GDS715.2.11.18 0.47 infection control adenovirus adenovirus carrying estrogen receptor beta agent negative control scopolamine methyl bromide GDS690.2.5.1 GDS1321.0.1 0.47 agent control TNFa disease state normal Barrett's esophagus GDS2333.1.2.3 GDS1956.0.3 0.47 infection wild type delta pilD mutant disease state normal amyotophic lateral sclerosis GDS2214.0.1 GDS1971.0.1 0.47 agent control lipopolysaccharide disease state healthy uncomplicated malaria GDS1956.0.3 GDS2414.0.1.4 -0.47 disease state normal amyotophic lateral sclerosis agent control trophoblast conditioned medium GDS1376.2.3.1 GDS2697.0.1 -0.47 disease state normal thrombocythemia disease state normal teratozoospermia GDS1376.2.3.1 GDS810.0.1 -0.47 disease state normal thrombocythemia disease state control incipient AD GDS1376.2.3.1 GDS2255.3.4.0 -0.47 disease state normal thrombocythemia agent untreated endotoxin GDS715.0.14.18 GDS2737.0.1.2 0.47 agent none R-(-)-apomorphine HCl disease state normal endometriosis GDS2852.0.1.5 GDS1220.0.1.3 0.47 agent control IL-13 disease state normal malignant pleural mesothelioma GDS2852.0.1.5 GDS715.0.9.18 0.47 agent control IL-13 agent none 5-fluorouridine GDS2767.7.8.0 GDS1062.2.3.0 0.47 agent water red wine disease state no metastasis metastasis GDS1062.2.3.0 GDS1989.1.2.0 0.47 disease state no metastasis metastasis disease state normal benign nevus GDS2767.7.8.3 GDS715.0.6.16 -0.47 agent water red wine agent none 16-ketoestradiol GDS484.0.1 GDS1732.0.1 0.47 disease state normal leiomyoma disease state normal papillary thyroid cancer GDS2649.3.5.1 GDS1362.0.2 -0.47 disease state uninfected chronic HIV infection disease state non-failing heart ischemic cardiomyopathy GDS266.0.1.2 GDS1956.0.6 0.47 disease state no atopy atopy disease state normal Emery-Dreifuss muscular dystrophy GDS2767.5.8.4 GDS2142.0.2 -0.47 agent water alcohol disease state normal severe cystic fibrosis GDS2767.6.8.0 GDS2367.0.1.3 -0.47 agent water grape juice agent vehicle estradiol GDS2649.3.5.0 GDS1850.0.1 0.47 disease state uninfected chronic HIV infection disease state healthy carious GDS715.1.2.18 GDS2414.0.1.4 0.47 agent negative control positive control agent control trophoblast conditioned medium GDS1259.0.1 GDS2649.4.5.0 -0.47 disease state normal dermatomyositis disease state uninfected non-progressive HIV infection GDS2250.0.2 GDS484.0.1 0.47 disease state normal BRCA1-associated cancer disease state normal leiomyoma GDS2643.0.1.5 GDS1062.2.3.0 -0.47 disease state normal Waldenstrom's macroglobulinemia disease state no metastasis metastasis GDS2221.1.2 GDS505.0.1 0.47 agent vehicle galectin-1 disease state normal RCC GDS1956.0.6 GDS2649.3.5.1 -0.47 disease state normal Emery-Dreifuss muscular dystrophy disease state uninfected chronic HIV infection GDS2021.0.1 GDS2649.3.5.1 -0.47 agent control metoprolol disease state uninfected chronic HIV infection GDS1447.0.1 GDS484.0.1 -0.47 agent control vanadium disease state normal leiomyoma GDS715.2.5.18 GDS2649.3.5.1 0.47 agent negative control sulmazole disease state uninfected chronic HIV infection GDS1362.0.1 GDS2649.3.5.1 -0.47 disease state non-failing heart non-ischemic cardiomyopathy disease state uninfected chronic HIV infection GDS1615.0.1 GDS2414.0.1.4 0.46 disease state normal ulcerative colitis agent control trophoblast conditioned medium GDS2332.0.2 GDS2221.1.3 0.46 infection uninfected delta frpC/frpA mutant agent vehicle lipopolysaccharide GDS2332.0.2 GDS2617.0.2 -0.46 infection uninfected delta frpC/frpA mutant disease state normal tumorigenic cancer cell GDS2332.0.2 GDS2362.6.7.2.5 -0.46 infection uninfected delta frpC/frpA mutant agent untreated chloroguine treated GDS651.0.1 GDS1333.0.1 0.46 disease state normal idiopathic dilated agent baseline oxandrolone GDS651.0.1 GDS1956.0.6 -0.46 disease state normal idiopathic dilated disease state normal Emery-Dreifuss muscular dystrophy GDS1259.0.1 GDS1667.0.1 0.46 disease state normal dermatomyositis infection HPV negative HPV positive GDS715.0.8.18 GDS1321.0.1 0.46 agent none 1,10-phenanthroline disease state normal Barrett's esophagus GDS2362.6.7.2.5 GDS715.0.4.18 0.46 agent untreated chloroguine treated agent none a-methyl-L-p-tyrosine GDS2362.6.7.2.5 GDS2200.0.2 -0.46 agent untreated chloroguine treated disease state normal squamous cell carcinoma GDS2362.6.7.2.5 GDS715.0.9.18 -0.46 agent untreated chloroguine treated agent none 5-fluorouridine GDS1333.0.1 GDS1428.0.1.10 0.46 agent baseline oxandrolone agent untreated Staphylococcus aureus GDS1333.0.1 GDS1220.0.1.3 -0.46 agent baseline oxandrolone disease state normal malignant pleural mesothelioma GDS1333.0.1 GDS2153.0.1 -0.46 agent baseline oxandrolone disease state normal dermatomyositis GDS2191.0.1 GDS1956.0.3 -0.46 disease state control bipolar disorder disease state normal amyotophic lateral sclerosis GDS2643.0.3.5 GDS1956.0.4 -0.46 disease state normal multiple myeloma disease state normal spastic paraplegia GDS2611.0.3.9 GDS2205.0.1 -0.46 agent untreated IFN-gamma disease state non-failing dilated cardiomyopathy GDS2215.0.2 GDS1375.0.1 0.46 agent control cyfluthrin disease state normal benign nevi GDS2215.0.2 GDS2428.0.1.2 -0.46 agent control cyfluthrin agent untreated 5-aza-dC GDS715.0.10.18 GDS715.2.15.18 -0.46 agent none pergolide methanesulfonate agent negative control cyclazosin HCl GDS2250.0.3 GDS715.0.4.18 -0.46 disease state normal basal-like cancer agent none a-methyl-L-p-tyrosine GDS2200.0.1 GDS289.0.1 -0.46 disease state normal actinic keratosis disease state control chronic obstructive pulmonary disease GDS1615.0.2 GDS715.2.15.18 0.46 disease state normal Crohn's disease agent negative control cyclazosin HCl GDS2652.0.1 GDS2057.0.2.3 0.46 agent control ARA and low DHA agent control RTI-018 GDS2414.0.1.3 GDS1736.0.1 0.46 agent control trophoblast conditioned medium agent control arachidonic acid GDS2414.0.1.3 GDS2428.0.1.2 0.46 agent control trophoblast conditioned medium agent untreated 5-aza-dC GDS1050.2.3.0 GDS2737.0.1.2 0.46 agent untreated valproic acid disease state normal endometriosis GDS1050.2.3.0 GDS1397.0.1 -0.46 agent untreated valproic acid agent untreated HIV GDS289.0.1 GDS1989.1.3.0 0.46 disease state control chronic obstructive pulmonary disease disease state normal atypical nevus GDS2643.0.1.5 GDS715.0.13.18 0.46 disease state normal Waldenstrom's macroglobulinemia agent none 8-(3-chlorostyryl) caffeine GDS2643.0.1.5 GDS1667.0.1 0.46 disease state normal Waldenstrom's macroglobulinemia infection HPV negative HPV positive GDS1257.0.2 GDS1746.2.4.0 -0.46 disease state normal SCD steady state disease state normal basaloid GDS715.2.12.18 GDS715.2.4.18 -0.46 agent negative control 5-fluorouracil agent negative control a-methyl-L-p-tyrosine GDS715.2.7.18 GDS715.0.12.18 0.46 agent negative control 4,5-dianilinophthalimide agent none 5-fluorouracil GDS1220.0.1.3 GDS2635.0.3 0.46 disease state normal malignant pleural mesothelioma disease state lobular control invasive ductal carcinoma GDS2617.0.2 GDS2307.0.1 0.46 disease state normal tumorigenic cancer cell agent untreated LDL GDS1736.0.1 GDS1917.0.1 0.46 agent control arachidonic acid disease state control schizophrenia GDS2221.1.2 GDS2611.0.3.9 0.46 agent vehicle galectin-1 agent untreated IFN-gamma GDS2221.1.2 GDS1282.0.2 0.46 agent vehicle galectin-1 disease state control clear cell sarcoma of the kidney GDS2221.1.2 GDS1405.0.1 -0.46 agent vehicle galectin-1 agent untreated DCI GDS2333.0.2.3 GDS715.0.6.16 -0.46 infection uninfected delta pilD mutant agent none 16-ketoestradiol GDS2333.0.2.3 GDS715.0.5.18 -0.46 infection uninfected delta pilD mutant agent none sulmazole GDS2333.0.2.3 GDS810.0.3 -0.46 infection uninfected delta pilD mutant disease state control severe AD GDS1630.2.3.0 GDS2643.0.3.5 0.46 agent untreated mevalonate disease state normal multiple myeloma GDS1956.0.11 GDS2362.6.7.2.5 -0.46 disease state normal FKRP mutation agent untreated chloroguine treated GDS1956.0.11 GDS1439.0.2 -0.46 disease state normal FKRP mutation disease state benign metastatic GDS1956.0.11 GDS715.0.6.16 -0.46 disease state normal FKRP mutation agent none 16-ketoestradiol GDS1397.0.1 GDS1427.0.2 -0.46 agent untreated HIV infection control v-Myb GDS1956.0.6 GDS2200.0.1 -0.46 disease state normal Emery-Dreifuss muscular dystrophy disease state normal actinic keratosis GDS1956.0.6 GDS1989.1.4.0 -0.46 disease state normal Emery-Dreifuss muscular dystrophy disease state normal melanoma in situ GDS2737.0.1.4 GDS1956.0.5 -0.46 disease state normal endometriosis disease state normal fascioscapulohumeral muscular dystrophy GDS2142.0.2 GDS690.2.3.0 0.46 disease state normal severe cystic fibrosis agent control flagellin GDS2142.0.2 GDS690.2.4.1 0.46 disease state normal severe cystic fibrosis agent control LTb GDS1384.0.1 GDS2250.0.2 -0.46 agent control c-Myb disease state normal BRCA1-associated cancer GDS2397.0.1 GDS715.0.1.18 0.46 disease state normal idiopathic myelofibrosis agent none positive control GDS1630.2.4.1 GDS2213.0.1 0.46 agent untreated atorvastatin agent untreated 5-aza-dC GDS715.2.9.18 GDS715.2.6.18 0.46 agent negative control 5-fluorouridine agent negative control 16-ketoestradiol GDS1331.0.1 GDS690.2.4.1 0.46 disease state normal presymptomatic agent control LTb GDS1956.0.4 GDS1453.0.1 0.46 disease state normal spastic paraplegia agent untreated camptothecin GDS1956.0.4 GDS2414.0.1.3 -0.46 disease state normal spastic paraplegia agent control trophoblast conditioned medium GDS1362.0.2 GDS1353.0.1.2 0.46 disease state non-failing heart ischemic cardiomyopathy agent control dexamethasone GDS1362.0.2 GDS2643.0.2.4 0.46 disease state non-failing heart ischemic cardiomyopathy disease state normal chronic lymphocytic leukemia GDS1362.0.2 GDS2084.0.1 0.46 disease state non-failing heart ischemic cardiomyopathy disease state control polycystic ovary syndrome GDS1667.0.1 GDS1956.0.7 -0.46 infection HPV negative HPV positive disease state normal Becker muscular dystrophy GDS715.0.6.18 GDS1956.0.10 0.46 agent none 16-ketoestradiol disease state normal dysferlin mutation GDS2118.0.3 GDS1375.0.1 0.46 disease state normal refractory anemia with excess blasts disease state normal benign nevi GDS2118.0.3 GDS1667.0.1 0.46 disease state normal refractory anemia with excess blasts infection HPV negative HPV positive GDS690.2.5.0 GDS1926.0.2.4 0.46 agent control TNFa agent control LTD4 GDS690.2.5.0 GDS2153.0.1 0.46 agent control TNFa disease state normal dermatomyositis GDS690.2.5.0 GDS1989.1.2.0 -0.46 agent control TNFa disease state normal benign nevus GDS2021.0.1 GDS690.2.5.1 0.46 agent control metoprolol agent control TNFa GDS1375.0.2 GDS1732.0.1 0.46 disease state normal malignant melanoma disease state normal papillary thyroid cancer GDS1375.0.2 GDS2362.6.7.2.5 -0.46 disease state normal malignant melanoma agent untreated chloroguine treated GDS2193.0.1 GDS1917.0.1 0.46 agent control Sox4 RNAi disease state control schizophrenia GDS2341.0.1.5 GDS715.0.1.16 0.46 agent untreated Type I IFN agent none positive control GDS2341.0.1.5 GDS1453.0.1 0.46 agent untreated Type I IFN agent untreated camptothecin GDS2214.0.2 GDS2221.1.3 0.46 agent control HMGB1 agent vehicle lipopolysaccharide GDS715.0.7.18 GDS1956.0.8 0.46 agent none 4,5-dianilinophthalimide disease state normal Duchenne muscular dystrophy GDS715.0.7.18 GDS715.0.11.18 0.46 agent none 4,5-dianilinophthalimide agent none scopolamine methyl bromide GDS715.0.7.18 GDS1542.0.1 0.46 agent none 4,5-dianilinophthalimide agent control tumor necrosis factor GDS2367.3.4.2 GDS2414.0.1.4 0.46 infection control adenovirus adenovirus carrying estrogen receptor beta agent control trophoblast conditioned medium GDS2367.3.4.2 GDS1480.0.1 0.46 infection control adenovirus adenovirus carrying estrogen receptor beta disease state lean obese GDS2367.3.4.2 GDS1439.0.1 -0.46 infection control adenovirus adenovirus carrying estrogen receptor beta disease state benign primary GDS2367.3.4.2 GDS1841.0.1 -0.46 infection control adenovirus adenovirus carrying estrogen receptor beta agent empty vector wild-type surfactant protein C GDS885.0.1 GDS2617.0.2 -0.46 agent control campthotecin disease state normal tumorigenic cancer cell GDS715.0.6.16 GDS651.0.1 0.46 agent none 16-ketoestradiol disease state normal idiopathic dilated GDS715.0.6.16 GDS690.2.5.0 -0.46 agent none 16-ketoestradiol agent control TNFa GDS715.0.6.16 GDS737.0.1 -0.46 agent none 16-ketoestradiol disease state no or mild emphysema severe emphysema GDS2118.0.1 GDS2213.0.3 0.46 disease state normal refractory anemia agent untreated 5-aza-dC plus TSA GDS2250.0.1 GDS2611.0.1.9 0.46 disease state normal non-basal-like cancer agent untreated keratinocyte growth factor GDS1956.0.8 GDS1321.0.1 0.46 disease state normal Duchenne muscular dystrophy disease state normal Barrett's esophagus GDS715.0.5.18 GDS1956.0.1 -0.46 agent none sulmazole disease state normal acute quadriplegic myopathy GDS2341.0.3.4 GDS1447.0.1 -0.46 agent untreated Types I and II IFNs agent control vanadium GDS2341.0.3.4 GDS860.0.1 -0.46 agent untreated Types I and II IFNs agent untreated endothelin-1 GDS715.0.9.18 GDS1956.0.6 0.46 agent none 5-fluorouridine disease state normal Emery-Dreifuss muscular dystrophy GDS715.0.3.18 GDS2307.0.2 0.46 agent none erythro-9-(2-hydroxy-3-nonyl)adenine HCl agent untreated ox-LDL GDS690.2.3.1 GDS1333.0.1 -0.46 agent control flagellin agent baseline oxandrolone GDS2221.0.3 GDS2635.0.3 0.46 agent untreated lipopolysaccharide disease state lobular control invasive ductal carcinoma GDS2221.0.3 GDS2611.0.3.9 0.46 agent untreated lipopolysaccharide agent untreated IFN-gamma GDS690.2.4.1 GDS2153.0.1 0.46 agent control LTb disease state normal dermatomyositis GDS1439.0.2 GDS1375.0.1 0.46 disease state benign metastatic disease state normal benign nevi GDS2617.0.1 GDS2214.0.2 -0.46 disease state normal non-tumorigenic cancer cell agent control HMGB1 GDS2341.0.3.5 GDS2418.0.1 0.46 agent untreated Types I and II IFNs disease state control vulvar intraepithelial neoplasia GDS2341.0.2.5 GDS2250.0.3 0.46 agent untreated Type II IFN disease state normal basal-like cancer GDS2367.3.4.1 GDS2057.0.2.4 -0.46 infection control adenovirus adenovirus carrying estrogen receptor beta agent control RTI-018 GDS1989.1.7.0 GDS2215.0.2 0.46 disease state normal lymph node metastasis agent control cyfluthrin GDS1685.0.1 GDS1989.1.5.0 0.46 disease state normal hereditary gingival fibromatosis disease state normal vertical growth phase melanoma GDS1685.0.1 GDS2216.0.2.5 0.46 disease state normal hereditary gingival fibromatosis agent control CyP GDS2414.0.1.4 GDS2250.0.3 0.46 agent control trophoblast conditioned medium disease state normal basal-like cancer GDS1630.2.4.0 GDS1665.0.1 0.46 agent untreated atorvastatin disease state normal papillary thyroid carcinoma GDS1353.0.1.2 GDS715.2.5.18 -0.46 agent control dexamethasone agent negative control sulmazole GDS1405.0.1 GDS715.0.7.18 -0.46 agent untreated DCI agent none 4,5-dianilinophthalimide GDS2307.0.2 GDS1989.1.6.0 0.46 agent untreated ox-LDL disease state normal metastatic growth phase melanoma GDS1447.0.1 GDS2221.1.2 0.46 agent control vanadium agent vehicle galectin-1 GDS1574.8.9.11 GDS715.2.8.18 0.46 agent control endotoxin agent negative control 1,10-phenanthroline GDS1574.8.9.11 GDS2118.0.2 -0.46 agent control endotoxin disease state normal refractory anemia with ringed sideroblasts GDS1331.0.2 GDS1956.0.2 0.46 disease state normal symptomatic disease state normal juvenile dermatomyositis GDS1331.0.2 GDS1956.0.6 0.46 disease state normal symptomatic disease state normal Emery-Dreifuss muscular dystrophy GDS1841.0.2 GDS1439.0.2 0.46 agent empty vector misfolded surfactant protein C disease state benign metastatic GDS1989.1.2.0 GDS2023.0.1.2 0.46 disease state normal benign nevus infection vehicle control RSV GDS1989.1.2.0 GDS2250.0.1 0.46 disease state normal benign nevus disease state normal non-basal-like cancer GDS1926.0.3.4 GDS690.2.5.0 0.46 agent control LTD4 and thrombin agent control TNFa GDS1326.2.3.0 GDS715.2.15.18 0.46 agent control E2 agent negative control cyclazosin HCl GDS1326.2.3.0 GDS715.0.15.18 0.46 agent control E2 agent none cyclazosin HCl GDS1630.2.5.1 GDS1447.0.2 0.46 agent untreated atorvastatin and mevalonate agent control zinc GDS1630.2.5.1 GDS1617.0.3 -0.46 agent untreated atorvastatin and mevalonate agent control MGd GDS2216.0.1.5 GDS1850.0.1 0.46 agent control LPS disease state healthy carious GDS1543.0.1 GDS1667.0.1 -0.46 agent control tumor necrosis factor infection HPV negative HPV positive GDS1926.0.2.4 GDS860.0.1 0.46 agent control LTD4 agent untreated endothelin-1 GDS1926.0.2.4 GDS1439.0.2 -0.46 agent control LTD4 disease state benign metastatic GDS2021.0.2 GDS2367.0.2.3 0.46 agent control nebivolol agent vehicle tamoxifen GDS2023.0.1.2 GDS2705.0.2 -0.46 infection vehicle control RSV agent control carboplatin GDS2428.0.1.4 GDS289.0.1 -0.46 agent untreated 5-aza-dC disease state control chronic obstructive pulmonary disease GDS1989.1.6.0 GDS1543.0.1 0.46 disease state normal metastatic growth phase melanoma agent control tumor necrosis factor GDS1989.1.6.0 GDS1956.0.2 0.46 disease state normal metastatic growth phase melanoma disease state normal juvenile dermatomyositis GDS715.2.15.18 GDS1971.0.2 0.46 agent negative control cyclazosin HCl disease state healthy complicated malaria GDS2697.0.1 GDS2362.6.7.2.5 0.46 disease state normal teratozoospermia agent untreated chloroguine treated GDS1282.0.2 GDS2250.0.3 0.46 disease state control clear cell sarcoma of the kidney disease state normal basal-like cancer GDS737.0.1 GDS1956.0.1 0.46 disease state no or mild emphysema severe emphysema disease state normal acute quadriplegic myopathy GDS2332.0.3 GDS715.0.14.18 0.46 infection uninfected delta pilD mutant agent none R-(-)-apomorphine HCl GDS1989.1.5.0 GDS2307.0.1 -0.46 disease state normal vertical growth phase melanoma agent untreated LDL GDS715.2.5.18 GDS1956.0.5 -0.46 agent negative control sulmazole disease state normal fascioscapulohumeral muscular dystrophy GDS1617.0.2 GDS715.0.4.18 0.46 agent control 50uM zinc agent none a-methyl-L-p-tyrosine GDS1617.0.2 GDS2250.0.2 0.46 agent control 50uM zinc disease state normal BRCA1-associated cancer GDS1617.0.2 GDS715.0.8.16 0.46 agent control 50uM zinc agent none 1,10-phenanthroline GDS1617.0.2 GDS715.0.12.18 -0.46 agent control 50uM zinc agent none 5-fluorouracil GDS1971.0.2 GDS2118.0.1 0.46 disease state healthy complicated malaria disease state normal refractory anemia GDS2367.0.2.3 GDS2723.0.1 0.46 agent vehicle tamoxifen disease state healthy primary immunodeficiency syndrome GDS2367.0.2.3 GDS885.0.1 -0.46 agent vehicle tamoxifen agent control campthotecin GDS2367.0.2.3 GDS1257.0.1 -0.46 agent vehicle tamoxifen disease state normal SCD with acute chest syndrome GDS2057.0.1.4 GDS1665.0.1 0.46 agent control DHT disease state normal papillary thyroid carcinoma GDS1362.0.1 GDS1050.0.1.2 0.46 disease state non-failing heart non-ischemic cardiomyopathy disease state normal polycystic ovary syndrome GDS1362.0.1 GDS1574.8.9.12 -0.46 disease state non-failing heart non-ischemic cardiomyopathy agent control endotoxin GDS1362.0.1 GDS1375.0.2 -0.46 disease state non-failing heart non-ischemic cardiomyopathy disease state normal malignant melanoma GDS1362.0.1 GDS651.0.1 -0.46 disease state non-failing heart non-ischemic cardiomyopathy disease state normal idiopathic dilated GDS1397.0.2 GDS2367.3.4.0 -0.46 agent untreated TNF-alpha infection control adenovirus adenovirus carrying estrogen receptor beta GDS2737.0.1.3 GDS1326.2.3.1 -0.46 disease state normal endometriosis agent control E2 GDS2255.3.4.0 GDS1447.0.1 0.46 agent untreated endotoxin agent control vanadium GDS2255.3.4.0 GDS1542.0.1 0.46 agent untreated endotoxin agent control tumor necrosis factor GDS2255.3.4.0 GDS2118.0.1 -0.46 agent untreated endotoxin disease state normal refractory anemia GDS690.2.3.0 GDS2215.0.1 0.46 agent control flagellin agent control chlorpyrifos GDS690.2.3.0 GDS2367.0.1.3 0.46 agent control flagellin agent vehicle estradiol GDS2432.0.1 GDS1427.0.2 0.46 disease state control pituitary adenoma predisposition infection control v-Myb GDS2221.0.2 GDS1989.1.4.0 0.46 agent untreated galectin-1 disease state normal melanoma in situ GDS2142.0.1 GDS1375.0.1 -0.46 disease state normal mild cystic fibrosis disease state normal benign nevi GDS2705.0.2 GDS2428.0.1.2 0.46 agent control carboplatin agent untreated 5-aza-dC GDS2705.0.1 GDS2307.0.1 0.46 agent control rosiglitazone agent untreated LDL GDS1428.0.1.10 GDS715.2.15.18 0.46 agent untreated Staphylococcus aureus agent negative control cyclazosin HCl GDS1428.0.1.10 GDS1574.8.9.11 0.46 agent untreated Staphylococcus aureus agent control endotoxin GDS1428.0.1.10 GDS2643.0.2.4 -0.46 agent untreated Staphylococcus aureus disease state normal chronic lymphocytic leukemia GDS2341.0.1.4 GDS1050.0.1.2 0.46 agent untreated Type I IFN disease state normal polycystic ovary syndrome GDS2341.0.1.4 GDS2205.0.1 -0.46 agent untreated Type I IFN disease state non-failing dilated cardiomyopathy GDS1439.0.1 GDS1989.1.4.0 0.46 disease state benign primary disease state normal melanoma in situ GDS2333.1.2.3 GDS1956.0.6 0.46 infection wild type delta pilD mutant disease state normal Emery-Dreifuss muscular dystrophy GDS2333.1.2.3 GDS2432.0.1 -0.46 infection wild type delta pilD mutant disease state control pituitary adenoma predisposition GDS2214.0.1 GDS1447.0.1 0.46 agent control lipopolysaccharide agent control vanadium GDS1630.2.3.1 GDS1257.0.1 -0.46 agent untreated mevalonate disease state normal SCD with acute chest syndrome GDS2332.1.2 GDS1050.2.3.0 0.46 infection wild type delta frpC/frpA mutant agent untreated valproic acid GDS2332.1.2 GDS1312.0.1 -0.46 infection wild type delta frpC/frpA mutant disease state normal cancer GDS2332.1.2 GDS1397.0.2 -0.46 infection wild type delta frpC/frpA mutant agent untreated TNF-alpha GDS715.0.12.18 GDS715.0.15.18 0.46 agent none 5-fluorouracil agent none cyclazosin HCl GDS1376.2.3.1 GDS2333.1.2.3 0.46 disease state normal thrombocythemia infection wild type delta pilD mutant GDS1376.2.3.1 GDS2216.0.3.5 0.46 disease state normal thrombocythemia agent control CyP plus LPS GDS1376.2.3.1 GDS2332.1.2 0.46 disease state normal thrombocythemia infection wild type delta frpC/frpA mutant GDS715.0.14.18 GDS2193.0.1 0.46 agent none R-(-)-apomorphine HCl agent control Sox4 RNAi GDS715.0.14.18 GDS1630.2.4.1 0.46 agent none R-(-)-apomorphine HCl agent untreated atorvastatin GDS715.0.14.18 GDS2428.0.1.3 0.46 agent none R-(-)-apomorphine HCl agent untreated 5-aza-dC GDS2767.7.8.0 GDS266.0.1.2 -0.46 agent water red wine disease state no atopy atopy GDS1062.2.3.0 GDS1220.0.1.3 -0.46 disease state no metastasis metastasis disease state normal malignant pleural mesothelioma GDS2767.7.8.3 GDS1956.0.9 -0.46 agent water red wine disease state normal Calpain 3 mutation GDS505.0.1 GDS2635.0.2 0.46 disease state normal RCC disease state lobular control invasive lobular carcinoma GDS505.0.1 GDS2611.0.1.9 0.46 disease state normal RCC agent untreated keratinocyte growth factor GDS484.0.1 GDS2332.0.2 -0.46 disease state normal leiomyoma infection uninfected delta frpC/frpA mutant GDS484.0.1 GDS1558.0.1.3 0.46 disease state normal leiomyoma disease state no atrial fibrillation permanent atrial fibrillation GDS2649.3.5.1 GDS1375.0.1 0.46 disease state uninfected chronic HIV infection disease state normal benign nevi GDS2767.6.8.0 GDS1736.0.1 -0.46 agent water grape juice agent control arachidonic acid GDS2649.3.5.0 GDS2341.0.1.4 0.46 disease state uninfected chronic HIV infection agent untreated Type I IFN GDS2649.2.5.1 GDS885.0.1 -0.46 disease state uninfected early HIV infection agent control campthotecin GDS2649.4.5.0 GDS1956.0.5 -0.46 disease state uninfected non-progressive HIV infection disease state normal fascioscapulohumeral muscular dystrophy GDS2649.4.5.0 GDS2635.0.3 -0.46 disease state uninfected non-progressive HIV infection disease state lobular control invasive ductal carcinoma GDS715.1.2.18 GDS1375.0.2 -0.46 agent negative control positive control disease state normal malignant melanoma GDS715.1.2.18 GDS1850.0.1 0.46 agent negative control positive control disease state healthy carious GDS2767.7.8.0 GDS715.2.10.18 -0.46 agent water red wine agent negative control pergolide methanesulfonate GDS2767.7.8.0 GDS1971.0.1 0.46 agent water red wine disease state healthy uncomplicated malaria GDS2767.7.8.0 GDS1427.0.2 0.46 agent water red wine infection control v-Myb GDS2367.0.1.3 GDS484.0.1 0.46 agent vehicle estradiol disease state normal leiomyoma GDS1331.0.1 GDS2649.4.5.0 -0.46 disease state normal presymptomatic disease state uninfected non-progressive HIV infection GDS1746.2.4.0 GDS484.0.1 -0.46 disease state normal basaloid disease state normal leiomyoma GDS1439.0.2 GDS484.0.1 0.46 disease state benign metastatic disease state normal leiomyoma GDS1331.0.2 GDS266.0.1.2 0.46 disease state normal symptomatic disease state no atopy atopy GDS2332.0.3 GDS715.1.2.18 0.46 infection uninfected delta pilD mutant agent negative control positive control GDS1783.0.2 GDS266.0.1.2 0.46 agent control high potassium disease state no atopy atopy GDS2737.0.1.3 GDS2649.3.5.1 0.46 disease state normal endometriosis disease state uninfected chronic HIV infection GDS1282.0.1 GDS484.0.1 0.46 disease state control Wilms' tumor disease state normal leiomyoma